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A B S T R A C T
Background
In people with chronic obstructive pulmonary disease (COPD) there is considerable variation in symptoms, limitations and well-
being, which often complicates medical care. To improve quality of life (QoL) and exercise tolerance, while reducing the number of
exacerbations, a multidisciplinary program including different elements of care is needed.
Objectives
To evaluate the effects of integrated disease management (IDM) programs or interventions in people with COPD on health-related
QoL, exercise tolerance and number of exacerbations.
Search methods
We searched the Cochrane Airways Group Register of trials, CENTRAL, MEDLINE, EMBASE and CINAHL for potentially eligible
studies (last searched 12 April 2012).
Selection criteria
Randomized controlled trials evaluating IDM programs for COPD compared with controls were included. Included interventions
consisted of multidisciplinary (two or more health care providers) and multi-treatment (two or more components) IDM programs with
a duration of at least three months.
Data collection and analysis
Two review authors independently assessed trial quality and extracted data; if required, we contacted authors for additional data. We
performed meta-analyses using random-effects modeling. We carried out sensitivity analysis for allocation concealment, blinding of
outcome assessment, study design and intention-to-treat analysis.
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Main results
A total of 26 trials involving 2997 people were included, with a follow-up ranging from 3 to 24 months. Studies were conducted in 11
different countries. The mean age of the included participants was 68 years, 68% were male and the mean forced expiratory volume
in one second (FEV1)% predicted value was 44.3% (range 28% to 66%). Participants were treated in all types of healthcare settings:
primary (n = 8), secondary (n = 12), tertiary care (n = 1), and in both primary and secondary care (n = 5). Overall, the studies were of
high to moderate methodological quality.
Compared with controls, IDM showed a statistically and clinically significant improvement in disease-specific QoL on all domains of
the Chronic Respiratory Questionnaire after 12 months: dyspnea (mean difference (MD) 1.02; 95% confidence interval (CI) 0.67 to
1.36); fatigue (MD 0.82; 95% CI 0.46 to 1.17); emotional (MD 0.61; 95% CI 0.26 to 0.95) and mastery (MD 0.75; 95% CI 0.38
to 1.12). The St. George’s Respiratory Questionnaire (SGRQ) for QoL reached the clinically relevant difference of four units only for
the impact domain (MD -4.04; 95% CI -5.96 to -2.11, P < 0.0001). IDM showed a significantly improved disease-specific QoL on
the activity domain of the SGRQ: MD -2.70 (95% CI -4.84 to -0.55, P = 0.01). There was no significant difference on the symptom
domain of the SGRQ: MD -2.39 (95% CI -5.31 to 0.53, P = 0.11). According to the GRADE approach, quality of evidence on the
SGRQ was scored as high quality, and on the CRQ as moderate quality evidence. Participants treated with an IDM program had a
clinically relevant improvement in six-minute walking distance of 43.86 meters compared with controls after 12 months (95%CI 21.83
to 65.89; P < 0.001, moderate quality). There was a reduction in the number of participants with one or more hospital admissions over
three to 12 months from 27 per 100 participants in the control group to 20 (95% CI 15 to 27) per 100 participants in the IDM group
(OR 0.68; 95% CI 0.47 to 0.99, P = 0.04; number needed to treat = 15). Hospitalization days were significantly lower in the IDM
group compared with controls after 12 months (MD -3.78 days; 95% CI -5.90 to -1.67, P < 0.001). Admissions and hospital days
were graded as high quality evidence. No adverse effects were reported in the intervention group. No difference between groups was
found on mortality (OR 0.96; 95%CI 0.52 to 1.74). There was insufficient evidence to refute or confirm the long term effectiveness
of IDM.
Authors’ conclusions
In these COPD participants, IDM not only improved disease-specific QoL and exercise capacity, but also reduced hospital admissions
and hospital days per person.
P L A I N L A N G U A G E S U M M A R Y
Integrated disease management for chronic obstructive pulmonary disease
Background
Chronic obstructive pulmonary disease (COPD) is a chronic respiratory (lung), disabling disease which affects a lot of people worldwide
and causes millions of deaths every year. People with COPD suffer differing levels of impairment, daily complaints/symptoms and
number of exacerbations.
Different health care providers, such as doctors, nurses and physiotherapists, typically provide different components of care (for example
medication, self management and education, exercise training) to people with COPD. The aim of an integrated disease management
(IDM) program is to establish a program of different components of care in which different health care providers are co-operating and
collaborating to provide efficient and good quality care.
Review question
We wished to determine the effect of such a program on quality of life, exercise tolerance and the number of exacerbations. We have
chosen these outcomes as they are most important for people with COPD.
What we found
We evaluated 26 studies in 2997 people with COPD. Overall the evidence found was of high to moderate quality. The trials were
conducted in 11 different countries. The average age of participants was 68 years, 68% of participants were men and the severity of
COPD on average was severe (according to lung function measures). Some of the trials took place in GP clinics and some in hospitals.
Overall, the studies were of good to moderate methodological quality.
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Peoplewhoparticipated in an IDMprogramhadbetter quality of life and improved their exercise tolerance after 12months. Furthermore,
in participants treated with such a program, the number of hospital admissions related to exacerbations decreased and the total number
of hospital days was reduced by three days. We found no evidence of an effect on mortality.
The results support an IDM program for people with COPD to optimize quality of life and exercise tolerance.
This plain language summary is up-to-date as of April 2012.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Integrated disease management compared to control for patients with chronic obstructive pulmonary disease
Patient or population: patients with chronic obstructive pulmonary disease
Settings: 8 studies in primary care, 12 studies in secondary care, 1 study in tertiary care, 5 studies in both primary and secondary care
Intervention: integrated disease management
Comparison: control
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Disease management
Quality of life mea-
sured on the SGRQ
(St George’s Respira-
tory Questionnaire) total
score. Scale from: 0 to
100. Lower score indi-
cates improvement
Follow-up: 3 to 12
months
The mean change in
the SGRQ (total score)
ranged from 3.4 lower to
6.24 higher
The mean SGRQ (total
score) in the intervention
groups was
3.71 lower
(5.83 to 1.59 lower)
MD -3.71 (-5.83 to -1.59) 1425
(13 studies)
⊕⊕⊕⊕
high2
MCID = -4 points, lower
score means improve-
ment
Quality of life measured
on the CRQ dyspnoea do-
main
Scale from: 0 to 7. Higher
score indicates improve-
ment
Follow-up: 3 to 12
months
The mean change in the
CRQ (dyspnoea domain)
ranged from 0 to 0.2
lower
The mean CRQ dyspnoea
domain in the intervention
groups was
1.02 higher
(0.67 to 1.36 higher)
MD 1.02 (0.67 to 1.36) 160
(4 studies)
⊕⊕⊕©
moderate1
MCID = 0.5 points
Results on the other do-
mains of the CRQ (fa-
tigue, emotion, mastery)
were also all statistically
and clinically relevant
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Functional exercise ca-
pacity
6-minute walking dis-
tance (6MWD)
Follow-up: 3 to 12
months
The mean change in the
6MWD ranged from 38
lower to 36 higher
The mean functional ex-
ercise capacity in the in-
tervention groups was
43.86 higher
(21.83 to 65.89 higher)
MD 43.86 (21.83 to 65.
89)
838
(14 studies)
⊕⊕⊕©
moderate3
MCID = 35 meters. Sen-
sitivity analysis did show
there was inconsistency
in the effect. After re-
moving low-quality stud-
ies, the MD was 15.15
meters (95% CI 6.37 to
23.93, P <0.001)
Respiratory-related hos-
pital admissions
Follow-up: 3 to 12
months
27 per 100 20 per 100
(15 to 27)
OR 0.68
(0.47 to 0.99)
1470
(7 studies)
⊕⊕⊕⊕
high
Hospital days per patient
(all causes)
Follow-up: 3 to 12
months
The mean change in hos-
pital days ranged from 1.
6 to 11.9 higher
The mean number of hos-
pital days per patient (all
causes) in the interven-
tion groups was
3.78 lower
(5.9 to 1.67 lower)
MD -3.78
(-5.9 to -1.67)
741
(6 studies)
⊕⊕⊕⊕
high
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; IDM: integrated disease management; MCID: minimal clinically important difference; MD: mean difference; OR: odds ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1We downgraded one as there was considerable risk of bias in two studies on allocation concealment and two studies did not blind the
outcome assessor.
2We did not downgrade due to risk of bias, as studies contributing more than 2.7% to the meta-analysis had a low risk of bias. Sensitivity
analysis on high-risk studies did not change the effect or significance of the effect.
3We downgraded one as all included studies were of moderate to low quality. If we removed studies which had high or unclear risk of
bias on allocation concealment, the effect decreased to 15 meters.
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B A C K G R O U N D
Description of the condition
Chronic obstructive pulmonary disease (COPD) is a heteroge-
neous, systemic condition characterized by restricted airflowwhich
is not fully reversible. It is a major cause of morbidity, due to
the ageing of the world’s population and the continued use of
tobacco and exposure to indoor biomass pollution. The preva-
lence of COPD is expected to increase substantially in the com-
ing decades (Lopez 2006; GOLD 2009). According to the World
Health Organization (WHO), COPD will be the third leading
cause of death in 2020 (Lopez 2006; WHO 2008). Given the
rise in prevalence, COPD has important financial consequences,
with high reported direct costs (healthcare resources, medication
prescriptions) and indirect costs (absence from paid work, conse-
quences of disability) (Britton 2003).
Optimal management of COPD is complex, as it is a multi-com-
ponent disease. Clinical, functional and radiological presentation
varies greatly from patient to patient, despite having a similar de-
gree of airflow limitation (Wedzicha 2000; GOLD 2009; Agusti
2010). Evidence suggests that the previous 2007 Global Initiative
for Chronic Obstructive Lung Disease (GOLD) classification of
disease severity, solely based upon the degree of airflow limitation,
is a poor predictor of other important negative features of COPD
(Agusti 2010; Burgel 2010).
Health-related quality of life (HRQoL) and exercise tolerance may
be more important to people with COPD than the more tradi-
tional measure of lung function. This is because COPD has a pro-
found impact on HRQoL and exercise tolerance, even in those
with modest airflow limitation (Engstrom 1996). Furthermore,
impaired HRQoL (Domingo-Salvany 2002; Fan 2002; Martinez
2006) and exercise tolerance (Gerardi 1996; Pinto-Plata 2004)
have been associated with an increased risk of mortality (Cote
2009).
In addition, some people are more prone than others to episodes
of acute exacerbations, which are an important cause of mor-
bidity, mortality, hospital admission and impaired health status
(Seemungal 1998;Wedzicha 2000; Calverley 2003). Although ex-
acerbations become more severe and occur more frequently with
increased severity of COPD, this is not always the case. There is
some evidence for a ’frequent-exacerbation’ phenotype (or group
of people) that exacerbate more often than would be expected
given their ’severity’ as predicted by lung function testing (Hurst
2010).
Episodes of exacerbations are often not reported by patients to
health care providers (Seemungal 2000). An important reason for
patients’ delay in reporting an increase in symptoms to their doctor
is the fear of being sent to hospital. This passive behavior can even-
tually lead to a respiratory crisis, indeed necessitating urgent refer-
ral. In order to break through the self reinforcing negative spiral of
dyspnoea, deconditioning and social deprivation doctors need to
collaborate with their patients, with a focus on self management
skills: “if symptoms increase, you need to let us know rapidly to
prevent further worsening” (Chavannes 2008). In viewing COPD
as a disease process with a clinical, heterogeneous picture of pro-
gressive deterioration, an integrated system of care could be built
on a disease management model. Ideally, it is based on active self
management to slow down progression of the disease, including
daily self care, patient-physician collaboration and exacerbation
management. Information should be tailored to the person’s needs,
knowledge level and clinical profile and be accessible by the pa-
tient when they need it most (Tiep 1997; Bourbeau 2013).
Description of the intervention
In the last decade, the concept of integrated disease manage-
ment (IDM) was introduced as a mean of improving quality
and efficiency of care. IDM interventions are aimed at reduc-
ing symptoms and avoiding fragmentation of care, while con-
taining costs. Therefore, IDM programs are generally believed to
be cost-effective, but the available evidence is inconclusive. Sev-
eral systematic reviews have shown positive results, at least for
some outcomes of chronic IDM, in people with chronic heart
failure (Gonseth 2004; Roccaforte 2005), diabetes (Norris 2002;
Knight 2005; Pimouguet 2010) and depression (Badamgarav
2003; Neumeyer-Gromen 2004).
However, there is no consensus in the literature about the defi-
nition of IDM. Several definitions have been proposed since the
introduction of the concept ’disease management’. In order to
facilitate the communication between researchers, policy makers
and IDM program leaders, Schrijvers proposed a definition, based
on earlier reported definitions (Care Continuum Alliance; Dellby
1996; Epstein 1996; Ellrodt 1997; Zitter 1997;Weingarten 2002;
Faxon 2004): “Disease management consists of a group of coherent
interventions designed to prevent or manage one or more chronic con-
ditions using a systematic, multidisciplinary approach and potentially
employing multiple treatment modalities. The goal of chronic disease
management is to identify persons at risk for one or more chronic
conditions, to promote self-management by patients and to address
the illness or conditions with maximum clinical outcome, effectiveness
and efficiency regardless of treatment setting(s) or typical reimburse-
ment patterns” (Schrijvers 2009). In addition, Peytremann-Bride-
vaux and Burnand added more elements, adapting the definition
as follows: “Chronic disease prevention and management consists of
a group of coherent interventions, designed to prevent or manage one
or more chronic conditions using a community wide, systematic and
structured multidisciplinary approach potentially employing multiple
treatment modalities. The goal of chronic disease prevention andman-
agement is to identify persons with one or more chronic conditions,
to promote self-management by patients and to address the illness or
conditions according to disease severity and patient needs and based
on the best available evidence, maximizing clinical effectiveness and
efficiency regardless of treatment setting(s) or typical reimbursement
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patterns. Routine process and outcome measurements should allow
feedback to all those involved, as well as to adapt the programme”
(Peytremann-Bridevaux 2009).
How the intervention might work
There is great variation in the symptoms, functional limitations
and degrees of psychological well-being of COPD patients, as well
as the speed of the progression of COPD towards more severe
stages (Agusti 2010). This calls for a multi-faceted response, in-
cluding different elements (e.g. smoking cessation, physiothera-
peutic reactivation, self management, optimal medication adher-
ence) targeted at the patient, professional or organizational level.
Therefore, IDM programs have been developed to improve effec-
tiveness and economic efficiency of chronic care delivery (Norris
2003) by combining patient-related, professional-directed and or-
ganizational interventions (Wagner 2001; Lemmens 2009).
Why it is important to do this review
As health-related quality of life, exercise tolerance and number of
exacerbations are the most important patient-related outcomes in
COPD, the focus in this reviewwill be on these primary outcomes.
Several systematic reviews have been published that evaluated the
effect of IDM in COPD patients (Adams 2007; Niesink 2007;
Peytremann-Bridevaux 2008; Lemmens 2009; Steuten 2009).
These reviews differ from our review in various ways. Adams’
review focused solely on interventions which could be arranged
according to the chronic care model of Wagner (Wagner 1996;
Adams 2007). Furthermore, Adams included studies between
1966 and 2005. Since then, several studies focusing on IDM in
COPDpatients have been published. Niesink and colleagues eval-
uated the quality of life in COPD patients, but did not report
outcomes of exacerbations or exercise tolerance. Furthermore, the
authors decided not to perform a meta-analysis; reasons for this
were not clearly described (Niesink 2007). Peytremann-Bridevaux
performed a meta-analysis and focused on quality of life, exacer-
bations and exercise tolerance. However, they did not take into ac-
count the differences in study design (randomised controlled trials
(RCT) versus before/after uncontrolled studies) in their conclu-
sions (Peytremann-Bridevaux 2008). Lemmens’ review examined
the effectiveness of IDM in a mix of patients with COPD, asthma
or both (Lemmens 2009). No subgroup analysis was performed
for patients with COPD. Furthermore, conclusions were drawn
irrespective of the study designs (i.e. RCTs, controlled clinical tri-
als, quasi-experimental, controlled before and after time studies
and time series designs; Lemmens 2009). Steuten et al aimed to
determine the cost-effectiveness of COPD programs and the au-
thors did not perform a meta-analysis of clinical effects (Steuten
2009).
Overall, all reviews suggested some beneficial effects on health sta-
tus. However, firm conclusions could not be made regarding the
effectiveness of IDM, due to the large heterogeneity in the inter-
ventions, study populations, outcomemeasurements andmethod-
ological quality. The literature searches of the aforementioned re-
views for relevant RCTs investigating the effectiveness of IDM for
patients with COPD were carried out between December 2006
and May 2008. Since then, several studies have been published.
Furthermore, none of the former published systematic reviews
were carried out according to the latest methods for conducting a
systematic review (Higgins 2011). Within the framework of The
Cochrane Collaboration, we have systematically and comprehen-
sively evaluated the effectiveness of IDM in people with COPD.
O B J E C T I V E S
To evaluate the effectiveness of IDM programs or interventions
in people with COPD on health-related quality of life, exercise
tolerance and the number of exacerbations.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included only randomised controlled trials (RCTs) in which
IDM programs or interventions were compared to controls in
people with COPD. Cluster-randomized trials were also eligible.
There were no restrictions regarding the language of the paper.
Types of participants
People with a clinical diagnosis of COPD according to the GOLD
criteria were included: people having chronic respiratory symp-
toms (i.e. coughing, sputum or dyspnoea) and a limited post-
bronchodilator forced expiratory volume in one second (FEV1) to
forced vital capacity (FVC) ratio of < 0.7. Severity of airflow ob-
struction was classified using the GOLD stages of 2009 (GOLD
2009). All GOLD stages were accepted. Studies including partic-
ipants with other diagnoses than COPD were only eligible if the
results of participants with COPD were available separately.
Types of interventions
We included studies where the IDM intervention consisted of
strategies to improve the care for participants with COPD, in-
cluding organizational, professional, patient-directed and finan-
cial interventions. We classified these according to the Cochrane
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Effective Practice and Organization of Care Group (EPOC) tax-
onomy of interventions (EPOC 2008), complemented with pa-
tient-directed interventions (i.e. self management and education).
Our definitive checklist consisted of the following components of
the IDM intervention that could be scored:
1. Education/self management: i.e. education, self-
management, personal goals and/or action plan, exacerbation
management
2. Exercise: i.e. (home) exercise training and/or strength and/
or endurance training
3. Psychosocial: cognitive behavioral therapy, stress
management, other psychological assessment and/or treatment
4. Smoking cessation
5. Medication: optimal medication/prescription of medication
adherence
6. Nutrition: dietary intervention
7. Follow-up and/or communication: structural follow-up
and/or communication, case management by nurses, optimal
diagnosis
8. Multidisciplinary team: active participation and formation
of teams of professional caregivers from different disciplines,
revision of professional roles, integration of services, local team
meetings
9. Financial intervention: fees/payment/grants for providing
IDM.
As IDM includes different components mentioned above, deliv-
ered by different healthcare disciplines, the RCT studies had to
include:
1. at least two components of interventions as mentioned
above;
2. active involvement of at least two different categories of
healthcare providers; and
3. a minimum duration of the IDM intervention of three
months.
In all studies, we determined the dominant component of the
program.
We compared IDM versus controls (varying from usual care or
no treatment to single interventions, mono-disciplinary interven-
tions).
Types of outcome measures
Primary outcomes
1. Health-related quality of life (HRQoL), as reported by one
of the following questionnaires: a validated disease-specific
questionnaire, e.g. Clinical COPD Questionnaire (CCQ; van
der Molen 2003; Kocks 2006), Chronic Respiratory
Questionnaire (CRQ; Guyatt 1987), St. George’s Respiratory
Questionnaire (SGRQ; Jones 1991; Jones 2005), COPD
Assessment Test (CAT; Jones 2009) or a generic questionnaire,
e.g. Short Form-36 (SF-36; Ware 1992), Euro Qol-5D (EQ-5D;
EuroQol Group 1990)).
2. Maximal or functional exercise capacity, as reported by one
of the following outcomes: the peak capacity measured in the
exercise laboratory using an incremental exercise test defined
according to the results of timed walk tests e.g. 6- or 12-minute
walk test (Redelmeier 1997) or shuttle run test (Singh 1992)).
3. Exacerbation-related outcomes, as reported by one of the
following: time to first exacerbation, number of exacerbations,
duration and/or severity, and measured by reporting of
symptoms, antibiotics or prednisolone prescriptions and/or
hospital admissions or hospital days related to exacerbations.
Secondary outcomes
Clinical outcomes
1. Dyspnea, as measured by the Medical Research Council
(MRC) Dyspnea Scale (Bestall 1999) or Borg score (Borg 1970).
2. Survival (mortality).
3. Lung function (FEV1, FVC).
4. Depression, as measured by the Hospital Anxiety and
Depression Scale (HADS) (Zigmond 1983) or the Beck
Depression Inventory (BDI) score (Beck 1961).
Process-related outcomes
1. Co-ordination of care, e.g. accessibility of care,
participation rate in the disease management program,
satisfaction of health care providers and participants with regard
to the program, or the extent to which disease management was
implemented, from the perspective of the patient (PACIC;
Glasgow 2005) and the caregiver (Bonomi 2002).
We evaluated outcomes at the following endpoints: a) short-term
(12 months or less); b) long-term (longer than 12 months) follow-
up, if possible.
Search methods for identification of studies
Electronic searches
We identified trials using the Cochrane Airways Group Regis-
ter of trials, the Cochrane Central Register of Controlled Trials
(CENTRAL) inTheCochrane Library,MEDLINE, EMBASE and
CINAHL. The search was performed without language restric-
tions, using the highly sensitive Cochrane Collaboration search
strategy, which aims to identify all randomised controlled trials
(Lefebvre 2009). We used specific MeSH headings and additional
keywords to identify all RCTs on IDMinCOPDpatients. As IDM
programs were first described in 1990, our search was restricted to
publications from 1990 onwards. The complete search strategies
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for the database searches are provided in the appendices (MED-
LINE Appendix 1; EMBASE Appendix 2; CINAHL Appendix
3; CENTRAL Appendix 4; Airways Register Appendix 5). The
search has been conducted up to April 2012. We ran an update
search on 12 April 2013, but the results have not been fully in-
corporated: nine studies have been added as ’ongoing studies’ and
three studies have been added as ’studies awaiting classification’.
Searching other resources
In order to identify all possible studies, we carried out an addi-
tional search for systematic reviews in the Cochrane Database of
Systematic Reviews. We screened reference lists of included RCTs
and systematic reviews for potential studies for this review. To
identify ongoing or new studies, we searched databases of ongoing
studies, including ClinicalTrials.gov and other relevant registers.
Data collection and analysis
Selection of studies
Two review authors (AK and NS) independently assessed the title
and abstract of all identified citations. We excluded all trials that
were not randomised controlled trials or in which participants had
no diagnosis of COPD. All studies excluded by the first two review
authors because of the nature of the intervention were double-
checked by a third review author (NC). Furthermore, if there was
any doubt, we retrieved the full-text article and examined it for
inclusion eligibility. Disagreements were discussed in a consensus
meeting.
Data extraction and management
We collected the following information from included studies in
our review: 1) the study design (i.e. randomisationmethod, sample
size, blinding); 2) participant characteristics (i.e. diagnosis COPD
according to GOLD criteria, age, sex); 3) interventions (i.e. set-
ting, number of professionals involved, elements of IDMprogram/
intervention, frequency and duration of intervention); 4) outcome
measures and timing of outcome assessment; 5) results (i.e. loss to
follow-up, outcomes). The outcome data were extracted by one
author (AK) and checked by another (NC) using a standardized
data extraction form. In case of missing data, we contacted the
authors of these studies for additional information or clarification.
Assessment of risk of bias in included studies
Two of us (AK and NC) independently assessed risk of bias for
each study using the criteria outlined in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011), according
to the following items:
1. Allocation sequence generation
2. Concealment of allocation
3. Blinding of participants and health care providers, in
relation to the intervention
4. Blinding of outcome assessment
5. Incomplete outcome data
6. Selective outcome reporting
As cluster-randomized trials were also considered for inclusion,
we added the following design-related criteria for these types of
studies:
1. Recruitment bias (i.e. individuals are recruited after the
clusters have been randomised)
2. Baseline imbalance between groups (i.e. the risk of baseline
differences can be reduced by using stratified or pair-matched
randomisation of clusters)
3. Loss of follow-up of clusters (i.e. missing clusters and
missing outcomes for individuals within clusters may lead to a
risk of bias in cluster-randomized trials)
4. Methods of analysis adequate for cluster-randomized
controlled trials (i.e. taking clustering into account in the
analysis) (Higgins 2011)
We judged all items as high, low or unclear risk of bias.We resolved
disagreements in a consensus meeting.
Measures of treatment effect
We analyzed the results of the studies using RevMan 5, using
random-effects modeling. We used forest plots to compare results
across trials. The results were related to the minimal clinically
important difference (MCID).
We expressed the results of each RCT as risk ratios (RR) with cor-
responding 95% confidence intervals (95% CI) for dichotomous
data, and mean difference (MD) or standardized mean difference
(SMD) for continuous data, depending on the similarity of out-
come measurement scale (i.e. MDs are used when all studies use
the same outcome measurement scale and SMDs when studies use
different outcome measurement scales). We summarized data in a
meta-analysis only if the data are clinically and statistically suffi-
ciently homogenous. If the meta-analysis led to statistically signif-
icant overall estimates, we transformed these results (pooled esti-
mate of RR, MD or SMD) back into measures which are clinically
useful in daily practice. We planned to use the number needed to
treat for an additional beneficial outcome (NNTB) and the abso-
lute and/or relative improvement on the original units in order to
report these as the final results of the review.
Unit of analysis issues
In case of a unit of analysis error occurrence in cluster-randomized
controlled trials, we adjusted for the design effect by reducing
the size of the trial to its “effective sample size” (Rao 1992). The
effective sample size of a single intervention group in a cluster-
randomized trial is its original sample size divided by a quantity
called the ’design effect’. The design effect is 1+ (M-1)* ICC,
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where M is the average cluster size and ICC is the intra-cluster
correlation coefficient. For dichotomous data, both the number of
participants and the number experiencing the event were divided
by the design effect. For continuous data, only the sample sizes
were reduced;means and standard deviations remainedunchanged
(Higgins 2011).
Dealing with missing data
In case of missing data, we planned to contact the authors for ad-
ditional information about the missing data for individuals. We
sent a reminder if we did not receive a response. Secondly, we
planned to assume the missing values to have a poor outcome. For
continuous outcomes (i.e. health-related quality of life, exercise
capacity) and dichotomous outcomes (i.e. mortality), we planned
to calculate the effect size (SMD, MD, RR) based on the number
of participants analyzed at the time point. If the number of par-
ticipants analyzed is not reported for each time point, we planned
to use the number of randomised participants in each group at
baseline. We planned to perform sensitivity analysis to investigate
whether our assumptions have been reasonable (i.e. comparing re-
sults using number of participants analyzed with number of par-
ticipants randomised).
Assessment of heterogeneity
We measured clinical and statistical heterogeneity using the I2
statistic (Higgins 2011). A P value of less than 0.10 or an I2 value
greater than 50% indicates substantial heterogeneity. In case of
heterogeneity, we assessed studies, if possible, with respect to:
1. control group: a) no treatment; b) treatment with one
health care provider; c) treatment with one component; d) other
disease management programs (short duration of therapies);
2. intervention group, with regard to a) type of health care
providers (i.e. general practitioner, lung specialist,
physiotherapist, practice nurse); b) different components as
listed by the EPOC classification (EPOC 2008); c) frequency
and duration of intervention.
In case of substantial heterogeneity, we explored the data fur-
ther, including subgroup analyses (see Subgroup analysis and
investigation of heterogeneity) in an attempt to explain the het-
erogeneity.
Assessment of reporting biases
In order to determine whether reporting bias was present, we
evaluated whether the protocol for the RCT was published be-
fore recruitment of patients of the study was started. For studies
published after 1 July 2005, we screened the Clinical Trial Reg-
ister at the International Clinical Trials Registry Platform of the
World Health Organization (http://apps.who.int/trialsearch) (De
Angelis 2004). For each study, we evaluated whether selective re-
porting of outcomes was present (outcome reporting bias). Fur-
thermore, we made a funnel plot to assess the possibility of report-
ing bias.
Data synthesis
We pooled results of the studies using the random-effects model.
For continuous data, we recorded the mean change from baseline
to endpoint and standard deviation (SD) for each group. For di-
chotomous data we recorded the number of participants with each
outcome event and calculated the odds ratio (OR).We used results
reported at three months, as our predetermined inclusion criteria
postulated a program of at least three months duration (to ensure
sufficient impact). If data at three months were unavailable, we
analyzed the data measured most closely to this time point. We
evaluated outcomes at short- (3 to 12 months) and long-term (>
12 months) follow-up.
We presented themain results of the review in a ’Summary of find-
ings’ table, which includes an overall grading of the evidence using
the GRADE approach in accordance with the recommendations
laid out in the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Higgins 2011). This involves making separate ratings for
quality of evidence for each patient-important outcome and iden-
tifies five factors that can lower the quality of evidence, including:
study limitations; indirectness of evidence (also called clinical het-
erogeneity with regard to study population, intervention, control
group and outcomes); unexplained heterogeneity or inconsistency
of results (i.e. statistical heterogeneity); imprecision of results (i.e.
due to small sample sizes and few events); and high probability
of publication bias. However, other factors can increase the qual-
ity of evidence, such as large magnitude of effect; plausible con-
founding, which could reduce the demonstrated effect; and dose-
response gradient (GRADEWorking Group 2004).We presented
the short- and long-term outcomes for our primary outcomes in
the ’Summary of findings’ table if possible.
Subgroup analysis and investigation of heterogeneity
In order to explain heterogeneity between the results of the in-
cluded studies, we planned the following subgroup analyses a pri-
ori (where data were available) to determine if outcomes differed
among:
1. patients with different severity of disease, according to
GOLD stage (GOLD 2009) or MRC Dyspnea Scale (Bestall
1999) (e.g. patients with GOLD 1/2 versus GOLD 3/4, and/or
patients with a MRC score 0 to 2 versus MRC 3 to 5);
2. the setting of the IDM intervention (e.g. primary,
secondary or tertiary care);
3. design of the studies (individually randomised patients
versus cluster-randomized patients (with and without adjusting
for design effect));
4. control group: a) no treatment; b) treatment with one
health care provider; c) treatment with one component; d) other
disease management interventions (short duration of therapies);
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5. intervention group, with regard to a) type of health care
provider (i.e. general practitioner, lung specialist,
physiotherapist, practice nurse); b) different components as
listed by the EPOC classification (EPOC 2008); c) frequency
and duration of intervention.
Sensitivity analysis
We carried out sensitivity analyses for the primary outcome mea-
surements, in order to explore effect size differences and the robust-
ness of conclusions. We planned sensitivity analysis determined a
priori based on:
1. studies without study limitations with regard to a)
allocation concealment; b) blinding of participants and
investigators; c) recruitment bias; d) baseline imbalance between
groups; e) loss of follow-up of clusters; f ) adequate analysis;
2. method of analysis: a) results of studies using number of
patients analyzed; b) studies using number of patients
randomised.
We presented the main results of the review in a ’Summary of
findings’ table, which includes an overall grading of the evidence
using the GRADE approach (GRADEpro; GRADE Working
Group 2004) and a summary of the available data on the main
outcomes, as described in Chapter 11 of the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011).
R E S U L T S
Description of studies
See Characteristics of included studies.
Results of the search
Our literature search identified 6700 titles and abstracts, resulting
in 4776 references after de-duplication. Two review authors (AK,
NS) screened the title/abstracts of these studies based on the pre-
determined inclusion criteria. Studies that were excluded because
of the IDM intervention were double-checked by a third review
author (NC).We retrieved the full-text articles of these studies and
they were discussed in a consensus meeting. Finally, we identified
49 potentially relevant articles about IDM in COPD patients. We
obtained full-text versions of these papers and data were extracted
by one review author (AK) and double-checked by a second review
author (NC). Finally, a total of 26 (cluster) randomised controlled
trials were included in the review. The PRISMA flow diagram is
presented in Figure 1.
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Figure 1. Study flow diagram.
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Included studies
Characteristics of the included studies are described in Table 1,
Table 2 and Characteristics of included studies.
Twenty-six RCTsmet the eligibility criteria for the review, of which
twowere cluster-randomized trials (Rea 2004;Wood-Baker 2006).
One trial was a cross-over trial (Cambach 1997). The studies were
published between 1994 and 2011. Five studies originated from
the Netherlands (Wijkstra 1994; Strijbos 1996; Cambach 1997;
van Wetering 2010; Trappenburg 2011), four studies from Spain
(Güell 2000; Farrero 2001; Güell 2006; Fernandez 2009), three
studies from Australia (Smith 1999; Boxall 2005; Wood-Baker
2006), three from the United Kingdom (Littlejohns 1991; Dheda
2004; Sridhar 2008) and three from the United States (Aiken
2006; Koff 2009; Rice 2010). Two studies were conducted inDen-
mark (Bendstrup 1997; Gottlieb 2011), two originated from Swe-
den (Engstrom 1999; Theander 2009) and one each from Brazil
(Mendes 2010), Canada (Bourbeau 2003), Japan (Wakabayashi
2011) and New Zealand (Rea 2004).
Participants
A total of 2997COPDpatients were randomised in the 26 studies,
with a range of 30 to 713 patients per study. Of these, 2523 (84%)
patients completed the studies (range 18 to 725). The mean age
of the study population was 68 years (SD 3.7), with 68% being
male. Patients had a mean FEV1% predicted of 44.3% (range 28
to 66).
Interventions
Patients were treated in all types of healthcare settings: primary
care (eight studies), secondary care (12 studies), tertiary care (one
study) and a combination of primary and secondary health care
(five studies). The number of health care providers involved in the
IDM program ranged from two to seven, with a mean number of
three. Furthermore, we calculated the number of components per
program, which ranged from two to eight, with a mean number
of four.
A priori, we planned to arrange the interventions in order to per-
form subgroup analysis based on type of intervention, according to
type of health care providers, different components, and frequency
and duration of intervention. However, it was not possible to de-
termine the mean intensity, frequency or duration of all programs,
due to lack of data. Furthermore, as the studies were too heteroge-
neous, it was not possible to arrange programs according to differ-
ent combinations of components or combinations of health care
providers. Therefore, we determined the dominant component of
the IDMprogram in all studies. Themain component of the inter-
vention could directly be determined in nine studies (Littlejohns
1991; Smith 1999; Farrero 2001; Bourbeau 2003; Dheda 2004;
Aiken 2006; Wood-Baker 2006; Koff 2009; Trappenburg 2011)
from the objective or title of the study. For example, in Aiken
2006: “The objective is to document outcomes of a randomised trial
of the PhoenixCare demonstration program of palliative care and co-
ordinated care/case management for seriously chronically ill individ-
uals who simultaneously received active treatment frommanaged care
organizations. Intensive home-based case management provided by
registered nurse case managers, in coordination with patients’ existing
source of medical care, comprised the intervention”.
In the remaining 17 studies, the main component was not directly
clear from the objective. In 15 studies (Wijkstra 1994; Strijbos
1996; Bendstrup 1997; Cambach 1997; Engstrom 1999; Güell
2000; Boxall 2005; Güell 2006; Fernandez 2009; Theander 2009;
Mendes 2010; Rice 2010; van Wetering 2010; Gottlieb 2011;
Wakabayashi 2011), we chose the main component of the inter-
vention as the component on which most of the time of the in-
tervention was spent. For example: Bendstrup 1997: “The inter-
vention programme lasted 12 weeks. The programme consisted of the
following components. Exercise training: the patients trained together
at the hospital for 1h, three times a week for 12 weeks. Occupational
therapy: two lessons each group. Education: 12 sessions. Smoking ces-
sation: only for patients wishing to stop smoking.”
In one study (Sridhar 2008) there were two components on which
most of the time of the intervention was spent (exercise and self
management action plan). In another study (Rea 2004) there were
two main components: self management action plan and struc-
tured follow-up. Therefore we arranged these two studies as sepa-
rate categories.
We made the following categories:
1. IDM dominant component exercise (13 studies: Wijkstra
1994; Strijbos 1996; Bendstrup 1997; Cambach 1997;
Engstrom 1999; Güell 2000; Boxall 2005; Güell 2006;
Fernandez 2009; Theander 2009; Mendes 2010; van Wetering
2010; Gottlieb 2011).
2. IDM dominant component self management with an
exacerbation action plan (five studies: Bourbeau 2003;
Wood-Baker 2006; Koff 2009; Rice 2010; Trappenburg 2011).
3. IDM structured follow-up with nurses/GP (five studies:
Littlejohns 1991; Smith 1999; Farrero 2001; Dheda 2004; Aiken
2006).
4. IDM exercise and self management action plan (one study:
Sridhar 2008).
5. IDM self management action plan and structured follow-
up (one study: Rea 2004)
6. IDM program of educational sessions, follow by a phase of
individually tailored education according to scores on the Lung
Information Needs Questionnaire score (one study: Wakabayashi
2011).
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In two studies, IDM was compared to another IDM intervention
and a control group (Strijbos 1996; Mendes 2010). Both studies
involved two intervention groups including an IDMprogramwith
a focus on exercise training and one control group. In both studies,
we combined and pooled data from the two intervention arms as
one group. One study had a cross-over design with drug treatment
after three months (Cambach 1997). Therefore, we used solely
the data for the intervention and control group at baseline and at
three months.
Control groups consisted of usual care in 20 studies, in two studies
control patients received a mono-disciplinary treatment includ-
ing optimization of drug treatment (Cambach 1997; Güell 2006)
and in four studies control patients received a treatment solely
with education (Wood-Baker 2006; Fernandez 2009; Rice 2010;
Wakabayashi 2011). Usual care consisted in all studies of regular
follow-up visits to health care providers, which depended on the
type of setting. There was access to health care providers on a ’need
to’ basis, without additional treatment or management programs.
In all studies, no attempts were made to influence this usual care.
Outcomes
We recorded the number of studies reporting a specific outcome
as follows:
• Quality of life (22 studies)
• Exercise capacity (18 studies)
• Exacerbation-related outcomes: measured by number of
exacerbations; hospital admissions; hospitalisation days;
emergency department (ED) visits; number of prednisolone or
antibiotics courses (15 studies)
• Lung function (14 studies)
• Survival, mortality (five studies)
• Depression (four studies)
• Dyspnea, measured by MRC Dyspnea score (three studies)
or Borg score (three studies)
• Co-ordination of care (three studies)
Details of the included studies are provided in Characteristics of
included studies.
We requested additional data from the authors of 14 studies. Of
these, 11 authors responded (79%) and six (43%) could provide
us with additional data. Therefore, it was not necessary to impute
missing data as described in our research protocol (see Dealing
with missing data).
Excluded studies
After the first selection based on abstract and title, 49 potentially
eligible studies were identified. Finally, after reading the full-text
papers, we excluded 23 studies for one of the following reasons:
1. not a RCT (n = 1);
2. no diagnosis of COPD or no obtainable results reported for
COPD as a subgroup (n = 2);
3. intervention includes one component of care (n = 3);
4. intervention includes one health care provider of different
disciplines (n = 4);
5. duration of intervention is less than three months (n = 4);
6. active treatment as a control group (n = 9).
The reasons for exclusion are further specified in Characteristics
of excluded studies. For ongoing studies, refer to Characteristics
of ongoing studies.
Risk of bias in included studies
For full details of ’Risk of bias’ judgments see Characteristics of
included studies and for an overview see Figure 2.
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Figure 2. ’Risk of bias’ summary: review authors’ judgments about each risk of bias item for each included
study.
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Allocation
Nineteen studies reported full details of adequate sequence gener-
ation and we judged them to be of low risk of bias. We judged the
remaining seven studies as having unclear risk of bias as they were
reported as randomised, but gave no description of the methods
used to conceal the sequence. Fourteen studies reported adequate
allocation concealment, while we judged four studies as high risk
of bias. There were insufficient details for the remaining six stud-
ies for us to reach a firm conclusion so we judged them to be at
unclear risk of bias. There were 13 studies in which both the se-
quence generation and concealment of allocation were adequately
described, thus selection bias was minimized in these studies.
Blinding
The nature of the intervention precludes the possibility of blind-
ing patients or health care providers. Therefore, we judged all the
studies, except Trappenburg 2011, to be at high risk of perfor-
mance bias. Trappenburg 2011 made a good attempt in using a
modified informed consent procedure (postponed information),
which meant that patients were unaware of the major aim of the
study (education and an action plan), thereby enabling a single-
blind study design (Trappenburg 2011). Therefore, we scored this
study as low risk of bias. While blinding of health care providers
and patients is impossible with this type of intervention, outcome
assessors could be blinded to participants’ allocation. This was re-
ported in nine trials indicating a low risk of bias. Outcome as-
sessors were unblinded in seven studies (high risk) and 10 studies
provided insufficient information (unclear risk).
Incomplete outcome data
We judged 19 out of the 26 studies as low risk of bias, as they had
low drop-out rates, drop-out rates were balanced across groups or
trial authors performed an intention-to-treat analysis. We rated
seven studies as high risk of bias and they were likely to be subject
to attrition bias. Three out of these seven studies (Dheda 2004;
Mendes 2010; Gottlieb 2011) had unbalanced drop-out rates,
with higher rates in the intervention group compared to the con-
trol group. One study had a high drop-out rate balanced in both
groups (31%) and the authors performed no intention-to treat-
analysis (Bendstrup 1997). Cambach 1997 excluded all patients
who did not return for one or more of the assessments from the
final analyses. In Farrero 2001, quality of life was only investigated
in the first 40 consecutive patients, therefore inducing risk of bias.
In Smith 1999, all control participants refused to fill in the quality
of life questionnaire and expressed that the burden of participating
in a study, including questionnaires, was greater than expected.
Selective reporting
We rated 21 studies as low risk of bias and five studies as high risk of
bias. Three studies (Rice 2010; van Wetering 2010; Trappenburg
2011) published a study protocol, with which we could compare
the results sections. In the other studies, we checked whether the
outcomes reported in the methods section of the article were re-
ported in the results section. Five studies (Littlejohns 1991; Smith
1999; Bourbeau 2003; Dheda 2004; Gottlieb 2011) selectively
reported outcomes. In two studies (Bourbeau 2003; Dheda 2004)
the authors reported no statistically significant difference in the
outcome and therefore did not present data, indicating selection
bias. In the other three studies (Littlejohns 1991; Smith 1999;
Gottlieb 2011), it remained unclear why it was planned to mea-
sure an outcome but it was not ultimately published.
Other potential sources of bias
We included two cluster-randomized trials (Rea 2004; Wood-
Baker 2006). Unfortunately, both studies introduced noteworthy
biases related to cluster-randomization in different ways. In one
study (Wood-Baker 2006) recruitment bias remained unclear, as
the authors provided insufficient information regarding the clus-
ter-randomization process. In contrast, we judged Rea 2004 to
have low risk of bias, as clusters were randomised before patients
were recruited. Furthermore, we rated both studies as high risk
of bias for baseline imbalance between groups, which could have
been reduced when stratified or if pair-matched randomisation
of the clusters had been used instead (Higgins 2011). In the Rea
2004 study, there was loss to follow-up of five clusters (four con-
trol and one intervention cluster), therefore this study was subject
to bias. There was no follow-up of clusters in Wood-Baker 2006
(low risk of bias). Finally, both studies introduced bias as they an-
alyzed data by incorrect statistical methods, not taking the clus-
tering into account. This may account for the over-precise results
and can result in much more weight in a meta-analysis (Higgins
2011). Therefore, in our meta-analyses we adjusted for the design
effect by reducing the size of the trial to its “effective sample size”
(Rao 1992). Based on similar primary care cluster-randomized tri-
als, we used an intra-class correlation coefficient (ICC) of 0.01
(Kerry 1998; Campbell 2001). For dichotomous data, we divided
both the number of participants and the number experiencing the
event by the design effect. For continuous data, we reduced the
sample sizes; means and standard deviations remained unchanged
(Higgins 2011).
Effects of interventions
See: Summary of findings for the main comparison Integrated
disease management compared to control for patients with chronic
obstructive pulmonary disease
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In the majority of the outcomes, heterogeneity was not encoun-
tered. However, there was substantial heterogeneity present in
SGRQ total score, six-minute walk distance (6MWD), CRQ dys-
pnoea (long-term), hospital admissions for all causes, hospital days
and ED visits. If possible, we performed sensitivity and subgroup
analysis on these outcomes to see if the heterogeneity could be
explained. Our a priori determined subgroup analysis based on
type of health care provider and the frequency and duration of in-
tervention was impossible, as there was large heterogeneity among
combinations of health care providers and the exact composition
in terms of duration, frequency and intensity of programs was of-
ten not clearly reported. In addition, we were not able to perform
subgroup analysis on GOLD stage or MRC Dyspnea score, as
most studies did not report GOLD stages or MRCDyspnea score.
Furthermore, the definitions and classifications of GOLD stages
have been changed over the years, resulting in large variation in
severity within subgroups.
Instead, we performed subgroup analysis based on type of setting
of the intervention (primary, secondary, tertiary care) and type of
control group. Furthermore, we performed subgroup analysis with
regard to the dominant component of the IDM program.
We used unadjusted data for meta-analyses, as only unadjusted
data were reported, with the exception of two studies (van
Wetering 2010; Trappenburg 2011).
Primary outcomes
1. Quality of life
Of the 26 included studies, 23 measured HRQoL using six differ-
ent instruments (see Characteristics of included studies):
1. St. George’s Respiratory Questionnaire (SGRQ) (13
studies);
2. Chronic Respiratory Questionnaire (CRQ) (eight studies);
3. Short Form-36 (SF-36) (three studies);
4. Sickness Impact Profile (SIP) (two studies);
5. Dartmouth Primary Care Co-operative Quality of Life
questionnaire (COOP) (one study).
The SGRQ and CRQ are both disease-specific quality of life ques-
tionnaires. However, a meta-analysis combining CRQ and SGRQ
score should not be used as Puhan 2006 has shown that the CRQ
is more responsive than the SGRQ. Furthermore, the included
generic quality of life questionnaires (SF-36, SIP and COOP)
measure other dimensions of generic health quality of life, and
therefore combining data in a meta-analysis across tools was not
possible.
1.1 Respiratory-specific QoL
1.1.1.1 SGRQ total score - short-term
The SGRQ is a disease-specific, validated questionnaire with a
scale from 0 (good health) to 100 (worse health status). A negative
sign on this questionnaire indicates improvement, and the min-
imal clinically important difference (MCID) is -4 points (Jones
1991). Thirteen studies with a total population of 1425 patients
provided data on the SGRQ total score with a follow-up of 3 to
12 months (Engstrom 1999; Bourbeau 2003; Dheda 2004; Boxall
2005; Wood-Baker 2006; Koff 2009; Fernandez 2009; Theander
2009;Rice 2010; vanWetering 2010;Gottlieb 2011;Trappenburg
2011; Wakabayashi 2011). The pooled mean difference (MD) on
the SGRQ total score was -3.71 in favor of IDM (95% confidence
interval (CI) of -5.83 to -1.59; Analysis 1.1; Figure 3; Summary
of findings for the main comparison) which reached statistical sig-
nificance (P < 0.001) and was close to, but did not reach, the
MCID of -4 points. In other words, those treated with IDM had
3.71 out of 100 points better quality of life on this questionnaire.
Pooling indicated a high degree of heterogeneity (I² = 56%, P =
0.01). Heterogeneity was due to differences in the quality of stud-
ies. We were able to reduce heterogeneity if we performed multi-
ple sensitivity analyses based on studies with adequate allocation
concealment, adequate blinding of outcome assessment, cluster-
randomization bias, or studies analyzing outcomes by intention-
to-treat. Sensitivity analysis on studies with adequate allocation
concealment (Bourbeau 2003; Boxall 2005; Koff 2009; Theander
2009; van Wetering 2010; Gottlieb 2011; Trappenburg 2011;
Wakabayashi 2011) demonstrated that there was still a statistically
significant effect in favor of the intervention group (MD -3.16;
95% CI -4.75 to -1.57, P < 0.001). In the same way, in trials
(Engstrom 1999; Bourbeau 2003; vanWetering 2010; Rice 2010;
Trappenburg 2011; Wakabayashi 2011) with adequate blinding
of outcome assessment the effect did not change (MD -3.16; 95%
CI -4.81 to -1.51, P < 0.001). A sensitivity analysis excluding the
cluster-randomized study of Wood-Baker 2006, in which there
was an unclear risk of recruitment bias and a high risk of bias on
baseline imbalance, the effect changed to a clinically and statisti-
cally significant MD in favor of IDM (-4.22; 95% CI -6.14 to -
2.30, P < 0.001). Lastly, a sensitivity analysis on the studies that
analyzed the data using the intention-to-treat principle (Bourbeau
2003; Rice 2010) showed a statistically significant and clinically
relevant difference in favor of IDM (MD -4.65; 95% CI -6.69 to
-2.62, P < 0.0001) compared to controls.
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Figure 3. Forest plot of comparison: 1 Integrated disease management versus control, outcome: 1.1 SGRQ:
short-term (3 to 12 months).
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Subgroup analysis based on type of setting
There were six studies conducted in primary care on 456 partic-
ipants (Boxall 2005; Wood-Baker 2006; Koff 2009; Fernandez
2009; van Wetering 2010; Gottlieb 2011) and seven studies in
secondary care on 969 participants (Engstrom 1999; Bourbeau
2003; Dheda 2004; Theander 2009; Rice 2010; Trappenburg
2011; Wakabayashi 2011). No studies were performed in tertiary
care. Subgroup analysis based on primary care studies showed a
clinically relevant mean difference of -4.68 (95% CI -8.80 to -
0.56) in favor of IDM. This result was statistically significant and
clinically relevant. Subgroup analysis on secondary care studies
showed a statistically significant difference of -3.41 (95%CI -5.97
to -0.85)(Analysis 1.3). This difference was not clinically relevant.
The test for subgroup difference did not show a statistically signif-
icant difference in treatment effects in patients treated in different
types of health care setting (Chi² = 0.27, df = 1 (P = 0.61)).
Subgroup analysis based on study design
We performed subgroup analysis based on study design and com-
pared RCTs (n = 1304) versus cluster-RCTs (n = 121). There was
no difference in SGRQ total score between intervention and con-
trol in the cluster-RCT ofWood-Baker 2006 (MD2.30; 95%CI -
1.62 to 6.22; Analysis 1.4). Pooled meta-analysis of RCTs showed
a clinically relevant effect in favor of the IDM group of -4.22 (95%
CI -6.14 to -2.30, P < 0.0001). The test for subgroup differences
showed a statistically significant difference between the pooled
analysis of the RCTs and the effect in the cluster-RCT (Chi² =
8.57, df = 1 (P = 0.003)).
Subgroup analysis based on type of control group
In nine studies including 744 participants, control patients re-
ceived usual care, and in four studies (n = 681) the control group
received a mono-disciplinary treatment of education. Meta-analy-
sis of the usual care studies showed a significant difference between
groups of -4.09 (95% CI -6.35 to -1.84, P < 0.001) (Analysis
1.5). Subgroup analysis of studies in which the control group re-
ceived education showedno significant difference in effect between
groups (MD -2.98; 95% CI -7.69 to 1.74, P = 0.022), which was
neither statistically nor clinically relevant. There was no statisti-
cally significant difference in the test for subgroup difference (Chi²
= 0.17, df = 1 (P = 0.68)).
Subgroup analysis based on dominant component of the
program
There were four studies including 942 patients (Bourbeau 2003;
Wood-Baker 2006; Koff 2009; Rice 2010) in which self manage-
ment was the dominant component, and six studies including 373
patients in which exercise training was the dominant component
(Engstrom 1999; Boxall 2005; Theander 2009; Fernandez 2009;
van Wetering 2010; Gottlieb 2011). One study (Wakabayashi
2011) evaluated an individual tailored education program and one
study (Dheda 2004) focused mainly on structured follow-up with
nurses and GPs. Subgroup analysis of the self management studies
revealed neither a statistically nor a clinically relevant mean differ-
ence:MD -2.76 (95%CI -5.88 to 0.36, P = 0.08). Subgroup anal-
ysis of exercise studies showed a statistically and clinically relevant
difference of -4.74 in favor of IDM (95% CI -7.05 to -2.43, P <
0.0001). There was no statistically significant difference between
subgroups (Chi² = 1.00, df = 1 (P = 0.32)) (Analysis 1.6).
1.1.1.2. SGRQ - long-term
Two studies including 189 participants measured the long-term
effect on the SGRQ total score: at 18 (Gottlieb 2011) and 24
(vanWetering 2010) months follow-up. There was no statistically
significant difference between groups (MD -0.22; 95% CI -7.43
to 6.99, P = 0.95; I² = 54%, P = 0.14)(Analysis 1.2).
1.1.2.1 SGRQ domain scores - short-term
Eleven studies with a total population of 1377 patients reported
scores on the SGRQ domains of symptoms, activity and impact.
For all domains, there was no significant heterogeneity (I² between
35% and 28%) (Analysis 1.1). We found the following results:
• Symptom domain: MD -2.39 (95% CI -5.31 to 0.53, P =
0.11)
• Activity domain: MD -2.70 (95% CI -4.84 to -0.55, P =
0.01)
• Impact domain: MD -4.04 (95% CI -5.96 to -2.11, P <
0.0001)
1.1.2.2. SGRQ domain scores - long-term
Two studies measured the long-term effect on the SGRQ at 18
months (van Wetering 2010; Gottlieb 2011). Mean differences
on all domains had wide confidence intervals and included zero
(Analysis 1.2).
1.1.3.1. CRQ domain scores - short-term
The Chronic Respiratory Disease Questionnaire (CRQ), with a
scale from 0 to 7 and a MCID of 0.5, was reported in eight trials
(Wijkstra 1994; Bendstrup 1997; Cambach 1997; Güell 2000;
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Farrero 2001;Rea 2004;Güell 2006; Sridhar 2008). Three of these
(Bendstrup 1997; Farrero 2001; Rea 2004) could not be used in a
meta-analysis. Bendstrup 1997 andRea 2004 reported insufficient
data and the authors could not provide us with additional data.
In addition, Farrero 2001 administered the CRQ in the first 40
consecutive patients and therefore outcomes were not published.
The pooled results of four studies including 160 participants
(Wijkstra 1994; Cambach 1997; Güell 2000; Güell 2006) mea-
suring the CRQ until 12 months follow-up are shown in Figure 4
and Analysis 1.7. For each of the CRQ domains, theMDwas well
above the MCID of 0.5 units and differences in scores were statis-
tically significant: dyspnoea (MD 1.02; 95% CI 0.67 to 1.36, P
< 0.0001), fatigue (MD 0.82; 95% CI 0.46 to 1.17, P < 0.0001),
emotion (MD 0.61; 95% CI 0.26 to 0.95, P < 0.0005) and mas-
tery (MD 0.75; 95% CI 0.38 to 1.12, P < 0.0001). The results
showed homogeneity across studies.
Figure 4. Forest plot of comparison: 1 Integrated disease management versus control, outcome: 1.7 CRQ:
short-term (3 to 12 months).
1.1.3.2. CRQ domain scores - long-term
Two studies (n = 151) (Güell 2000; Sridhar 2008) measured the
long-term effectiveness on CRQ domain scores at 24 months fol-
low-up(Analysis 1.8). There was no difference between groups on
the CRQ dyspnoea domain: MD 0.47 (95% CI -0.31 to 1.25, P
= 0.24). Pooled data showed substantial heterogeneity (I² = 70%,
P = 0.07), which was related to differences in the type of interven-
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tion (exercise in the Güell 2000 study versus structured follow-up
with a respiratory nurse and exacerbation plan in Sridhar 2008).
Güell 2000 demonstrated a significant difference in favor of IDM
(MD 0.92; 95% CI 0.19 to 1.65, P = 0.01). In contrast, there was
no statistically significant difference between groups on the CRQ
dyspnoea domain in Sridhar 2008 (MD 0.12; 95% CI -0.32 to
0.58, P = 0.61).
Pooled mean differences on the domains fatigue, emotion and
mastery showed homogeneity across studies. On the CRQ fatigue
domain, there was a statistically significant but not clinically rele-
vant difference of 0.45 in favor of IDM (95% CI 0.05 to 0.85, P =
0.03). On the CRQ emotion and mastery domain, the statistically
and clinically relevant effect was in favor of IDM: emotion MD
0.53 (95%CI 0.10 to 0.95, P = 0.02) and masteryMD0.80 (95%
CI 0.37 to 1.23, P < 0.01).
1.2 General health-related QoL
General HRQoL was measured with the SF-36 in three studies
(Dheda 2004;Rea 2004; Aiken 2006). The authors of these studies
could not provide us with sufficient data for pooling in a meta-
analysis. Neither study found a significant effect between groups.
Two of these studies (Dheda 2004; Aiken 2006) suffer from small
sample sizes varying from 15 to 10 patients per group per study,
whichmakes it difficult to detect an effect (underpowered studies).
We pooled the data from two studies (Littlejohns 1991; Engstrom
1999) reporting data on the SIP (Analysis 1.9). No between-group
differences in any domain of the SIP were found. One other study
used the YorkQuality of LifeQuestionnaire (Bendstrup 1997) and
reported no significant difference. Smith 1999 used a modified
version of the Dartmouth Primary COOP. In this study, the au-
thors analyzed only the data from the intervention group (n = 30)
due to lack of data in the control group. The authors concluded
that the total COOP scores in the intervention group significantly
improved HRQoL at 12 months.
2. Exercise capacity
Seventeen studies measured exercise capacity using either the
6MWD or the cycle ergometer test. The MCID on the 6MWD is
estimated at 35 meters (Puhan 2008). There is noMCID reported
in the current literature for the cycle ergometer test. Results are
shown in Figure 5.
Figure 5. Forest plot of comparison: 1 Integrated disease management versus control, outcome: 1.10
Functional exercise capacity: 6MWD mean difference.
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2.1.1 Functional exercise capacity - short-term
We pooled data from 14 studies using the 6MWD including 871
participants. One study could not be pooled, as the authors re-
ported no data because there was no significant difference between
groups at 12 months follow-up (Bourbeau 2003).
Patients treatedwith IDMimproved their 6MWDby a statistically
and clinically relevant 43.86 meters (95% CI 21.83 to 65.89)(
Figure 5; Analysis 1.10). There was heterogeneity between the
results of the studies (I² = 83%). This heterogeneity is explained
by differences in the quality of studies. We performed sensitivity
analysis on studies with adequate allocation concealment, which
reduced heterogeneity (I² = 0%) and reduced the effect to a MD
of 15.15 meters, which was still statistically significant (95% CI
6.37 to 23.93, P < 0.001), however no longer clinically relevant.
Furthermore, we performed subgroup analysis based on type of
setting, type of control group and dominant component of the
intervention.
Subgroup analysis based on type of setting
There were seven studies with 427 participants (Wijkstra 1994;
Cambach 1997; Boxall 2005; Fernandez 2009; van Wetering
2010; Mendes 2010; Gottlieb 2011) conducted in primary care,
seven studies with 438 participants (Littlejohns 1991; Bendstrup
1997; Engstrom 1999; Güell 2000; Theander 2009; Mendes
2010; Wakabayashi 2011) in secondary care and one study in ter-
tiary care with 35 participants (Güell 2006). Both subgroup anal-
yses showed similar statistically and clinically relevant improve-
ments: exercise training in primary care revealed a MD of 45.16
meters (95%CI 8.65 to 81.67, P = 0.02), whereas in the secondary
care setting the MD was 49.18 meters (95% CI 14.28 to 84.08,
P = 0.006). The tertiary care study showed a significant effect in
favor of IDM of 85 meters (95% CI 30.43 to 139.57). Results are
shown in Analysis 1.11 and Figure 6.
Figure 6. Forest plot of comparison: 1 Integrated disease management versus control, outcome: 1.11
Subgroup analysis 6MWD based on type of setting.
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Subgroup analysis based on control group
We pooled four studies with 180 participants in which control
patients received a treatment with optimal medication (Cambach
1997; Güell 2006) or an education session (Fernandez 2009;
Wakabayashi 2011) in a subgroup analysis. In the same way, we
pooled 10 studies (Littlejohns 1991; Wijkstra 1994; Bendstrup
1997; Engstrom 1999; Güell 2000; Boxall 2005; Theander 2009;
Mendes 2010; van Wetering 2010; Gottlieb 2011) including 691
participants in which the control group consisted of usual care.
Subgroup analysis in which one component of treatment was used
showed no difference between groups (MD 35.99; 95% CI -5.34
to 77.31, P = 0.09)(Analysis 1.12). In studies in which the control
group consisted of usual care, the 6MWD improved clinically and
statistically significantly by 46.59 meters in favor of IDM (95%
CI 19.68 to 73.51, P = 0.0007). However, the test for subgroup
differences did not show any difference between control groups
(Chi² = 0.18, df = 1 (P = 0.67)).
Subgroup analysis based on dominant component of
intervention
Twelve out of the 14 studies (n = 653) measuring exercise capacity
incorporated some kind of exercise training in their IDM pro-
grams. We performed subgroup analysis, which showed that the
6MWDimproved by 51.47meters (95%CI 26.53 to 76.40). This
effect was statistically and clinically relevant. In the remaining two
studies (n = 218), exercise was not part of the IDM programs.
In one study (Wakabayashi 2011), which consisted of individu-
ally tailored education sessions, there was no difference between
groups (MD 0.40; 95% CI -39.64 to 40.44, P = 0.98). The other
study (Littlejohns 1991), in which there was a focus on structured
follow-up with GP and nurses, revealed no effect (MD 3.50; 95%
CI -28.31 to 35.31, P = 0.83). In conclusion, studies incorporat-
ing exercise training in their IDM programs demonstrated larger
effect sizes; this was statistically significant using the test for sub-
group difference (Chi² = 7.49, df = 2 (P = 0.02))(Analysis 1.13).
2.1.2 Functional exercise capacity - long-term
Two studies on 184 participants published long-term results on
the 6MWD (van Wetering 2010; Gottlieb 2011). Both studies
showed that IDM statistically significantly improved exercise ca-
pacity measured on the 6MWD by 16.8 meters (MD 16.84; 95%
CI 3.01 to 30.67) compared to the control group. However, this
effect did not exceed the MCID. There was no heterogeneity
present. Results are shown in Figure 5 and Analysis 1.10.
2.2. Maximal exercise capacity
Four studies on 298 participants assessed the maximal exercise
capacity (in Watts) using the cycle ergometer test. Both studies
showed that IDM statistically significantly improved the maximal
exercise capacity by 7 Watts (MD 6.99; 95% CI 2.96 to 11.02, P
< 0.0001)(Analysis 1.14).
3. Exacerbations
3.1.1 Number of patients experiencing at least one
exacerbation - short-term
Two studies (Bourbeau 2003; Trappenburg 2011) including 407
patients reported on the number of patients experiencing at least
one exacerbation during 12 months of follow-up. Both studies
used the same definition and defined an exacerbation as an increase
in symptoms, with deterioration of dyspnoea or purulent sputum.
Pooled meta-analysis showed homogeneity and a pooled OR of
1.21 (95% CI 0.77 to 1.91) (Analysis 1.15), which showed no
statistically or clinically relevant difference between groups. The
trial authors of the Bourbeau 2003 study reported that although
there were more patients experiencing at least one exacerbation in
the intervention group (85 versus 81), the total number of exac-
erbations was higher in the control group (362) compared to the
intervention group (299). This was of borderline significance (P =
0.06). Similarly, the number of patients experiencing three ormore
exacerbations during 12-month follow-up was higher in the con-
trol group (67.9%), compared to the action plan group (62.3%).
Exacerbations in the intervention group were treated successfully
at an early stage, which probably resulted in fewer patients with a
hospital admission (17.2% versus 36.3%, P < 0.01). Trappenburg
2011 reported similar findings: although exacerbation rates did
not differ between groups, exacerbations in the action plan group
were perceived as substantially milder by patients, and they re-
ported on average three days faster than those in the control group.
3.1.2. Number of patients experiencing at least one
exacerbation - long-term
Two studies (Sridhar 2008; van Wetering 2010) including 301
patients assessed the number of patients experiencing at least one
exacerbation at 24 months follow-up. Both studies related the def-
inition of an exacerbation to health care. Sridhar 2008 stated they
defined an exacerbation as the “unscheduled need for healthcare, or
need for steroid tablets, or antibiotics for worsening of their COPD”.
Similarly, van Wetering 2010 defined a moderate exacerbation as
“a visit to the general practitioner or respiratory physician in com-
bination with a prescription of antibiotics and/or prednisolone or a
visit to the emergency department or day care of a hospital, which ac-
cording to the patient, was related to a COPD exacerbation. A severe
exacerbation was defined as a hospitalisation for a COPD exacerba-
tion”. Pooled meta-analysis demonstrated no difference between
groups (OR 1.53; 95% CI 0.90 to 2.60, P = 0.12) (Analysis 1.16).
There was homogeneity between studies. Sridhar 2008 stated that
patients in the intervention group were more likely to have ex-
acerbations treated with oral steroids alone or oral steroids and
antibiotics than the control group. The initiator of treatment was
statistically more likely to be the patient themselves compared to
the GP in the control group.
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3.1.3 Mean exacerbation rate - long-term
Two studies (Güell 2000; van Wetering 2010) including 226 par-
ticipants reported on the exacerbation rate in both groups at 24
months follow-up. Data on exacerbations were skewed in the van
Wetering study, therefore we decided not to pool both studies in
a meta-analysis. In Güell 2006, control group patients (n = 23)
experienced 207 exacerbations, with an average of 6.9 (3.9) exac-
erbations per patients, ranging from 0 to 16 exacerbations during
the 24 months. The IDM group experienced 111 exacerbations,
with an average of 3.7 (2.2) exacerbations per patients, ranging
from 0 to 9 exacerbations during the 24 months. This difference
was statistically significant (P < 0.0001) favoring IDM. In van
Wetering 2010, the exacerbation rate was 2.78 in the IDM group
and 2.16 in the control group, resulting in a rate ratio of 1.29
(95% CI 0.89 to 1.87), which was not statistically significant (P
= 0.113).
3.2.1 Hospital admissions, all causes - short-term
Two studies on 266 participants (Littlejohns 1991; Rea 2004)
reported data on the number of patients who were admitted for
all causes until 12 months follow-up. There was no heterogeneity
and there was no difference between groups (OR 0.62; 95% CI
0.36 to 1.07, P = 0.49) (Analysis 1.17).
3.2.2. Hospital admissions, all causes - long-term
Two studies including a total of 283 patients (Sridhar 2008; van
Wetering 2010) assessed the number of patients admitted until
24 months follow-up. Pooled results showed heterogeneity (I² =
53%), which could be explained as van Wetering 2010 showed
a positive effect in favor of IDM and Sridhar 2008 showed no
significant difference in effect between groups. Therefore, a pooled
meta-analysis showed no difference between groups (OR 0.78;
95% CI 0.38 to 1.57)(Analysis 1.18).
3.3.1. Respiratory-related admissions - short-term
We pooled data from seven studies (Smith 1999; Bourbeau 2003;
Rea 2004; Boxall 2005; Koff 2009; Rice 2010; Trappenburg 2011)
measuring respiratory-related admissions until 12 months follow-
up in a meta-analysis. Studies were homogeneous. Pooled esti-
mates showed a statistically significant difference in favor of IDM
(OR 0.68; 95% CI 0.47 to 0.99, P = 0.04)(Analysis 1.19). In the
control group 27 people out of 100 had a respiratory-related hos-
pital admission over 3 to 12 months, compared to 20 (95% CI
15 to 27) out of 100 in the integrated disease management group,
as presented in Figure 7. Over the course of a year, the number
needed to treat with IDM to prevent one hospital admission was
NNT(B) 15 (95% CI 9 to 506).
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Figure 7. In the control group 27 people out of 100 had a respiratory-related hospital admission over 3 to 12
months, compared to 20 (95% CI 15 to 27) out of 100 for integrated disease management group.
3.3.2. Respiratory-related admissions - long-term
Data from one trial (van Wetering 2010) presented data on the
number of patients admitted until 24 months follow-up. There
was no difference between the control and IDM group on the
number of respiratory-related admissions (OR 0.59; 95%CI 0.28
to 1.22, P = 0.16)(Analysis 1.20).
3.4.1 Hospital days per patient - short-term
Six studies on 741 patients (Engstrom 1999; Farrero 2001;
Bourbeau 2003; Rea 2004; Boxall 2005; Trappenburg 2011) re-
ported the difference in mean hospitalisation days per patient per
group (intervention versus control). Patients treated with IDM
were on average discharged from the hospital nearly four days ear-
lier compared to control patients, with a confidence interval from
six to two days (MD -3.78; 95% CI -5.90 to -1.67, P < 0.001)
(Analysis 1.21). There was heterogeneity in the results (I² = 55%).
Inspection of the forest plot shows that this was the result of one
outlying study (Engstrom 1999), which reported more days for
intervention patients. The authors stated that the data on admis-
sion days in his study were skewed, as one patient accounted for
50% of the increase in the IDM group. Reanalysis with exclusion
of this trial did not change the significance, direction or effect of
the mean difference.
3.4.2. Hospital days per patient - long-term
One trial with 175 patients (van Wetering 2010) reported the
difference in mean number of total hospital days per patient per
group at 24 months follow-up. There was no difference between
groups (MD 0.60; 95% CI -3.01 to 4.21, P = 0.74) (Analysis
1.22).
3.5 Emergency Department (ED) visits
Six trials (Smith 1999; Farrero 2001; Bourbeau 2003; Rea 2004;
Rice 2010; Wakabayashi 2011) assessed in various ways the num-
ber of ED visits. We were able to pool the data from four studies
with 1161 patients (Smith 1999; Bourbeau 2003; Rea 2004; Rice
2010), which revealed no difference between groups with high
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heterogeneity (OR 0.64; 95%CI 0.33 to 1.25; I² = 71%)(Analysis
1.23). Sensitivity analysis on two studies which analyzed by in-
tention-to-treat and which blinded outcome assessors revealed a
mean difference of 0.49 in favor of the control group (MD 0.49;
95% CI 0.36 to 0.67, P < 0.0001, I² = 0%). Three studies could
not be pooled, due to lack of required data. Of these excluded
studies, Trappenburg 2011 and Wakabayashi 2011 reported the
mean ED visits per patient at baseline and follow-up. Both stud-
ies concluded no statistically significant difference between groups
compared to baseline. On the other hand, Farrero 2001 reported
a significant decrease in ED visits per patient in favor of the IDM
group (0.45 ± 0.83 for intervention group, 1.58 ± 1.96 for control
group; P = 0.0001). There were no data presented on the number
of ED visits at long-term follow-up.
3.6 Patients using at least one course of oral steroids
We pooled data from three studies including 348 patients
(Littlejohns 1991; Farrero 2001; Rea 2004) on the number of pa-
tients using at least one course of oral steroids until 12 months
follow-up. Results were homogeneous and there was no differ-
ence between groups (OR 1.13; 95% CI 0.64 to 2.01, P = 0.66)
(Analysis 1.24).
3.7. Patients using at least one course of antibiotics
There were two studies with 236 participants (Littlejohns 1991;
Rea 2004) reporting on the number of patients using at least one
course of antibiotics. The studies presented conflicting results and
heterogeneity was large, as Rea 2004 was a primary care, cluster-
randomized trial and Littlejohns 1991 was a RCT in the secondary
care setting. The number of patients using at least one course of
antibiotics was not different between groups, and the OR had a
wide confidence interval (OR 1.43; 95% CI 0.24 to 8.48, P =
0.69)(Analysis 1.25).
Secondary outcomes
4. Dyspnea
Four studies reported the MRC Dyspnea Scale as an outcome
(Mendes 2010; van Wetering 2010; Gottlieb 2011; Wakabayashi
2011), however Gottlieb failed to publish any results. We pooled
data from the remaining three studies, including 345 patients.
Dyspnea was improved in the IDM group by -0.30 points (MD -
0.30; 95% CI -0.48 to -0.11, I² = 0%, P < 0.001)(Analysis 1.26).
Furthermore, three studies on 145 patients used the Borg score to
detect changes in perceived dyspnoea (Güell 2000; Boxall 2005;
Gottlieb 2011). These data were pooled and revealed no change
in dyspnoea (MD 0.14; 95% CI -0.70 to 0.98, P = 0.74, I² =
39%)(Analysis 1.27).
5. Mortality
Five trials assessing 1207 patients explicitly recorded mortality as
an outcome. Of these, four trials assessed mortality at 12 months
(Littlejohns 1991; Smith 1999; Farrero 2001; Rice 2010) and one
study at 24 months (Sridhar 2008). There was no statistically sig-
nificant difference between groups at short- (OR 0.96; 95% CI
0.52 to 1.74, P = 0.33; I² = 59%) and long-term follow-up (OR
0.45; 95%CI 0.16 to 1.28, P = 0.13) (Analysis 1.28).Heterogene-
ity in the short-term studies is due to different dominant compo-
nents of the interventions.
6. Lung function
Lung function was measured in three different ways in 10 tri-
als (Littlejohns 1991; Wijkstra 1994; Güell 2000; Farrero 2001;
Bourbeau 2003; Wood-Baker 2006; Sridhar 2008; Fernandez
2009; vanWetering 2010;Wakabayashi 2011). Therefore, we cre-
ated three different subgroups, which we pooled in two different
meta-analyses: forced expiratory volume in one second (FEV1) in
liters and FEV1 as per cent predicted for age, gender and height
(FEV1% predicted), as well as themean difference in FEV1% pre-
dicted from baseline. All pooled data on short- as well as on long-
term outcome revealed no significant difference in lung function
between groups(Analysis 1.29; Analysis 1.30).
7. Anxiety and depression
Four studies assessed depression as an outcome (Engstrom 1999;
Littlejohns 1991; Güell 2006; Trappenburg 2011). Two studies
(Littlejohns 1991; Trappenburg 2011) used the HADS, one study
(Engstrom 1999) used the Mood Adjective Check List (MACL)
and one study (Güell 2006) used a Revised Symptom Check-
list. We pooled results on the HADS in a meta-analysis includ-
ing 316 patients, which revealed no statistically significant dif-
ference between groups for anxiety (MD 0.22; 95% CI -0.41
to 0.85, I² = 0%) or depression (MD 0.21, 95% CI -0.39 to
0.81, I² = 0%)(Analysis 1.31). Engstrom 1999 used the MACL,
a shortened 38-item version covering three basic dimensions of
mood: pleasantness/unpleasantness, activation/deactivation and
calmness/tension. No significant differences were found between
groups. The aim of Güell 2006 was specifically to evaluate the ef-
fect of a pulmonary rehabilitation program on psychosocial mor-
bidity (without including any specific psychological intervention),
as well as effort capacity and HRQoL. Therefore, the authors used
a Revised Symptom Checklist, containing 90 items, which in-
cluded depression and anxiety. Following a per protocol analysis,
the intervention group showed a significant improvement in de-
pression (P ≤ 0.01) and anxiety (P ≤ 0.05).
8. Co-ordination of care
Three studies (Littlejohns 1991; Bendstrup 1997; Koff 2009) re-
ported in some way on the co-ordination of care. However, these
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studies had different intervention programs and reported on co-
ordination of care in different ways. Therefore, interpretation of
outcomes is difficult. Bendstrup 1997 reported an attendance rate
of 78% of patients following a 12-week IDM program (consist-
ing of education, exercise training, smoking cessation and occu-
pational therapy).
Patient satisfaction with regard to the provided health care was
measured in two studies. In Koff 2009, satisfaction with a self
management/action plan programwas assessed on a scale from1 to
10 in the intervention group, with 1 being strongly dissatisfied and
10 completely satisfied. Patients expressed high satisfactionwith all
of the equipment used, except for the pedometer. Littlejohns 1991
designed a satisfaction questionnaire for his study, which included
questions on satisfaction with level of care, the information given
to patients and their knowledge of medication. The questionnaire
was used in both study groups. At 12 months follow-up, there was
little difference in the level of satisfaction with the service provided
between groups.
D I S C U S S I O N
Summary of main results
We reviewed the results of 26 randomised controlled trials evaluat-
ing the effect of an integrated diseasemanagement (IDM)program
in patients with COPD. All included studies contained a program
provided by caregivers from at least two different disciplines, with
two different components (for example exercise, education, self
management etc) and with a duration of at least three months.
Firstly, pooled data showed statistically and clinically relevant im-
provements in disease-specific quality of life on the CRQ in the
IDM group: dyspnoea (MD 1.02; 95% CI 0.67 to 1.36); fatigue
(0.82; 95% CI 0.46 to 1.17); emotional (0.61; 95% CI 0.26 to
0.95) and mastery (0.75; 95% CI 0.38 to 1.12). All domains (dys-
pnoea, fatigue, emotional and mastery) exceeded the minimum
clinically relevant difference until 12 months follow-up. Only two
studies measured long-term results on the CRQ, which showed
that the positive effect wasmaintained for the fatigue, emotion and
mastery domains at 24 months follow-up. Furthermore, disease-
specific quality of life was also measured with the SGRQ. There
was considerable heterogeneity in the score on the SGRQ. After
multiple sensitivity analyses, we concluded that there was a dif-
ference in the SGRQ total score in favor of patients treated with
IDM, which lies around the minimal clinically relevant difference
of four units. The effect was greatest for the impact domain. We
could not find a difference in the SGRQ total score at long-term
follow-up. Remarkably, only two studies could provide data.
Second, the pooled data showed statistically significant improve-
ments in maximal and functional exercise capacity, with an im-
provement of 7 Watts and 44 meters in favor of the IDM group,
respectively. Sensitivity analysis of the 6MWD lowered the effect
to 15 meters, indicating the likelihood of an overestimated effect
in the lower quality studies.
Thirdly, the total number of patients with at least one respiratory-
related hospital admission decreased from 27 per 100 to 20 per
100 patients in favor of the intervention group, with a number
needed to treat of 15 patients to prevent one being admitted to
hospital over three to 12 months. Mean hospitalisation days de-
creased on average by three days in the IDM group. The effects
on the aforementioned primary outcomes are summarized in the
Summary of findings for the main comparison. There was no evi-
dence of an effect on generic quality of life, the number of patients
with at least one exacerbation, the number of hospital admissions
for all causes, emergency department visits, courses of antibiotics/
prednisolone, dyspnoea, lung function parameters or depression
scores.
Overall completeness and applicability of
evidence
We found sufficient studies to address the objective of this review.
All studies reported at least one primary outcome, and all studies
were included in at least one pooled analysis. The COPD pop-
ulation in the included studies ranged from mild to very severe
COPD and trials were conducted across all types of healthcare
settings in a range of different countries. Although the results of
this review appear therefore to be applicable to all COPD patients
worldwide, one should bear in mind that applicability may de-
pend on the context of available healthcare resources. The IDM
programs included in this review differed in the type of health care
providers involved, type of components and duration of interven-
tion, reflecting the diversity of daily practice. Overall, programs
containing at least two health care providers and two different el-
ements, showed improvements in quality of life and exercise ca-
pacity, and reduced the number of hospital admissions and days
spent in the hospital. We found no differences in quality of life
and exercise tolerance between patients treated in primary or sec-
ondary care. Although the mean differences between groups were
lower in studies using a mono-disciplinary treatment as a control
group compared to usual care, the subgroup difference did not
reach statistical significance. Furthermore, subgroup analysis on
studies focusing mainly on exercise programs showed a statisti-
cally significant greater improvement in exercise capacity. Further
research is required to define the optimal combination, intensity
and duration of components in IDM programs.
Quality of the evidence
We included RCTs only and found 26 trials assessing almost 3000
participants. A priori, we intended to perform meta-analyses on
some outcomes when feasible. However, with this amount of data
we were able to perform pooled data analysis for all outcomes. As
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a result of the complex intervention, there was a certain amount of
clinical and statistical heterogeneity among studies.We have incor-
porated heterogeneity into the estimated effects by using random-
effects analyses, where possible. Using the GRADE approach, we
specified the levels of quality of the evidence (high, moderate, low
and very low) in our ’Summary of findings’ table. According to
this approach, we checked if the included trials had limitations in
terms of design, indirectness of the evidence, unexplained hetero-
geneity or inconsistency of the results, imprecision of the results
or high probability of publication bias. If one of these factors was
present, we downgraded the evidence. On the SGRQ, there was
considerable variation in risk of bias between studies. Risk of bias
tended to be lower in the more recently published trials compared
to older trials. Sensitivity analyses based on studies with low qual-
ity did not change the direction, significance or magnitude of the
effect. Therefore we concluded that the quality of the evidence
was ’high’. For the CRQ, there were four studies which were all of
moderate quality and presented with some form of bias, therefore
we did downgrade the evidence to ’moderate’ quality. We down-
graded the evidence on functional exercise capacity for inconsis-
tency, as substantial heterogeneity (I² = 84%) was present. After
performing sensitivity analysis, the mean difference substantially
decreased to 15 meters. We did not downgrade for respiratory-
related admissions or hospitalisation days, as we feel the studies
presented consistent, homogeneous results. We expect that addi-
tional trials with proper description of their methods and data
collection could upgrade the quality of evidence and further our
findings.
Potential biases in the review process
Several methodological strengths minimized the risk of bias in
this review. As definitions of IDM are still under debate, we
a priori strictly determined the inclusion criteria for an IDM
program, which was published in our protocol. Our defini-
tion was derived from the definitions published in the literature
(Peytremann-Bridevaux 2009; Schrijvers 2009). Overall, they re-
ported on “multiple interventions, designed to manage chronic
conditions, with a focus on a multidisciplinary approach”. Fur-
thermore, these definitions suggest that IDM interventions should
“focus on maximum clinical outcome, regardless of treatment set-
ting(s) or typical reimbursement patterns”. As a result, we chose
to include all interventions, independent of treatment setting, and
to keep our definition as simple as possible, in order to be eas-
ily understandable for readers and easy to use for us as authors
when checking on all relevant literature. Therefore, we restricted
the inclusion of trials to multi-component, multidisciplinary pro-
grams of at least three months duration. Furthermore, we per-
formed comprehensive searches to identify possible studies, lead-
ing to almost 4800 potentially relevant abstracts being identified.
Subsequently, three different assessors assessed the abstracts. All
studies that were excluded by two authors because of the type of
intervention were triple-checked by a third review author to make
sure all studies describing an IDM program were included. We
reached consensus on all included studies. Although we followed
the inclusion criteria for IDM as stated in our protocol, final de-
cisions on the inclusion of studies are open to interpretation or
criticism.
Limitations of this review include possible bias from inconsistent
reporting of data from included studies. We requested additional
data from 14 authors and received an answer from 11. Six of them
could provide us with additional data, which could potentially
have biased the results. Furthermore, only three out of 26 studies
published a study protocol with which we could compare the re-
sults sections. In the other studies, we examined whether the out-
comes reported in the methods section of the paper were reported
in the results section. It is possible that this could have introduced
bias if the authors blanked out outcomes from their methods sec-
tion.
Lastly, there was heterogeneity present in the control group as
we used a broad a priori definition of controls, varying from no
treatment to treatment including one component of COPD care.
We acknowledge the fact that controls and usual care differ be-
tween countries and between healthcare settings. Therefore, we
performed subgroup analysis to investigate to what extent a differ-
ence between the control groups possibly influenced the results.
From these analyseswe concluded that the effect between interven-
tion and control groups is less strong if patients in control groups
receive one component of IDM compared to patients receiving no
treatment or usual care.
Agreements and disagreements with other
studies or reviews
This review adds to the results of four earlier systematic reviews
analyzing IDM for COPD patients (Adams 2007; Niesink 2007;
Peytremann-Bridevaux 2008; Lemmens 2009). The current re-
view brings together new trials that were not included in any of
these reviews. Some of these earlier reviews analyzed some of our
primary outcomes. Adams 2007 examined the effectiveness of pro-
grams for COPD patients including chronic care model compo-
nents and pooled six trials including at least two components.
Pooled results did not demonstrate statistically significant differ-
ences on the SGRQ. Patients with COPD who received inter-
ventions with two or more chronic care model components had
lower rates of hospitalisation and a shorter length of stay compared
with control groups, comparable to our results. Lemmens 2009
examined the effectiveness of multiple interventions in asthma
and COPD patients. The authors pooled data on the SGRQ from
three studies in which two components of IDMwere compared to
usual care and three studies in which three components of IDM
were compared to usual care. The effect on the SGRQwas larger if
three components of IDMwere used (MD -4.69; 95%CI -8.34 to
-0.83 versus MD -0.95; 95% CI -4.23 to 2.34). Pooled data from
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five studies showed a decrease in the number of respiratory-related
hospitalizations, with a pooled OR of 0.58, which is comparable
to the OR of 0.67 found in this review. Niesink 2007 evaluated
quality of life in COPD patients, but did not perform a meta-
analysis; reasons for this were not clearly described. Five out of 10
studies showed a clinically relevant improvement in quality of life.
Peytremann-Bridevaux 2008 examined the effectiveness of IDM
in COPD patients on exercise tolerance, quality of life, hospital
admissions and mortality. Only data on hospital admissions and
exercise tolerance were pooled. Positive effects on exercise capacity
are in line with this review. The authors demonstrated a mean
improvement of 32 meters on the 6MWD in five studies, which
is comparable to our results. Furthermore, a pooled odds ratio of
0.85 (95% CI 0.54 to 1.36) for mortality is comparable to our
review. Differences between this review and these other reviews are
related to differences in the inclusion criteria for patients and the
focus of programs. All reviews used different definitions of IDM;
however there was some overlap with this review. Lemmens 2009
et al also based their definition on the EPOC list (EPOC 2008),
whereas Adams 2007 and Steuten 2009 based their definition of
IDM on the chronic care model as reported byWagner 1996. The
definition used by Peytremann-Bridevaux 2008 was similar to our
definition, with the only difference being a duration of the inter-
vention of at least 12 months instead of three months. Finally,
all the aforementioned systematic reviews included study designs
other than RCTs.
Our findings from the St. George’s Respiratory Questionnaire
(SGRQ) showed improvements of a similar magnitude to those
reported in two recentCochrane reviews evaluating two other sup-
posedly important pharmaceutical cornerstones of COPD treat-
ment, tiotropium (Karner 2012a) and inhaled corticosteroids
(Yang 2012). IDM resulted in a higher MD on the SGRQ of -
3.71 compared to the MD of tiotropium (-2.89); however, the
confidence interval for IDM is wider (95% CI -5.83 to -1.59)
compared to the confidence interval (95% CI -3.35 to -2.44) for
tiotropium.
Eight studies in this review are also evaluated in a Cochrane review
assessing the effectiveness of pulmonary rehabilitation (Lacasse
2006) and four studies included in this review are also evaluated
in a Cochrane review assessing the effect of self management pro-
grams (Effing 2007). In line with the review of Effing 2007 (OR
0.64; 95% CI 0.47 to 0.89) we found a decrease in respiratory-
related hospital admissions (OR 0.64; 95% CI 0.47 to 0.89). Fur-
thermore, both reviews demonstrated improvements in disease-
specific quality of life, although the effects tended to be higher and
clinically relevant in the pulmonary rehabilitation review (Lacasse
2006), whereas in the self management review the improvement
was too small to be of clinical relevance (Effing 2007). A priori
we determined subgroup analyses on the type of dominant in-
tervention in the program. Subgroup analysis of studies contain-
ing some form of exercise training showed greater improvement
in quality of life, which exceeded the clinically relevant threshold
on almost all domains. These results are in line with the Lacasse
review. However, a subgroup analysis performed on studies that
mainly focused on self management did not exceed the minimum
clinically important difference, in line with the Effing review.
Furthermore, Effing 2007 and Lacasse 2006 reported pooled es-
timates for functional exercise capacity. Not surprisingly, as the
focus in most included pulmonary rehabilitation studies lies on
exercise training, the 6MWD improved significantly by 48 meters
in the Lacasse review. This effect size is comparable to our overall
estimate of 44 meters and our subgroup analyses on studies in-
cluding an exercise program in which we found a mean difference
of 50 meters. In contrast to these results, Effing did not find any
significant differences in exercise capacity at all (weighted mean
difference -6.25; 95% CI -24.05 to 11.05).
We did not find a difference between groups in the number of pa-
tients with at least one exacerbation. However, we concluded that
there was a reduction in the number of patients admitted and the
mean number of hospital days related to exacerbations. Self man-
agement education including the use of action plans might lead to
more and better self treatment of exacerbations. As a result, hospi-
tal admissions will decrease (Effing 2007). In our included studies,
a self management program caused patients to respond three days
sooner on complaints (Trappenburg 2011). Furthermore, patients
more often initiated treatment by themselves, which could then
be successfully treated with oral steroids at an early stage (Sridhar
2008). As a result, perceived exacerbations were rated as substan-
tially milder (Trappenburg 2011) and were less likely to result in
an admission (Bourbeau 2003).
In the past few years, several systematic reviews evaluating IDM
for various other chronic conditions have been published (Norris
2002; Badamgarav 2003; Gonseth 2004; Neumeyer-Gromen
2004; Knight 2005; Roccaforte 2005; Pimouguet 2010). Overall,
quality of care improvedwith these programs, however some of the
differences were in fact clinically modest (Peytremann-Bridevaux
2008). We found that the results of this review were most compa-
rable to a systematic review evaluating patients with heart failure,
which demonstrated that all-cause and heart failure-related hos-
pitalisation rates were significantly reduced: OR 0.76 (CI 0.69 to
0.94, P < 0.0001) and OR 0.58 (CI 0.50 to 0.67, P < 0.0001),
respectively (Roccaforte 2005). In studies evaluating depression
and diabetes, differences in health care use and quality of care were
less clear (Neumeyer-Gromen 2004; Knight 2005).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This meta-analysis provides evidence for the efficacy of integrated
disease management (IDM) programs of at least three months
duration for chronic obstructive pulmonary disease (COPD) pa-
tients, for up to 12 months follow-up. We found positive effects
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on disease-specific quality of life and exercise capacity in studies
containing an exercise program, suggesting that exercise training is
an important element in an IDM program. Long-term effects are
still unclear, as only a few studies evaluated these. The magnitude
of improvement in disease-specific quality of life was clinically
relevant, especially using the Chronic Respiratory Questionnaire
(CRQ).
We calculated that seven hospital admissions related to respira-
tory problems can be prevented for every 100 patients treated
with IDM for three to 12 months, giving to a number needed
to treat of 15 patients to prevent one being admitted. Further-
more, hospitalisation decreased by three days in patients treated
with IDM compared to controls. This is of utmost importance,
as hospitalizations contribute to the highest burden and costs in
patients with COPD. The effects of IDM on the total number
of patients suffering at least one exacerbation still remain unclear.
It is possible that patients who have learned from education and
have an action plan may recognize exacerbations at an early stage
and can start medical treatment directly. It is therefore likely that
further worsening of health status and hospital admissions can be
prevented in these patients.
Implications for research
The following issues could be assessed if authors are planning
future trials regarding the effectiveness of IDM:
1. Study quality: Overall, studies included in this systematic
review were of moderate quality, as not all aspects of risk of bias
were appropriately addressed. Therefore, there is a need for
future trials to report a proper description of the processes of
randomisation and data collection. Preferentially, a study
protocol including measured outcomes should be published in
advance to minimize selection and reporting bias.
2. More detailed description of intervention: A detailed
description of the precise nature of the intervention is important,
in order to be able to determine in the future which components,
duration and intensity of a program are most effective. Ideally, we
wish to determine which combination of health care providers
and which components are most effective in IDM programs.
3. Consensus on reporting common outcomes: Given the
huge variation in outcome measures and follow-up time points,
we strongly recommend consensus on the reporting of common
outcomes, such as change from baseline in health-related quality
of life, in order to be able to combine more results in future
meta-analyses. We advise future trial authors to measure at least
one of the following outcomes: quality of life, exercise tolerance
or exacerbation-related outcomes.
4. Adequate power calculation and methods of analysis: two
cluster-randomized controlled trials introduced noteworthy bias
due to inadequate methods of analysis, not taking the clustering
into account (Rea 2004; Wood-Baker 2006) and loss to follow-
up of clusters (Rea 2004). Therefore, we recommend performing
a proper power calculation beforehand and, if needed, adjusting
this calculation for intra-cluster effects (Guyatt 2011; Higgins
2011).
Finally, given the heterogeneity of interventions, there is a need to
reach consensus on which interventions are likely to yield the best
results when applying integrated care programs for COPD.
A C K N OW L E D G E M E N T S
The authors would like to thank Liz Stovold for her help with the
development of the search strategy. We acknowledge the authors
of the studies who provided additional data.
Julia Walters was the Editor for this review. Julia commented crit-
ically on the review and assisted the Co-ordinating Editor with
signing off the review for publication.
R E F E R E N C E S
References to studies included in this review
Aiken 2006 {published and unpublished data}
Aiken LS, Butner J, Lockhart CA, Volk-Craft BE, Hamilton
G, Williams FG. Outcome evaluation of a randomized
trial of the PhoenixCare intervention: program of case
management and coordinated care for the seriously
chronically ill. Journal of Palliative Medicine 2006;9(1):
111–26.
Bendstrup 1997 {published data only}
Bendstrup KE, Ingemann Jensen J, Holm S, Bengtsson B.
Out-patient rehabilitation improves activities of daily living,
quality of life and exercise tolerance in chronic obstructive
pulmonary disease. European Journal of Respiratory Diseases
1997;10(12):2801–6.
Bourbeau 2003 {published data only}
Bourbeau J, Collet JP, Schwartzman K, Ducruet T, Nault D,
Bradley C. Economic benefits of self-management education
in COPD. Chest 2006;130(6):1704–11. [PUBMED:
17166985]
∗ Bourbeau J, Julien M, Maltais F, Rouleau M, Beaupre A,
Begin R, et al.Reduction of hospital utilization in patients
with chronic obstructive pulmonary disease: a disease-
specific self-management intervention. Archives of Internal
Medicine 2003;163(5):585–91.
Sedeno MF, Nault D, Hamd DH, Bourbeau J. A self-
30Integrated disease management interventions for patients with chronic obstructive pulmonary disease (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
management education program including an action plan
for acute COPD exacerbations. COPD 2009;6(5):352–8.
[PUBMED: 19863364]
Boxall 2005 {published data only}
Boxall AM, Barclay L, Sayers A, Caplan GA. Managing
chronic obstructive pulmonary disease in the community.
A randomized controlled trial of home-based pulmonary
rehabilitation for elderly housebound patients. Journal of
Cardiopulmonary Rehabilitation 2005;25(6):378–85.
Cambach 1997 {published data only}
Cambach W, Chadwick-Straver RV, Wagenaar RC, van
Keimpema AR, Kemper HC. The effects of a community-
based pulmonary rehabilitation programme on exercise
tolerance and quality of life: a randomized controlled trial.
European Respiratory Journal 1997;10(1):104–13.
Dheda 2004 {published data only}
Dheda K, Crawford A, Hagan G, Roberts CM.
Implementation of British Thoracic Society guidelines
for acute exacerbation of chronic obstructive pulmonary
disease: impact on quality of life. Postgraduate Medical
Journal 2004;80(941):169–71. [PUBMED: 15016940]
Engstrom 1999 {published data only}
Engstrom CP, Persson LO, Larsson S, Sullivan M. Long-
term effects of a pulmonary rehabilitation programme in
outpatients with chronic obstructive pulmonary disease:
a randomized controlled study. Scandinavian Journal of
Rehabilitation Medicine 1999;31(4):207–13.
Farrero 2001 {published data only}
Farrero E, Escarrabill J, Prats E, Maderal M, Manresa
F. Impact of a hospital-based home-care program on
the management of COPD patients receiving long-term
oxygen therapy. Chest 2001;119(2):364–9. [PUBMED:
11171710]
Fernandez 2009 {published data only}
Fernandez AM, Pascual J, Ferrando C, Arnal A, Vergara
I, Sevila V. Home-based pulmonary rehabilitation in
very severe COPD: is it safe and useful?. Journal of
Cardiopulmonary Rehabilitation and Prevention 2009;29(5):
325–31. [PUBMED: 19561524]
Gottlieb 2011 {published data only}
Gottlieb V, Lyngso AM, Nybo B, Frolich A, Backer V.
Pulmonary rehabilitation for moderate COPD (GOLD
2)--does it have an effect?. COPD 2011;8(5):380–6.
[PUBMED: 21936683]
Güell 2000 {published and unpublished data}
Güell R, Casan P, Belda J, Sangenis M, Morante F, Guyatt
GH, et al.Long-term effects of outpatient rehabilitation of
COPD: A randomized trial. Chest 2000;117(4):976–83.
[PUBMED: 10767227]
Güell 2006 {published and unpublished data}
Güell R, Resqueti V, Sangenis M, Morante F, Martorell
B, Casan P, et al.Impact of pulmonary rehabilitation on
psychosocial morbidity in patients with severe COPD. Chest
2006;129(4):899–904. [PUBMED: 16608936]
Koff 2009 {published data only}
Koff PB, Jones RH, Cashman JM, Voelkel NF, Vandivier
RW. Proactive integrated care improves quality of life in
patients with COPD. European Respiratory Journal 2009;33
(5):1031–8. [PUBMED: 19129289]
Littlejohns 1991 {published data only}
Littlejohns P, Baveystock CM, Parnell H, Jones PW.
Randomised controlled trial of the effectiveness of a
respiratory health worker in reducing impairment, disability,
and handicap due to chronic airflow limitation. Thorax
1991;46(8):559–64. [PUBMED: 1926024]
Mendes 2010 {published and unpublished data}
Mendes de Oliveira JC, Studart Leitao Filho FS, Malosa
Sampaio LM, Negrinho de Oliveira AC, Hirata RP,
Costa D, et al.Outpatient vs. home-based pulmonary
rehabilitation in COPD: a randomized controlled trial.
Multidisciplinary Respiratory Medicine 2010;5(6):401–8.
[PUBMED: 22958267]
Rea 2004 {published data only}
Rea H, McAuley S, Stewart A, Lamont C, Roseman P,
Didsbury P. A chronic disease management programme can
reduce days in hospital for patients with chronic obstructive
pulmonary disease. Internal Medicine Journal 2004;34(11):
608–14. [PUBMED: 15546454]
Rice 2010 {published and unpublished data}
Rice KL, Dewan N, Bloomfield HE, Grill J, Schult TM,
Nelson DB, et al.Disease management program for chronic
obstructive pulmonary disease: a randomized controlled
trial. American Journal of Respiratory and Critical Care
Medicine 2010;182(7):890–6. [PUBMED: 20075385]
Smith 1999 {published data only}
Smith BJ, Appleton SL, Bennett PW, Roberts GC, Del
Fante P, Adams R, et al.The effect of a respiratory home
nurse intervention in patients with chronic obstructive
pulmonary disease (COPD). Australian and New Zealand
Journal of Medicine 1999;29(5):718–25. [PUBMED:
10630654]
Sridhar 2008 {published data only}
Sridhar M, Taylor R, Dawson S, Roberts NJ, Partridge
MR. A nurse led intermediate care package in patients
who have been hospitalised with an acute exacerbation of
chronic obstructive pulmonary disease. Thorax 2008;63(3):
194–200. [PUBMED: 17901162]
Strijbos 1996 {published data only}
Strijbos JH, Postma DS, van Altena R, Gimeno F, Koeter
GH. A comparison between an outpatient hospital-
based pulmonary rehabilitation program and a home-care
pulmonary rehabilitation program in patients with COPD.
A follow-up of 18 months. Chest 1996;109(2):366–72.
[PUBMED: 8620707]
Theander 2009 {published data only}
Theander K, Jakobsson P, Jorgensen N, Unosson M. Effects
of pulmonary rehabilitation on fatigue, functional status
and health perceptions in patients with chronic obstructive
pulmonary disease: a randomized controlled trial. Clinical
Rehabilitation 2009;23(2):125–36. [PUBMED: 19164400]
31Integrated disease management interventions for patients with chronic obstructive pulmonary disease (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Trappenburg 2011 {published data only}
Trappenburg JC, Koevoets L, de Weert-van Oene GH,
Monninkhof EM, Bourbeau J, Troosters T, et al.Action
Plan to enhance self-management and early detection of
exacerbations in COPD patients; a multicenter RCT. BMC
Pulmonary Medicine 2009;9:52. [PUBMED: 20040088]
∗ Trappenburg JC, Monninkhof EM, Bourbeau J, Troosters
T, Schrijvers AJ, Verheij TJ, et al.Effect of an action plan
with ongoing support by a case manager on exacerbation-
related outcome in patients with COPD: a multicentre
randomised controlled trial. Thorax 2011;66(11):977–84.
[PUBMED: 21785156]
van Wetering 2010 {published and unpublished data}
Hoogendoorn M, van Wetering CR, Schols AM, Rutten-
van Molken MP. Is INTERdisciplinary COMmunity-
based COPD management (INTERCOM) cost-effective?
. European Respiratory Journal 2010;35(1):79–87.
[PUBMED: 19574331]
∗ van Wetering CR, Hoogendoorn M, Mol SJ, Rutten-van
Molken MP, Schols AM. Short- and long-term efficacy of a
community-based COPD management programme in less
advanced COPD: a randomised controlled trial. Thorax
2010;65(1):7–13. [PUBMED: 19703824]
Wakabayashi 2011 {published and unpublished data}
Wakabayashi R, Motegi T, Yamada K, Ishii T, Jones RC,
Hyland ME, et al.Efficient integrated education for older
patients with chronic obstructive pulmonary disease using
the Lung Information Needs Questionnaire. Geriatrics &
Gerontology International 2011;11(4):422–30. [PUBMED:
21447136]
Wijkstra 1994 {published data only}
Wijkstra PJ, Ten Vergert EM, van Altena R, Otten V, Kraan
J, Postma DS, et al.Long term benefits of rehabilitation at
home on quality of life and exercise tolerance in patients
with chronic obstructive pulmonary disease. Thorax 1995;
50(8):824–8. [PUBMED: 7570431]
Wijkstra PJ, Van Altena R, Kraan J, Otten V, Postma
DS, Koeter GH. Quality of life in patients with chronic
obstructive pulmonary disease improves after rehabilitation
at home. European Respiratory Journal 1994;7(2):269–73.
[PUBMED: 8162979]
Wijkstra PJ, van der Mark TW, Kraan J, van Altena R,
Koeter GH, Postma DS. Effects of home rehabilitation on
physical performance in patients with chronic obstructive
pulmonary disease (COPD). European Respiratory Journal
1996;9(1):104–10. [PUBMED: 8834342]
Wijkstra PJ, van der Mark TW, Kraan J, van Altena
R, Koeter GH, Postma DS. Long-term effects of home
rehabilitation on physical performance in chronic
obstructive pulmonary disease. American Journal of
Respiratory and Critical Care Medicine 1996;153(4 Pt 1):
1234–41. [PUBMED: 8616547]
Wood-Baker 2006 {published data only}
Wood-Baker R, McGlone S, Venn A, Walters EH. Written
action plans in chronic obstructive pulmonary disease
increase appropriate treatment for acute exacerbations.
Respirology (Carlton, Vic.) 2006;11(5):619–26. [PUBMED:
16916336]
References to studies excluded from this review
Aimonino 2008 {published data only}
Aimonino Ricauda N, Tibaldi V, Leff B, Scarafiotti C,
Marinello R, Zanocchi M, et al.Substitutive “hospital
at home” versus inpatient care for elderly patients with
exacerbations of chronic obstructive pulmonary disease:
a prospective randomized, controlled trial. Journal of the
American Geriatrics Society 2008;56(3):493–500.
Bischoff 2012 {published data only}
Bischoff EW, Akkermans R, Bourbeau J, van Weel
C, Vercoulen JH, Schermer TR. Comprehensive self
management and routine monitoring in chronic obstructive
pulmonary disease patients in general practice: randomised
controlled trial. BMJ (Clinical research ed.) 2012;345:
e7642. [PUBMED: 23190905]
Carrieri 2005 {published data only}
Carrieri-Kohlman V, Nguyen HQ, Donesky-Cuenco
D, Demir-Deviren S, Neuhaus J, Stulbarg MS. Impact
of brief or extended exercise training on the benefit of
a dyspnea self-management program in COPD. Journal
of Cardiopulmonary Rehabilitation 2005;25(5):275–84.
[PUBMED: 16217231]
Casas 2006 {published data only}
Casas A, Troosters T, Garcia-Aymerich J, Roca J, Hernandez
C, Alonso A, et al.Integrated care prevents hospitalisations
for exacerbations in COPD patients. European Respiratory
Journal 2006;28(1):123–30. [PUBMED: 16611656]
De Godoy 2003 {published data only}
De Godoy DV, De Godoy RF. A randomized controlled trial
of the effect of psychotherapy on anxiety and depression in
chronic obstructive pulmonary disease. Archives of Physical
Medicine and Rehabilitation 2003;84(8):1154–7.
Eaton 2009 {published data only}
Eaton T, Young P, Fergusson W, Moodie L, Zeng I, O’Kane
F, et al.Does early pulmonary rehabilitation reduce acute
health-care utilization in COPD patients admitted with an
exacerbation? A randomized controlled study. Respirology
2009;14(2):230–8. [PUBMED: 19272084]
Effing 2009 {published data only}
Effing T, Kerstjens H, van der Valk P, Zielhuis G, van
der Palen J. (Cost)-effectiveness of self-treatment of
exacerbations on the severity of exacerbations in patients
with COPD: the COPE II study. Thorax 2009;64(11):
956–62. [PUBMED: 19736179]
Efraimsson 2008 {published data only}
Efraimsson EO, Hillervik C, Ehrenberg A. Effects of COPD
self-care management education at a nurse-led primary
health care clinic. Scandinavian Journal of Caring Sciences
2008;22(2):178–85. [PUBMED: 18489687]
Elliott 2004 {published data only}
Elliott M, Watson C, Wilkinson E, Musk AW, Lake
FR. Short- and long-term hospital and community
32Integrated disease management interventions for patients with chronic obstructive pulmonary disease (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
exercise programmes for patients with chronic obstructive
pulmonary disease. Respirology 2004;9(3):345–51.
[PUBMED: 15363006]
Garcia 2007 {published data only}
Garcia-Aymerich J, Hernandez C, Alonso A, Casas A,
Rodriguez-Roisin R, Anto JM, et al.Effects of an integrated
care intervention on risk factors of COPD readmission.
Respiratory Medicine 2007;101(7):1462–9. [PUBMED:
17339106]
Gohl 2006 {published data only}
Gohl O, Linz H, Schonleben T, Otte B, Weineck J, Worth
H. Benefits of a multimodular outpatient training program
for patients with COPD [Effekte eines multimodularen
ambulanten Trainingsprogramms fur Patienten mit
COPD]. Pneumologie (Stuttgart, Germany) 2006;60(9):
529–36. [PUBMED: 17006787]
Goldstein 1994 {published data only}
Goldstein RS, Gort EH, Stubbing D, Avendano MA,
Guyatt GH. Randomised controlled trial of respiratory
rehabilitation. Lancet 1994;344(8934):1394–7.
[PUBMED: 7968075]
Guell 2008 {published data only}
Guell MR, de Lucas P, Galdiz JB, Montemayor T, Rodriguez
Gonzalez-Moro JM, Gorostiza A, et al.Home vs hospital-
based pulmonary rehabilitation for patients with chronic
obstructive pulmonary disease: a Spanish multicenter
trial [Comparacion de un programa de rehabilitacion
domiciliario con uno hospitalario en pacientes con
EPOC: estudio multicentrico espanol.]. Archivos de
Bronconeumologia 2008;44(10):512–8. [PUBMED:
19006630]
Hughes 2000 {published data only}
Hughes SL, Weaver FM, Giobbie-Hurder A, Manheim
L, Henderson W, Kubal JD, et al.Effectiveness of team-
managed home-based primary care: a randomized
multicenter trial. JAMA 2000;284(22):2877–85.
[PUBMED: 11147984]
Liu 2006 {published data only}
Liu YF. Effects of the comprehensive pulmonary
rehabilitation programme on the quality of life of the
patients with COPD in recovery period (Chinese). Chinese
Journal of Clinical Rehabilitation 2002;21:3170–1.
Maltais 2008 {published data only}
Maltais F, Bourbeau J, Shapiro S, Lacasse Y, Perrault
H, Baltzan M, et al.Effects of home-based pulmonary
rehabilitation in patients with chronic obstructive
pulmonary disease: a randomized trial. Annals of Internal
Medicine 2008;149(12):869–78. [PUBMED: 19075206]
Martin 2004 {published data only}
Martin IR, McNamara D, Sutherland FR, Tilyard MW,
Taylor DR. Care plans for acutely deteriorating COPD: a
randomized controlled trial. Chronic Respiratory Disease
2004;1(4):191–5. [PUBMED: 16281645]
McGeoch 2006 {published data only}
McGeoch GR, Willsman KJ, Dowson CA, Town GI,
Frampton CM, McCartin FJ, et al.Self-management plans
in the primary care of patients with chronic obstructive
pulmonary disease. Respirology 2006;11(5):611–8.
[PUBMED: 16916335]
Monninkhof 2003 {published data only}
Monninkhof E, van der Valk P, van der Palen J, van
Herwaarden C, Zielhuis G. Effects of a comprehensive
self-management programme in patients with chronic
obstructive pulmonary disease. European Respiratory Journal
2003;22(5):815–20. [PUBMED: 14621090]
Ries 2003 {published data only}
Ries AL, Kaplan RM, Myers R, Prewitt LM. Maintenance
after pulmonary rehabilitation in chronic lung disease:
a randomized trial. American Journal of Respiratory and
Critical Care Medicine 2003;167(6):880–8. [PUBMED:
12505859]
Soler 2006 {published data only}
Soler JJ, Martinez-Garcia MA, Roman P, Orero R, Terrazas
S, Martinez-Pechuan A. Effectiveness of a specific program
for patients with chronic obstructive pulmonary disease and
frequent exacerbations [Eficacia de un programa especifico
para pacientes con EPOC que presentan frecuentes
agudizaciones]. Archivos de Bronconeumologia 2006;42(10):
501–8. [PUBMED: 17067516]
Steele 2008 {published data only}
Steele BG, Belza B, Cain KC, Coppersmith J,
Lakshminarayan S, Howard J, et al.A randomized clinical
trial of an activity and exercise adherence intervention in
chronic pulmonary disease. Archives of Physical Medicine
and Rehabilitation 2008;89(3):404–12. [PUBMED:
18295615]
Zhou 2010 {published data only}
Zhou Y, Hu G, Wang D, Wang S, Wang Y, Liu Z, et
al.Community based integrated intervention for prevention
and management of chronic obstructive pulmonary disease
(COPD) in Guangdong, China: cluster randomised
controlled trial. BMJ (Clinical research ed.) 2010;341:
c6387. [PUBMED: 21123342]
References to studies awaiting assessment
Baumann 2012 {published data only}
Baumann HJ, Kluge S, Rummel K, Klose H, Hennigs JK,
Schmoller T, et al.Low intensity, long-term outpatient
rehabilitation in COPD: a randomised controlled trial.
Respiratory Research 2012;13:86. [PUBMED: 23017153]
Fan 2012 {published data only}
Fan VS, Gaziano JM, Lew R, Bourbeau J, Adams SG,
Leatherman S, et al.A comprehensive care management
program to prevent chronic obstructive pulmonary disease
hospitalizations: a randomized, controlled trial. Annals
of Internal Medicine 2012;156(10):673–83. [PUBMED:
22586006]
Zwar 2012 {published data only}
Zwar NA, Hermiz O, Comino E, Middleton S, Vagholkar
S, Xuan W, et al.Care of patients with a diagnosis of chronic
obstructive pulmonary disease: a cluster randomised
33Integrated disease management interventions for patients with chronic obstructive pulmonary disease (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
controlled trial. Medical Journal of Australia 2012;197(7):
394–8. [PUBMED: 23025736]
References to ongoing studies
Bower 2012 {published data only}
Bower P, Kennedy A, Reeves D, Rogers A, Blakeman T,
Chew-Graham C, et al.A cluster randomised controlled trial
of the clinical and cost-effectiveness of a ’whole systems’
model of self-management support for the management
of long- term conditions in primary care: trial protocol.
Implementation Science : IS 2012;7:7. [PUBMED:
22280501]
Bunker 2012 {published data only}
Bunker JM, Reddel HK, Dennis SM, Middleton S,
Van Schayck C, Crockett AJ, et al.A pragmatic cluster
randomized controlled trial of early intervention for chronic
obstructive pulmonary disease by practice nurse-general
practitioner teams: Study Protocol. Implementation Science
: IS 2012;7:83. [PUBMED: 22958678]
Byrnes 2012 {published data only}
Byrnes JM, Goldstein S, Venator B, Pollicino C, Ng SK,
Veroff D, et al.The impact of population-based disease
management services for selected chronic conditions: the
Costs to Australian Private Insurance--Coaching Health
(CAPICHe) study protocol. BMC Public Health 2012;12:
114. [PUBMED: 22325668]
Freund 2011 {published data only}
Freund T, Peters-Klimm F, Rochon J, Mahler C, Gensichen
J, Erler A, et al.Primary care practice-based care management
for chronically ill patients (PraCMan): study protocol for a
cluster randomized controlled trial [ISRCTN56104508].
Trials 2011;12:163. [PUBMED: 21714883]
Gomez 2006 {published data only}
Gomez A, Roman M, Larraz C, Esteva M, Mir I, Thomas
V, et al.Efficacy of respiratory rehabilitation on patients
with moderate COPD in primary care and maintenance of
benefits at 2 years [Eficacia de la rehabilitacion respiratoria
en pacientes con EPOC moderada en atencion primaria y
mantenimiento de los beneficios a los 2 anos]. Atencion
Primaria / Sociedad Espanola de Medicina de Familia y
Comunitaria 2006;38(4):230–3. [PUBMED: 16978561]
Jones 2009a {published data only}
Jones SM, Albert P, Warburton CJ, Calverley PMA, Davies
L. Effect of a case management study on primary care use
and prescribing for AECOPD. British Thoracic Society
Winter Meeting; 2009 December 2-4; London. Lonodn,
2009.
Kruis 2013 {published data only}
Kruis AL, Boland MR, Schoonvelde CH, Assendelft WJ,
Rutten-van Molken MP, Gussekloo J, et al.RECODE:
design and baseline results of a cluster randomized trial
on cost-effectiveness of integrated COPD management
in primary care. BMC Pulmonary Medicine 2013;13:17.
[PUBMED: 23522095]
Murphy 2011 {published data only}
Murphy K, Casey D, Devane D, Cooney A, McCarthy B,
Mee L, et al.A cluster randomised controlled trial evaluating
the effectiveness of a structured pulmonary rehabilitation
education programme for improving the health status
of people with chronic obstructive pulmonary disease
(COPD): The PRINCE Study protocol. BMC Pulmonary
Medicine 2011;11:4. [PUBMED: 21244668]
Roman 2013 {published data only}
Roman M, Larraz C, Gomez A, Ripoll J, Mir I, Miranda
EZ, et al.Efficacy of pulmonary rehabilitation in patients
with moderate chronic obstructive pulmonary disease: a
randomized controlled trial. BMC Family Practice 2013;14:
21. [PUBMED: 23399113]
Additional references
Adams 2007
Adams SG, Smith PK, Allan PF, Anzueto A, Pugh JA,
Cornell JE. Systematic review of the chronic care model
in chronic obstructive pulmonary disease prevention and
management. Archives of Internal Medicine 2007;167(6):
551–61. [PUBMED: 17389286]
Agusti 2010
Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD,
Lomas DA, et al.Characterisation of COPD heterogeneity
in the ECLIPSE cohort. Respiratory Research 2010;11:122.
[PUBMED: 20831787]
Badamgarav 2003
Badamgarav E, Weingarten SR, Henning JM, Knight K,
Hasselblad V, Gano A Jr, et al.Effectiveness of disease
management programs in depression: a systematic review.
American Journal of Psychiatry 2003;160(12):2080–90.
[PUBMED: 14638573]
Beck 1961
Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An
inventory for measuring depression. Archives of General
Psychiatry 1961;4:561–71. [PUBMED: 13688369]
Bestall 1999
Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW,
Wedzicha JA. Usefulness of the Medical Research Council
(MRC) dyspnoea scale as a measure of disability in patients
with chronic obstructive pulmonary disease. Thorax 1999;
54(7):581–6. [PUBMED: 10377201]
Bonomi 2002
Bonomi AE, Wagner EH, Glasgow RE, VonKorff M.
Assessment of chronic illness care (ACIC): a practical tool
to measure quality improvement. Health Services Research
2002;37(3):791–820. [PUBMED: 12132606]
Borg 1970
Borg G. Perceived exertion as an indicator of somatic stress.
Scandinavian Journal of Rehabilitation Medicine 1970;2(2):
92–8. [PUBMED: 5523831]
Bourbeau 2013
Bourbeau J, Saad N. Integrated care model with self-
management in chronic obstructive pulmonary disease:
34Integrated disease management interventions for patients with chronic obstructive pulmonary disease (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
From family physicians to specialists. Chronic Respiratory
Disease 2013;10:93–4. [PUBMED: 23382555]
Britton 2003
Britton M. The burden of COPD in the U.K.: results from
the Confronting COPD survey. Respiratory Medicine 2003;
97(Suppl C):S71–9. [PUBMED: 12647945]
Burgel 2010
Burgel PR, Paillasseur JL, Caillaud D, Tillie-Leblond I,
Chanez P, Escamilla R, et al.Clinical COPD phenotypes:
a novel approach using principal component and cluster
analyses. European Respiratory Journal 2010;36(3):531–9.
[PUBMED: 20075045]
Calverley 2003
Calverley PM, Walker P. Chronic obstructive pulmonary
disease. Lancet 2003;362(9389):1053–61. [PUBMED:
14522537]
Campbell 2001
Campbell MK, Mollison J, Grimshaw JM. Cluster trials
in implementation research: estimation of intracluster
correlation coefficients and sample size. Statistics inMedicine
2001;20(3):391–9. [PUBMED: 11180309]
Care Continuum Alliance
Care Continuum Alliance (CCA) Definition of Disease
Management. www.carecontinuum.org/ (accessed 19 May
2011).
Chavannes 2008
Chavannes NH. Integrated chronic obstructive pulmonary
disease management in primary care. Disease Management
& Health Outcomes 2008;16(5):1.
Cote 2009
Cote CG, Celli BR. BODE index: a new tool to stage
and monitor progression of chronic obstructive pulmonary
disease. Pneumonologia i Alergologia Polska: organ
Polskiego Towarzystwa Ftyzjopneumonologicznego, Polskiego
Towarzystwa Alergologicznego, i Instytutu Gruzlicy i Chorob
Pluc 2009;77(3):305–13. [PUBMED: 19591105]
De Angelis 2004
De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey
J, Horton R, et al.Clinical trial registration: a statement
from the International Committee of Medical Journal
Editors. Annals of Internal Medicine 2004;141(6):477–8.
[PUBMED: 15355883]
Dellby 1996
Dellby U. Drastically improving health care with focus on
managing the patient with a disease: the macro and micro
perspective. International Journal of Health Care Quality
Assurance 1996;9(2):4–8. [PUBMED: 10157563]
Domingo-Salvany 2002
Domingo-Salvany A, Lamarca R, Ferrer M, Garcia-
Aymerich J, Alonso J, Felez M, et al.Health-related quality of
life and mortality in male patients with chronic obstructive
pulmonary disease. American Journal of Respiratory and
Critical Care Medicine 2002;166(5):680–5. [PUBMED:
12204865]
Effing 2007
Effing T, Monninkhof EEM, van der Valk PP, Zielhuis
GGA, Walters EH, van der Palen JJ, et al.Self-management
education for patients with chronic obstructive pulmonary
disease. Cochrane Database of Systematic Reviews 2007, Issue
4. [DOI: 10.1002/14651858.CD002990.pub2]
Ellrodt 1997
Ellrodt G, Cook DJ, Lee J, Cho M, Hunt D, Weingarten S.
Evidence-based disease management. JAMA 1997;278(20):
1687–92. [PUBMED: 9388089]
Engstrom 1996
Engstrom CP, Persson LO, Larsson S, Ryden A, Sullivan
M. Functional status and well being in chronic obstructive
pulmonary disease with regard to clinical parameters and
smoking: a descriptive and comparative study. Thorax
1996;51(8):825–30. [PUBMED: 8795672]
EPOC 2008
Cochrane Effective Practice and Organization of
Care Review Group. Data collection checklist.
http://www.google.co.uk/url?sa=t&rct=j&q=&esrc=
s&source=web&cd=1&ved=0CEgQFjAA&url=
http%3A%2F%2Fepoc.cochrane.org%2Fsites%2Fepoc.cochrane.org%2Ffiles%2Fuploads%2Fdatacol
ei=nI9OUr-JD8Sf7gawloGwCA&usg=AFQjC-
NFVkZnWv1phsYMRgjKiVmxcSgdSgg&bvm=
bv.53537100,d.ZGU&cad=rja (accessed 4/10/13).
Epstein 1996
Epstein RS, Sherwood LM. From outcomes research to
disease management: a guide for the perplexed. Annals
of Internal Medicine 1996;124(9):832–7. [PUBMED:
8610953]
EuroQol Group 1990
The EuroQol Group. EuroQol--a new facility for the
measurement of health-related quality of life. Health Policy
1990;16(3):199–208. [PUBMED: 10109801]
Fan 2002
Fan VS, Curtis JR, Tu SP, McDonell MB, Fihn SD. Using
quality of life to predict hospitalization and mortality in
patients with obstructive lung diseases. Chest 2002;122(2):
429–36. [PUBMED: 12171813]
Faxon 2004
Faxon DP, Schwamm LH, Pasternak RC, Peterson
ED, McNeil BJ, Bufalino V, et al.Improving quality
of care through disease management: principles and
recommendations from the American Heart Association’s
Expert Panel on Disease Management. Circulation 2004;
109(21):2651–4. [PUBMED: 15173048]
Gerardi 1996
Gerardi DA, Lovett L, Benoit-Connors ML, Reardon JZ,
ZuWallack RL. Variables related to increased mortality
following out-patient pulmonary rehabilitation. European
Respiratory Journal 1996;9(3):431–5. [PUBMED:
8730000]
Glasgow 2005
Glasgow RE, Wagner EH, Schaefer J, Mahoney LD, Reid
RJ, Greene SM. Development and validation of the Patient
35Integrated disease management interventions for patients with chronic obstructive pulmonary disease (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Assessment of Chronic Illness Care (PACIC). Medical Care
2005;43(5):436–44. [PUBMED: 15838407]
GOLD 2009
GOLD. Global strategy for the diagnosis, management, and
prevention of chronic obstructive pulmonary disease 2009.
http://www.goldcopd.com/ (accessed 4/10/13).
Gonseth 2004
Gonseth J, Guallar-Castillon P, Banegas JR, Rodriguez-
Artalejo F. The effectiveness of disease management
programmes in reducing hospital re-admission in older
patients with heart failure: a systematic review and meta-
analysis of published reports. European Heart Journal 2004;
25(18):1570–95. [PUBMED: 15351157]
GRADE Working Group 2004
GRADE Working Group. Grading quality of evidence and
strength of recommendations. BMJ 2004;328:1490–4.
Guyatt 1987
Guyatt GH, Berman LB, Townsend M, Pugsley SO,
Chambers LW. A measure of quality of life for clinical
trials in chronic lung disease. Thorax 1987;42(10):773–8.
[PUBMED: 3321537]
Guyatt 2011
Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-
Coello P, et al.GRADE guidelines: 4. Rating the quality of
evidence--study limitations (risk of bias). Journal of Clinical
Epidemiology. Elsevier, 2011; Vol. 64, issue 4:407–15.
Higgins 2011
Higgins JPT, Green S, editors. Cochrane Handbook for
Systematic Reviews of Interventions Version 5.1 [updated
March 2011]. The Cochrane Collaboration, 2011.
Available from www.cochrane-handbook.org.
Hurst 2010
Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H,
Tal-Singer R, et al.Susceptibility to exacerbation in chronic
obstructive pulmonary disease. New England Journal of
Medicine 2010;363(12):1128–38. [PUBMED: 20843247]
Jones 1991
Jones PW, Quirk FH, Baveystock CM. The St George’s
Respiratory Questionnaire. Respiratory Medicine 1991;85
Suppl B:25-31; discussion 33-7. [PUBMED: 1759018]
Jones 2005
Jones PW. St. George’s Respiratory Questionnaire: MCID.
COPD 2005;2(1):75–9. [PUBMED: 17136966]
Jones 2009
Jones PW, Harding G, Berry P, Wiklund I, Chen WH,
Kline Leidy N. Development and first validation of the
COPD Assessment Test. European Respiratory Journal 2009;
34(3):648–54. [PUBMED: 19720809]
Karner 2012a
Karner C, Chong J, Poole P. Tiotropium versus placebo for
chronic obstructive pulmonary disease. Cochrane Database
of Systematic Reviews 2012, Issue 7. [DOI: 10.1002/
14651858.CD009285.pub2]
Kerry 1998
Kerry SM, Bland JM. The intracluster correlation coefficient
in cluster randomisation. BMJ (Clinical research ed.) 1998;
316(7142):1455. [PUBMED: 9572764]
Knight 2005
Knight K, Badamgarav E, Henning JM, Hasselblad V, Gano
AD Jr, Ofman JJ, et al.A systematic review of diabetes disease
management programs. American Journal of Managed Care
2005;11(4):242–50. [PUBMED: 15839184]
Kocks 2006
Kocks JW, Tuinenga MG, Uil SM, van den Berg JW, Stahl
E, van der Molen T. Health status measurement in COPD:
the minimal clinically important difference of the clinical
COPD questionnaire. Respiratory Research 2006;7:62.
[PUBMED: 16603063]
Lacasse 2006
Lacasse Y, Goldstein R, Lasserson TJ, Martin S. Pulmonary
rehabilitation for chronic obstructive pulmonary disease.
Cochrane Database of Systematic Reviews 2006, Issue 4.
[DOI: 10.1002/14651858.CD003793.pub2]
Lefebvre 2009
Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching
for studies. In Higgins JPT, Green S (editors). Cochrane
Handbook for Systematic Reviews of Interventions 5.1
[updated March 2011]. The Cochrane Collaboration,
2011. Available from www.cochrane-handbook.org.
Lemmens 2009
Lemmens KM, Nieboer AP, Huijsman R. A systematic
review of integrated use of disease-management
interventions in asthma and COPD. Respiratory Medicine
2009;103(5):670–91. [PUBMED: 19155168]
Lopez 2006
Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL,
Held LS, et al.Chronic obstructive pulmonary disease:
current burden and future projections. European Respiratory
Journal 2006;27(2):397–412. [PUBMED: 16452599]
Martinez 2006
Martinez FJ, Foster G, Curtis JL, Criner G, Weinmann
G, Fishman A, et al.Predictors of mortality in patients
with emphysema and severe airflow obstruction. American
Journal of Respiratory and Critical Care Medicine 2006;173
(12):1326–34. [PUBMED: 16543549]
Neumeyer-Gromen 2004
Neumeyer-Gromen A, Lampert T, Stark K, Kallischnigg G.
Disease management programs for depression: a systematic
review and meta-analysis of randomized controlled
trials. Medical Care 2004;42(12):1211–21. [PUBMED:
15550801]
Niesink 2007
Niesink A, Trappenburg JC, de Weert-van Oene GH,
Lammers JW, Verheij TJ, Schrijvers AJ. Systematic review
of the effects of chronic disease management on quality-of-
life in people with chronic obstructive pulmonary disease.
Respiratory Medicine 2007;101(11):2233–9. [PUBMED:
17804213]
36Integrated disease management interventions for patients with chronic obstructive pulmonary disease (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Norris 2002
Norris SL, Nichols PJ, Caspersen CJ, Glasgow RE, Engelgau
MM, Jack L, et al.The effectiveness of disease and case
management for people with diabetes. A systematic review.
American Journal of Preventive Medicine 2002;22(Suppl 4):
15–38. [PUBMED: 11985933]
Norris 2003
Norris SL, Glasgow RE, Engelgau MM, O’Connor PJ,
McCulloch D. Chronic disease management: a definition
and systematic approach to component interventions.
Disease Management and Health Outcomes 2003;11(8):
477–88.
Peytremann-Bridevaux 2008
Peytremann-Bridevaux I, Staeger P, Bridevaux PO, Ghali
WA, Burnand B. Effectiveness of chronic obstructive
pulmonary disease-management programs: systematic
review and meta-analysis. American Journal of Medicine
2008;121(5):433–43.e4. [PUBMED: 18456040]
Peytremann-Bridevaux 2009
Peytremann-Bridevaux I, Burnand B. Letter to the editor.
Disease management: a proposal for a new definition.
International Journal of Integrated Care 2009;9:1.
Pimouguet 2010
Pimouguet C, Le Goff M, Thiebaut R, Dartigues JF, Helmer
C. Effectiveness of disease-management programs for
improving diabetes care: a meta-analysis. Canadian Medical
Association Journal 2010;183(2):E115–27. [PUBMED:
21149524]
Pinto-Plata 2004
Pinto-Plata VM, Cote C, Cabral H, Taylor J, Celli BR.
The 6-min walk distance: change over time and value as a
predictor of survival in severe COPD. European Respiratory
Journal 2004;23(1):28–33. [PUBMED: 14738227]
Puhan 2006
Puhan MA, Soesilo I, Guyatt GH, Schunemann HJ.
Combining scores from different patient reported outcome
measures in meta-analyses: when is it justified?. Health
and Quality of Life Outcomes 2006;4:94. [PUBMED:
17156420]
Puhan 2008
Puhan MA, Mador MJ, Held U, Goldstein R, Guyatt GH,
Schunemann HJ. Interpretation of treatment changes in 6-
minute walk distance in patients with COPD. European
Respiratory Journal 2008;32(3):637–43. [PUBMED:
18550610]
Rao 1992
Rao JNK, Scott AJ. A simple method for the analysis of
clustered binary data. Biometrics 1992;48:577–85.
Redelmeier 1997
Redelmeier DA, Bayoumi AM, Goldstein RS, Guyatt GH.
Interpreting small differences in functional status: the Six
Minute Walk test in chronic lung disease patients. American
Journal of Respiratory and Critical Care Medicine 1997;155
(4):1278–82. [PUBMED: 9105067]
RevMan 5
The Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager (RevMan). 5.1. Copenhagen: The Nordic
Cochrane Centre, The Cochrane Collaboration, 2008.
Roccaforte 2005
Roccaforte R, Demers C, Baldassarre F, Teo KK, Yusuf
S. Effectiveness of comprehensive disease management
programmes in improving clinical outcomes in heart failure
patients. A meta-analysis. European Journal of Heart Failure
2005;7(7):1133–44. [PUBMED: 16198629]
Schrijvers 2009
Schrijvers G. Disease management: a proposal for a new
definition. International Journal of Integrated Care 2009;9:
e06. [PUBMED: 19340329]
Seemungal 1998
Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries
DJ, Wedzicha JA. Effect of exacerbation on quality of life
in patients with chronic obstructive pulmonary disease.
American Journal of Respiratory and Critical Care Medicine
1998;157(5 Pt 1):1418–22. [PUBMED: 9603117]
Seemungal 2000
Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ,
Wedzicha JA. Time course and recovery of exacerbations
in patients with chronic obstructive pulmonary disease.
American Journal of Respiratory and Critical Care Medicine
2000;161(5):1608–13. [PUBMED: 10806163]
Singh 1992
Singh S. The use of field walking tests for assessment
of functional capacity in patients with chronic airways
obstruction. Physiotherapy 1992;78:102–4.
Steuten 2009
Steuten LM, Lemmens KM, Nieboer AP, Vrijhoef HJ.
Identifying potentially cost effective chronic care programs
for people with COPD. International Journal of Chronic
Obstructive Pulmonary Disease 2009;4:87–100. [PUBMED:
19436687]
Tiep 1997
Tiep BL. Disease management of COPD with pulmonary
rehabilitation. Chest 1997;112(6):1630–56. [PUBMED:
9404764]
van der Molen 2003
van der Molen T, Willemse BW, Schokker S, ten Hacken
NH, Postma DS, Juniper EF. Development, validity and
responsiveness of the Clinical COPDQuestionnaire. Health
and Quality of Life Outcomes 2003;1:13. [PUBMED:
12773199]
Wagner 1996
Wagner EH, Austin BT, Von Korff M. Improving outcomes
in chronic illness. Managed Care Quarterly 1996;4(2):
12–25. [PUBMED: 10157259]
Wagner 2001
Wagner EH, Austin BT, Davis C, Hindmarsh M, Schaefer
J, Bonomi A. Improving chronic illness care: translating
evidence into action. Health Affairs (Project Hope) 2001;20
(6):64–78. [PUBMED: 11816692]
37Integrated disease management interventions for patients with chronic obstructive pulmonary disease (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ware 1992
Ware JE Jr, Sherbourne CD. The MOS 36-item short-form
health survey (SF-36). I. Conceptual framework and item
selection. Medical Care 1992;30(6):473–83. [PUBMED:
1593914]
Wedzicha 2000
Wedzicha JA. The heterogeneity of chronic obstructive
pulmonary disease. Thorax 2000;55(8):631–2. [PUBMED:
10899236]
Weingarten 2002
Weingarten SR, Henning JM, Badamgarav E, Knight K,
Hasselblad V, Gano A Jr, et al.Interventions used in disease
management programmes for patients with chronic illness -
which ones work? Meta-analysis of published reports. BMJ
(Clinical Research Ed.) 2002;325(7370):925. [PUBMED:
12399340]
WHO 2008
World Health Organization. World Health Statistics 2008.
Available from: http://www.who.int/whosis/whostat/2008/
en/index.html.
Yang 2012
Yang IA, Clarke MS, Sim EHA, Fong KM. Inhaled
corticosteroids for stable chronic obstructive pulmonary
disease. Cochrane Database of Systematic Reviews 2012, Issue
7. [DOI: 10.1002/14651858.CD002991.pub3]
Zigmond 1983
Zigmond AS, Snaith RP. The hospital anxiety and
depression scale. Acta Psychiatrica Scandinavica 1983;67(6):
361–70. [PUBMED: 6880820]
Zitter 1997
Zitter M. A new paradigm in health care delivery: disease
management. In: Todd WE, Nash D editor(s). Disease
Management: a Systems Approach to Improving Patient
Outcomes. Chicago: American Hospital Association, 1997:
1–25.
∗ Indicates the major publication for the study
38Integrated disease management interventions for patients with chronic obstructive pulmonary disease (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aiken 2006
Methods RCT; follow-up: unknown; control group: usual care, which means patients receiving
care from managed care organizations (MCO)
Participants Eligible: 192 (COPD and congestive heart failure)
Randomized COPD: 61
Mean age/sex: not reported for COPD patients
Inclusion criteria: COPDor congestive heart failure patients, palliative treatment residing
at home, receiving care by MCO, mean life expectancy of 2 years, saturation < 88%,
oxygen usage, marked limitation of physical functioning, recent exacerbation
Interventions Phoenix Care palliative intervention services were added to treatment services of local
MCOs. Registered nurse case managers (serving 30 to 35 patients) provided the inter-
vention service. These nurses worked with protocols and held contact with the attending
physicians. Furthermore, they developed care plans, provided education to patients and
tailored self management of the disease. They supported services including assessing psy-
chological and spiritual needs. During exacerbation episodes, the nurses assessed medical
status, implemented a symptom control intervention and contacted the physician
Included health care providers (HCP): GP, nurse case manager
Outcomes SF-36, medical utilization
Notes Main component of program: structured follow-up with nurses/GP
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was carried out
within diagnosis, in blocks of 30 patients
(15 intervention, 15 control) by a member
of the project administration staff.”
Allocation concealment (selection bias) Low risk Quote: “Sealed-envelopes, colour-codedby
diagnosis and containing the assignment to
condition, were shuffled and assigned to
participants in order of shuffling (..) the
enroller, blinded to condition, opened the
sealed envelope that identified the patients’
study condition. ”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and treating therapists not
likely to have been blinded to group allo-
cation
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Aiken 2006 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “All participants received an inter-
view administered by a professional inter-
viewing firm; interviewers were blind to
condition and diagnosis”
Incomplete outcome data (attrition bias)
All outcomes
Low risk The authors performed an attrition analysis
according to the Jurs and Glass procedure
Selective reporting (reporting bias) Low risk All outcomes reported
Bendstrup 1997
Methods RCT; follow-up: 24 weeks; control group: no treatment
Participants Eligible: 47
Completed: 32
Mean age I: 64 yrs, C: 65 yrs
Sex (% male) both groups: 56%
Inclusion criteria: diagnosis of COPD according to GOLD, FEV1 of 25% to 55% of
predicted value, Tiffeneau index less than 70%, stable condition for 4 weeks (no change
in exercise status, sputum color/quantity, no change in medication)
Major exclusions: heart disease, musculoskeletal disease limiting exercise, intermittent
claudication limiting exercise
Interventions 12 week program including:
- Exercise training (strength training, backwards/sideways walking, endurance training):
3 times per week for 1 hour during 12 weeks. Patients were encouraged to train at home
- Occupational therapy: 2 group sessions
- Education: 12 sessions, including proper administration, inhalation techniques, psy-
chological education, socioeconomic problems and nutrition
- Smoking cessation: free nicotine patches, education
Included HCP: practice nurse, physiotherapist, dietician, psychologist, occupational
therapist, social worker, physician
Outcomes Chronic Respiratory Disease Questionnaire (CRDQ), York Quality of Life Question-
naire (YQLQ), 6MWD, lung function, patient attendance, staff working hours
Notes Main component of program: exercise
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The patients were randomly allo-
cated to either an intervention or a control
group”; no information on allocation pro-
cedure provided
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Bendstrup 1997 (Continued)
Allocation concealment (selection bias) Unclear risk The methods used to conceal the sequence
of treatment group allocation were not
available
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and treating therapists not
likely to have been blinded to group allo-
cation
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk We could not ascertain how and whether
outcome assessors were blinded to treat-
ment group assignment
Incomplete outcome data (attrition bias)
All outcomes
High risk High drop-out rate (31%) and no inten-
tion-to-treat analysis
Selective reporting (reporting bias) Low risk The study protocol is not available but it
is clear that the published reports include
all expected outcomes, including those that
were pre-specified
Bourbeau 2003
Methods RCT; follow-up: 12 months; control group: usual care
Participants Eligible: 469
Randomized: 191
Completed: 165
Mean age: I: 69 yrs; C: 70 yrs
Sex (% male): I: 52%; C: 59%
Inclusion criteria: stable COPD with at least one hospitalisation for an exacerbation in
preceding year, age≥ 50 yrs, pack yrs≥ 10 yrs, FEV1% predicted (post-bronchodilator)
: 25% to 70%, FEV1/VC < 70%
Major exclusions: noprevious diagnosis of asthmaor left congestive heart failure, terminal
disease, dementia, uncontrolled psychiatric disease, no pulmonary rehab < 1 yrs ago, no
long-term facility stays
Interventions A disease-specific self management program (Living Well with COPD) of 7 to 8 weeks
of follow-up including:
- Individual sessions of education by an experienced health professional at the patient’s
home
- Content of education: COPD knowledge, breathing and coughing techniques, energy
conservation during day-by-day activities, relaxation exercises; preventing and control-
ling symptoms through inhalation techniques, understanding and using a plan of action
for acute exacerbation, adopting a healthy lifestyle, leisure activities and travelling, a
simple home exercise program and long-term home oxygen therapy
- An action plan for acute exacerbations was customized for each patient
Intensity: education 1 hour per week during 7 to 8 weeks, follow-up first 2 months
weekly telephone calls, then once a month a telephone call. Exercise evaluation (not
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Bourbeau 2003 (Continued)
mandatory): 3 times per week, 30 to 45-min/session + exercise teaching
Included HCP: nurse, physiotherapist, physician, pulmonologist
Outcomes SGRQ, exacerbations, spirometry, FEV1 (L), forced vital capacity, hospital admissions,
symptoms, emergency room visits, outpatients visits, 6MWT, walking distance
Notes Main component of program: self management (including action plan)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “patients underwent randomisa-
tion with the use of a central computer-
generated list of random numbers. Ran-
domization was stratified per centre and
in blocks of 6, and patients were assigned
to the self management program (interven-
tion group) or to usual care.”
Allocation concealment (selection bias) Low risk Quote: “The blocking factor was not
known by the investigators or their staff in
each participating centre”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Since a double-blind design was
impossible ...”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “.. an independent evaluator un-
aware of the patient assignmentwas respon-
sible for the evaluation process in each cen-
tre. The evaluator was cautioned not to ask
about the workbook modules and types of
contact”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “An intention to treat analysis in-
cluded all available study patients”
Selective reporting (reporting bias) High risk Data on the 6MWD not presented, but
only stated as “not statistically significant”,
and authors can not provide us with addi-
tional data
42Integrated disease management interventions for patients with chronic obstructive pulmonary disease (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Boxall 2005
Methods RCT; follow-up 12 weeks; control group: usual care
Participants Eligible: not clear
Randomized: 60
Completed: 46
Mean age I: 78 yrs; C: 76 yrs
Sex (% male): I: 48%; C: 65%
Inclusion criteria: diagnosis of COPD by a respiratory specialist, age > 60 yrs, dyspnoea
on exertion, live locally, motivated to exercise daily unsupervised, stable for 2 weeks,
functionally housebound
Major exclusions: attending outpatient based PR, restricted shoulder movement, living
in nursing home, previous lung volume surgery, pain limiting mobility
Interventions 12 week program including:
- Exercise consisting of walking (level 1 to 10) and arm exercises (1 to 18) + education
sessions. Patients were required to carry out exercise daily. Weekly physiotherapy visits
were scheduled for the first 6 weeks, and then visits were made until week 12 of the
program. Visits were used to monitor exercise performance, progress exercises, retest
6MWT at regular intervals (weeks 1, 4, 6, 8 and 12 of the program) and provide
encouragement to patients
- Educational sessions for patients and carers were conducted by physiotherapists, nurses
and occupational therapy staff in their homes. Those sessions covered: anatomy and
physiology of the lungs, use of respiratory devices, medications, breathing techniques,
secretion removal techniques, energy conservation, use of adaptive aids and stress man-
agement. Patients received on average 11 home visits during the program
Included HCP: physiotherapists, nurses, occupational therapist
Outcomes Health status: SGRQ, 6MWD, hospital admissions, average length of stay, dyspnoea
Borg Scale
Notes Main component of program: exercise
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomised to equal
groups using computer-generated random
numbers”
Allocation concealment (selection bias) Low risk Quote: “Random number were coded into
opaque envelopes by a person independent
from the study, they retained the envelopes
until initial assessment was completed.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Neither assessors nor participants
were blinded to group assignment in this
study”
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Boxall 2005 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “Neither assessors nor participants
were blinded to group assignment in this
study”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcomedata balanced innumbers
(23/23 analyzed in both groups) across in-
tervention and control group, with similar
reasons for missing data across groups
Selective reporting (reporting bias) Low risk The study protocol is not available but it
is clear that the published reports include
all expected outcomes, including those that
were pre-specified
Cambach 1997
Methods RCT with cross-over design; follow-up 6 months; control group: drug treatment only
Participants Eligible: 89 (asthma and COPD)
Analyzed: 23 (COPD)
Mean age I : 62 yrs, C: 62 yrs
Sex (% male): I: 47%, C: 75%
Diagnosis of asthma or COPD according to guidelines, evidence of dyspnoea and de-
creased exercise tolerance as a result of obstructive lung disease, 18 to 75 yrs, ability
to travel independently to the physiotherapy practice, medication prescribed by a pul-
monary physician, motivation to improve self care, informed consent
Major exclusions: 1) manifest cardiac complaints, 2) hypercapnia and/or hypoxia
Interventions 12 weeks intervention including:
Exercise group sessions of 3 to 4 participants including techniques of breathing retraining
and evacuation of mucus, exercise training, patient education, relaxation techniques and
recreational activities. Training was 3 days a week for 90 minutes. Exercise training was
performed twice a week on a cycle ergometer and by stair-walking. Recreational activities
were once a week for 45 min. Education sessions were every week for 45 min
Included HCP: nurse, physiotherapist
Outcomes 6MWT, incremental cycle ergometer test, CRQ
Notes Main component of program: exercise
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”block randomisation procedure;
four closed envelopes for condition RC and
four closed envelopes for condition CR“
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Cambach 1997 (Continued)
Allocation concealment (selection bias) Low risk Quote: ”Four closed envelopes“
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and treating therapists not
likely to have been blinded to group allo-
cation
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcome assessors not likely to have been
blinded to intervention, as patients were
tested for exercise capacity in their prac-
tices, by their treated physiotherapist, who
was probably not blinded to group alloca-
tion
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “Data obtained from patients who
did not return for one or more of the assess-
ments (i.e. baseline (t0), after 3months (t3)
and/or after 6 months (t6), or patients who
were not measured within 3 weeks (from
t0, t3 and t6) were excluded fromdata anal-
ysis”. Comment: exclusion of non-respon-
ders may have affected outcome data
Selective reporting (reporting bias) Low risk The study protocol is not available but it
is clear that the published reports include
all expected outcomes, including those that
were pre-specified
Dheda 2004
Methods RCT; follow-up 6 months; control group: primary care follow-up
Participants Eligible: 33
Completed: 25
Mean age I: 68 yrs, C: 71 yrs
Sex (% male) both groups: unknown
Diagnosis COPD according to British Thoracic Society guidelines, patients with a first
admission to hospital, with progressive symptoms, a smoking history of > 20 pack-years
Major exclusions: another dominant medical condition, a mandatory reason for hospital
follow-up
Interventions Intervention program of 6 months
A respiratory nurse and/or chest physician reviewed the intervention group at least 4
times in the 6 month period (at 6, 8, 12 or 16 weeks). The following interventions
were made at some or all of these visits: spirometry with reversibility, review of inhaler
technique and peak flow diary, ambulatory oxygen assessment, smoking cessation advice,
steroid trial, nebuliser assessments, review of medication, advice about nutrition and
exercise, and introduction to a patient support group
Included HCP: nurse, chest physician
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Dheda 2004 (Continued)
Outcomes SGRQ, SF-36
Notes Main component of program: structured follow-up with nurse/GP
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not reported
Allocation concealment (selection bias) Unclear risk The methods used to conceal the sequence
of treatment group allocation were not
available
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and treating therapists not
likely to have been blind to group alloca-
tion
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported and therefore unclear who
scored outcome assessments (patients, care-
givers, outcome assessors?)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not clearwhether the results in SGRQwere
described in the total population, as well as
in the patients who withdrew (n = 8) from
the study
Selective reporting (reporting bias) High risk Not all outcomemeasurements are given in
measures but only reported as “there was no
significant difference at 6months in FEV1”
Engstrom 1999
Methods RCT; follow-up 12 months; control group: usual outpatient care
Participants Eligible: 58
Randomized: 55
Completed: 50
Mean age I: 66 yrs, C: 67 yrs
Sex (% male) I: 54%, C: 50%
Clinical diagnosis of COPD, developing after at least 10 yrs of smoking, FEV1 < 50%,
debut of symptoms after 40 yrs of age, dyspnoea mainly elicited by exercise or infections,
no allergy
Major exclusions: disabling or severe diseases, co-existence of other causes of impaired
pulmonary function
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Engstrom 1999 (Continued)
Interventions 12 months rehabilitation program including:
- Exercise training sessions (bicycle, arm and breathing techniques), 2/week for 6 weeks,
once weekly for 6 weeks, once every second week for 6 weeks and then once a month
for remaining period. Every session: 45 min. Furthermore, instructions for daily walks
and an individualized daily 30-min home-training program
- Individualized educational program with outpatient team (nurse and physician) on
visit every 3 months
- Occupational therapist gave 2 group sessions about energy saving techniques and 2
global education sessions
- Dietician gave information about nutrition in COPD patients and intervened in mal-
nutrition
Included HCP: physiotherapist, nurse, physician, dietician, occupational therapist
Outcomes SGRQ, 6-MWD, W-max, days in hospital, SIP, Mood Adjective Check List (MACL)
Notes Main component of program: exercise
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information reported
Allocation concealment (selection bias) High risk Quote: “Patients with COPD were re-
cruited consecutively and,when a sufficient
number had been collected, randomised to
produce a rehab group and a control group
of equal size.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and treating therapists not
likely to have been blinded to group allo-
cation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “All the physiological and QOL as-
sessments were blinded, except the walking
test, which was performed by the nurse in
the rehabilitation team”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcomedata balanced innumbers
across intervention and control group (2
versus 3 persons)
Selective reporting (reporting bias) Low risk The study protocol is not available but it
is clear that the published reports include
all expected outcomes, including those that
were pre-specified
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Farrero 2001
Methods RCT; follow-up 12 months; control group: usual care
Participants Randomized: 122
Completed: 94
Mean age I: 69 yrs, C: 69 yrs
Clinical diagnosis of COPD, requiring oxygen for at least 6 months, with willingness to
participate in a hospital based home-care program, and with residence within easy reach
of the hospital
Interventions Hospital based home-care program of 12 months with the aim of combining home-care
management and easy access to hospital resources. Program included:
- Monthly telephone calls and 3-monthly home visits from a nurse, working closely
with a physician. Patients could also request with an immediate response, which varied
according to a home visit, a hospital visit, telephone advice or a control visit.
Included HCP: nurse and physician
Outcomes CRQ, spirometry, mortality, hospital admissions, hospital days, ED visits
Notes Main component of program: structured follow-up with nurses
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “After this initial evaluation, in-
formed consent was obtained and patients
were allocated randomly to the HCP treat-
ment group or to the control group”. Com-
ment: unclear if patients were randomised
by sequence generated or based on, for ex-
ample, date of admission
Allocation concealment (selection bias) Low risk Quote: “Codes of randomisation were kept
in sealed envelopes”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and treating therapists not
likely to have been blinded to group allo-
cation
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “Patients in the control group were
evaluated by the HCP team at the outpa-
tient department in the initial visit, and af-
ter 1 year.” Comment: as the HCP team
was the intervention team and was not
blinded to which group a patient was ran-
domised, it is likely that assessment can be
influenced by no blinding of the outcome
assessor
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Farrero 2001 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “Quality of life was investigated in
the first 40 consecutive patients included in
the study (..) applied before the study and
after 3months and12months.”Comment:
reason for missing outcome data likely to
be related to true outcome, with imbalance
in numbers
Selective reporting (reporting bias) Low risk The study protocol is not available but it
is clear that the published reports include
all expected outcomes, including those that
were pre-specified
Fernandez 2009
Methods RCT; follow-up 12 months; control group: education (mono-disciplinary intervention)
Participants Eligible: 50
Randomized: 50 (I: 30; C: 20)
Mean age: 66 yrs, C: 70 yrs
Sex: 100% male (both groups)
Inclusion criteria: GOLD 4 patients, younger than 80 yrs of age, stable COPD, defined
as a period of 2 months without any exacerbations, defined as signs of acute dyspnoea
requiring medical attention, changes in the quantity and characteristics of sputum, an
increase in pulmonary noise or an increase in the necessity for medication, the correct
administration of pharmacological treatment according to GOLD, home treatment with
oxygen for at least 6 months prior to the commencement of the study
Major exclusions: severe cardiovascular pathology, unstable angina, acute myocardial
infarction, cerebral vascular accident, or physical or psychological disorder that impede
the practice of physical exercise
Interventions Rehab program of 11 months
At the start: 2 one-hour sessions of respiratory re-education in the hospital, where exercises
at home were taught
Home-rehab program :
- 1 hour of exercise per day (respiratory reeducation, muscular inspiratory training,
muscular training of upper and lower limbs)
- First 2 months: attendance of physiotherapist at home (who visited twice monthly for
1 hour)
- Month 2 to 9: single monthly visits physiotherapist, included resistance training, res-
piratory reeducation, isotonic training, training of respiratory muscles
- 3 respiratory education sessions by nursing staff (handling of inhalers, knowledge of
the illness, what to do in the event of attack)
Included HCP: nurse, physiotherapist
Outcomes Pulmonary function, SGRQ, 6MWD
Notes Main component of program: exercise
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Fernandez 2009 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “50patientswere prospectively ran-
domised to block of 5 patients and ran-
domly divided into 2 groups.”
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and treating therapists not
likely to have been blinded to group allo-
cation
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk Drop-out rates between groups comparable
Selective reporting (reporting bias) Low risk All outcomes in methods section provided
Gottlieb 2011
Methods RCT; follow-up: 18 months; control group: usual care
Participants Eligible: 133
Randomized: 61
Completed: 26
Mean age I: 74 yrs, C: 73 yrs
Sex (% male): I: 32%, C: 35%
Inclusion criteria: a diagnosis of moderate COPD, FEV1/FVC < 0.7 and 50% ≤ FEV1
< 80% with motivation for pulmonary rehabilitation
Exclusion criteria:
1. Co-morbidity contraindicating rehabilitation
2. Participation in PR within the last year
3. Cognitive disorders limiting the ability to participate in physical training and educa-
tional sessions
Interventions Program of intensive training for 7 weeks, with maintenance program for 6 months,
including:
- Intensive 7-week physical training and educational phase led by a multidisciplinary
team. Furthermore, smoking cessation counseling given on an individual basis and a
dietary intervention consisted of group cookery classes and individual sessions
- Final interview following completion of the program, in which participants’ achieve-
ments were compared to the original goals
- Maintenance program for 6 months, including a 90-min monthly session focusing on
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Gottlieb 2011 (Continued)
ways of incorporating exercise in daily life, and 2 sessions on exercise activities in the
local community, and another 2 sessions on exercise as well as on repetition of relevant
topics
Included HCP: multidisciplinary team, not further specified. Authors were unreachable
for further information
Outcomes SGRQ, 6MWD, MRC, Borg dyspnoea scale, Sit-to-Stand test
Notes Main component of program: exercise
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Subjects were randomised 1:1 to
pulmonary rehabilitation and control”
Allocation concealment (selection bias) Low risk Quote: “Randomizationwas performedus-
ing sealed opaque envelopes randomly as-
signed to participants”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and treating therapists not
likely to have been blinded to group allo-
cation
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk We could not ascertain how and whether
outcome assessors were blinded to treat-
ment group assignment
Incomplete outcome data (attrition bias)
All outcomes
High risk Drop-out rate equally divided: 39% inter-
vention group, 23% control group
Selective reporting (reporting bias) High risk Results on MRC Dyspnea Scale not re-
ported in results section
Güell 2000
Methods RCT; follow-up: 24 months; control group: usual care
Participants Eligible: 65
Randomized: 60; I: 30, C: 30
Completed (24 months): 47 (I: 23; C: 24)
Mean age I: 66 yrs, C: 64 yrs
Sex (% male) both groups: 100%
Inclusion criteria: age ≤ 75 years, FEV1 < 70%, FEV1/FVC < 65%, PaO2 > 55 mm
Hg at rest with no indication for prescribing home oxygen therapy
Major exclusion criteria: clinically apparent heart disease, bone or joint disease
Exacerbation or hospitalisation in previous month
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Güell 2000 (Continued)
Interventions 6months intensive rehabilitation program, followed by a 6-monthmaintenance program
- First 3 months: 2 30-min sessions each week: breathing retraining, combined with a
low-level home exercise program. If indicated, patients also received chest physiother-
apy, which involved teaching effective cough and postural drainage. Patients attended
educational sessions on the anatomy and basic physiology of the respiratory system as
well as on the nature of their disease and of PR
- Month 3 to 6: exercise training program of 5 30-min sessions weekly on a stationary
cycle ergometer. During this period, patients also began a program of home exercise with
either 30 min of pedaling on a stationary cycle or 1 h of walking
- Month 6 to 12: single weekly session in groups during which they performed exercises
for breathing and leg-arm co-ordination
- Month 12 to 24: instructed to do home exercises without supervision
Included HCP: nurse, physiotherapist, pulmonologist
Outcomes Lung function, 6MWD, cycle ergometer, VAS, MRC, CRQ, exacerbations, hospital
admissions
Notes Main component of program: exercise
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Randomization was done at inclu-
sion of consecutive patients”
Allocation concealment (selection bias) High risk Quote: “Randomization was not con-
cealed”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “same physician saw patients at
each visit”. It was unlikely that the health
care professional was blinded to treatment
group allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The technicians, who collected
data for outcome measures at every visit, as
explained below, were blinded to a patient’s
allocation to PR or control groups”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcome data balanced in num-
bers across intervention groups, with simi-
lar reasons for missing data across groups
Selective reporting (reporting bias) Low risk The study protocol is not available but it
is clear that the published reports include
all expected outcomes, including those that
were pre-specified
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Güell 2006
Methods RCT; follow-up: 4 months; control group: usual care
Participants Randomized: 40; I: 20; C: 29
Completed: 35; I: 18, C: 17
Mean age: I: 68 yrs, C: 66 yrs
Male: I: 88%, C: 100%
Inclusion criteria: age ≤ 75 years, FEV1 < 70%, FEV1/FVC < 65%, PaO2 > 55 mm
Hg at rest with no indication for prescribing home oxygen therapy
Exclusion criteria: psychiatric disturbances, no heart, bone or joint disease. Exacerbation
or hospitalisation in previous 2 months
Interventions PR program of 4 months, including:
- First 2months: 2 30-min sessions each week, including relaxation techniques, breathing
retraining, and chest wall and abdominal muscle wall work. Patients attended 4 45 to
60-min educational sessions
- Month 2 to 4: 5 30-min sessions weekly exercise training on cycle ergometer
Included HCP: nurse, physiotherapist, pulmonologist
Outcomes Millon Behavior Health Inventory (MBHI), Revised Symptom Checklist (SCL-90-R),
6MWD, CRQ
Notes Main component of program: exercise
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Randomization was done at inclu-
sion of consecutive patients”
Comment: it is not clear how the sequence
was generated
Allocation concealment (selection bias) High risk Quote: “Randomization was not con-
cealed”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Neither patients nor clinicians
were blinded to allocation”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “the technicians who collected the
data were blinded to patient allocation, as
were the data analysts until the analysis was
deemed complete”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up comparable between
groups (2 versus 3)
Selective reporting (reporting bias) Low risk All outcomes reported
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Koff 2009
Methods RCT; follow-up 3 months; control group: usual care
Participants Eligible: 40; randomised: 40; completed 38
Mean age I: 67 yrs, C: 65 yrs
Sex (% male): I: 45%, C: 50%
Inclusion criteria: clinical diagnosis of COPD, GOLD 3+4, with a telephone land line
Exclusion criteria: active treatment for lung cancer, illiteracy, non-English speaking,
inability to complete a 6MWD
Interventions 3-month intervention program, including:
- Disease-specific education, by respiratory therapist at enrolment and daily by Health
Buddy System (tele healthcare) Education included disease description, medications and
their use, nutrition, breathing techniques
- Teaching of self management skills (use of an oximeter and increased awareness of clin-
ical changes/problems). Patients could contact the co-ordinator in case of deterioration
- Patients were remotely monitored 5 days per week with the Health Buddy system for
change in symptoms, saturation, 6MWD and lung function. The study co-ordinator
reviewed these results and patients were contacted if they were at high risk for exacerba-
tion. They started exacerbation management or had contact with respiratory physician/
GP
Included HCP: physician, pulmonologist
Outcomes SGRQ, 6MWD, exacerbations, hospitalizations, EDvisits, equipment satisfaction, num-
ber of calls
Notes Main component of program: self management
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “patients randomly selected their
group assignment (by choosing a blinded
envelope that contained a group indicator”
Allocation concealment (selection bias) Low risk Quote: “patients randomly selected their
group assignment (by choosing a blinded
envelope that contained a group indicator”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “because of the type of interven-
tion, it was not possible to blind the sub-
jects or investigators as to whether they
were randomised to the treatment or con-
trol arms of the trial”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “primary end-point was collected
by the coordinator, and analysed by R.H.
Jones.” The co-ordinator was also respon-
sible for the intervention and was therefore
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Koff 2009 (Continued)
not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Drop-out rates balanced in numbers across
groups
Selective reporting (reporting bias) Low risk All outcomes reported
Littlejohns 1991
Methods RCT; follow-up 12 months; control group: usual care
Participants Eligible: 166
Randomized: 152; I:73, C: 79
Completed (12 months): 133; I: 68, C: 65
Mean age I: 63 yrs, C: 63 yrs
Sex (% male): I: 67, C: 63
Inclusion criteria: COPD diagnosed by spirometry, according to guidelines. Inclusion
criteria: age 30 to 75 yrs, prebronchial FEV1 % < 60%, stable state, no change in
medication for at least 6 weeks before recruitment, no other major disease
Interventions Intervention group received the care of the respiratory health worker while continuing
with their routine outpatient appointments during 12 months. The health worker pro-
vided:
- Health education directed at the patient and the primary care team
- Monitoring of treatment compliance and optimizing treatment by ensuring correct
inhalation techniques and supervision of domiciliary oxygen
- Monitoring of the results of spirometry and the patients’s symptoms to enable acute
exacerbations and worsening heart failure to be detected and treated early
- Liaison between GP and hospital-based services (including domiciliary physiotherapy
services and social services)
Included HCP: GP, respiratory health worker
Outcomes Mortality, spirometry, 6MWD, step test,MRCchronic bronchitis questionnaire,HADS,
SIP, hospital admissions, drug prescriptions, visits to GP or clinic, satisfaction
Notes Main component of program: structured follow-up with respiratory health worker
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “random numbers were generated
by tables in permuted blocks of four, strat-
ified by age and sex”
Allocation concealment (selection bias) Low risk Quote: “the groups to which successive pa-
tients were to be allocated were noted in
sealed, numbered envelopes, which were
55Integrated disease management interventions for patients with chronic obstructive pulmonary disease (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Littlejohns 1991 (Continued)
kept centrally”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “the physician was aware which
group the patient was in”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk Drop-out rates comparable between groups
Selective reporting (reporting bias) High risk The outcomes on the MRC chronic bron-
chitis questionnaire are not reported
Mendes 2010
Methods RCT; follow-up 12 weeks; 2 intervention groups (at home PR versus outpatient PR), 1
control group: usual care
Participants Eligible: 117
Randomized: 117 (Intervention I: 42; Intervention II: 46; Control: 29)
Analyzed: 85 (Intervention group I: 33; Intervention II: 23; Control: 29)
Mean age: Intervention I: 66 yrs, Intervention II: 71, Control: 71
Sex (% male): Intervention I: 82%, Intervention II: 83, Control: 66%
Inclusion criteria: diagnosis of COPD according to GOLD, stable at inclusion
Major exclusions: hospitalisation or COPD instability, presence of neuromuscular dis-
ease, associated respiratory disease, orthopedic or neurological disease that affected gait,
recent impairment due to co-morbidities, such as myocardial infarction, heart failure,
stroke or neoplasm; prior pneumonectomy or other thoracic surgery
Interventions Intervention program of 3 months performed either at home or at the outpatient clinic:
- Both intervention groups received 1 session of education about COPD, treatment and
relevance of PR
- Both intervention groups trained 3 mornings a week for 3 months, with aerobic and
strengthening exercises. Patients in the outpatient clinic trained under supervision; pa-
tients who trained at home were instructed in the clinic and received support by tele-
phone calls
Included HCP: physiotherapist, pulmonologist
Outcomes 6-MWD, MRC, FEV1, BMI, all included in BODE index (body mass, obstruction,
dyspnoea, exercise tolerance- index)
Notes Main component of program: exercise
Risk of bias
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Mendes 2010 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “patients were randomised elec-
tronically by a computer”
Allocation concealment (selection bias) High risk Distribution of patients was unequal: 42
in at-home group, 46 in outpatient group
versus 29 in control group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and treating therapists not
likely to have been blinded to group allo-
cation
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “Two duly trained health care pro-
fessionals were responsible for the evalua-
tions, which were performed by the same
evaluators for all patients”. Comment: not
clear if these professionals were blinded to
group allocation
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “19 out of 46 of out-patient inter-
vention group were lost to follow up, com-
pared to 7 out of 42.”
Comment: the reasons for missing out-
come data likely to be related to true out-
come, with imbalance in numbers of miss-
ing data
Selective reporting (reporting bias) Low risk The study protocol is not available but it
is clear that the published reports include
all expected outcomes, including those that
were pre-specified
Rea 2004
Methods Cluster RCT; follow-up: 12 months; control: conventional care
Participants Eligible: 158
Randomized: 135; I: 83, C: 52
Completed: 117
Mean age of both groups: 68 yrs
Sex (% male) of both groups: 41.5%
Inclusion criteria: COPD diagnosed by ICD-9-CM codes and GP records for a clinical
diagnosis of moderate to severe COPD
Major exclusion criteria for patients: chronic asthma, bronchiectasis, comorbidity more
significant than COPD, unable to give informed consent, prognosis < 12 months, long-
term oxygen therapy or too unwell, deceased
Major exclusion criteria GP: no longer enrolled with participating GP practice or moved
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Rea 2004 (Continued)
out of area, unable to contact patient, insufficient practice nurse resource
Interventions A chronic disease management program was implemented including:
- An action plan, which was implemented by patient’s own GP and practice nurse,
with advice from the respiratory nurse and specialist physician. The plan comprised a
timetable for regular maintenance checks and set achievable goals for lifestyle changes
- Patients visited the nurse monthly, the GP 3 monthly and at other times if worsening
symptoms demanded more visits
- Patients received education about smoking cessation, medication. Annual influenza
vaccination and pulmonary rehabilitation were recommended
Included HCP: GP, nurse, pulmonologist
Outcomes Health status, SF-36, CRQ, shuttle walk test, spirometry, hospital admissions, medica-
tion, courses of oral steroids, courses of antibiotics, smoking cessation
Randomization at cluster level, analysis at patient level
Notes Main component of program: self management/action plan and structured follow-up by
GP/nurse
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Practices were randomised, using
a set of computer-generated numbers”
Allocation concealment (selection bias) Unclear risk No information available
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and health care providers not
likely to have been blinded to group allo-
cation
Blinding of outcome assessment (detection
bias)
All outcomes
High risk The health care providers involved in the
program administered outcome measure-
ments at visit
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcome data balanced between
groups, with similar reasons for missing
data across groups
Selective reporting (reporting bias) Low risk All outcomes reported
Recruitment bias Low risk Quote: “Written information about the
trial was provided to patients and consent
was obtained before patients knew whether
they belonged to an intervention or control
practice”
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Baseline imbalance between groups High risk No stratified or pair-matched randomisa-
tion was used, resulting in baseline imbal-
ance of 99 eligible patients in the interven-
tion group and 59 patients in the control
group
Loss to follow-up of clusters High risk Quote: “After randomisation, two prac-
tices declined to participate and in three,
changes of either GP’s or practice nurses
prevented participation before enrolment
had begun”
Adequate analysis methods for CRT High risk Inadequate methods of analysis: randomi-
sation done at level of GP practice, analysis
performed at level of patients
Rice 2010
Methods RCT; follow-up 12 months; control: single intervention (one page of information and
telephone number)
Participants Eligible: 743
Randomized: 743; I: 372, C: 371
Completed: 743
Mean age I: 69 yrs, C: 71 yrs
Sex (% male) I: 98%, C: 98%
Inclusion criteria: COPD diagnosed by spirometry. Inclusion criteria: at high risk for
hospitalisation as predicted by one or more of the following during the previous year:
hospital admission or ED visit for COPD, chronic home oxygen use, or a course of
systemic corticosteroids for COPD
Major exclusion criteria: any condition that might preclude effective participation in the
study or that would reduce life expectancy to less than a year, or no access to a telephone
Interventions Chronic disease management program of 12 months, including:
- Group session (1-1, 5-hour): general information about COPD, medication, smoking
cessation, vaccinations and exercise
- All patients received an individualized written action plan including prescriptions for
prednisone and antibiotics with contact information with a case manager. Participants
were in possession of action plan medications at all times and were to refill prescriptions
immediately upon initiating the action plan
- The case manager made monthly telephone calls
Included HCP: case manager, pharmacist
Outcomes ED and hospital admissions related to COPD, SGRQ, mortality, number of telephone
contacts
Notes Main component of program: self management/action plan
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “We assigned subjects in equal pro-
portions to each of the two treatment arms
by permuted Block randomisation”
Allocation concealment (selection bias) Unclear risk Information not available
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and treating therapists not
likely to have been blinded to group allo-
cation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Blinded pulmonologists indepen-
dently reviewed all discharge summaries
and ED reports and assigned a primary
cause for each”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All outcome data reported. Concordance
between outcome observers was tested in
subset and was 96.5%
Selective reporting (reporting bias) Low risk No missing outcome data
Smith 1999
Methods RCT; follow-up 12 months; control: usual care
Participants Eligible: 105
Randomized: 96; I: 48, I: 48
Completed: 36 (data only completed in Intervention group)
Mean age I: 70 yrs, C: 70 yrs
Major inclusion criteria: COPD diagnosis according to guidelines, age > 40 years, FEV1/
FVC less than 60%, in a stable state, have a carer involved in their management, be able
to speak and read English and give written consent
Major exclusion criteria: no other active illness
Interventions An intervention of 12 months including:
- Follow-up planning of in- and outpatients with a nurse in shared care approach with
GP andmedical staff. Goals for discharge and nurses discussed with theGP the needs and
facilitated involvement of domiciliary service. Goals were inserted into patients’ notes
- During 12 months every 2 to 4 weeks there was a home visit including education,
spirometry, optimal medication, exacerbation management, smoking cessation and fit-
ness advice
Included HCP: nurse, GP, social worker, hospital medical officer
Outcomes COOP (HRQoL), mortality, hospital admissions, lung function
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Notes Main component of program: structured follow-up with nurses/GP
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “patients were randomised as they
were enrolled, following discharge from
hospital (..), into the HBNI or control
groups from two lists of randomly com-
puter generated numbers”
Allocation concealment (selection bias) Low risk Quote: “patients were randomised as they
were enrolled, following discharge from
hospital”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “This study was unblinded”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “This study was unblinded”
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “Attempts to perform question-
naires in the control subjects were unsuc-
cessful due to a combination of (I) these
subjects perceived no immediate benefit of
the trial; and (ii) the burden of participat-
ing in a study”
Comment: no outcomes reported in con-
trol group
Selective reporting (reporting bias) High risk One or more primary outcomes in the re-
view (COOP, spirometry) are reported in-
completely so that they cannot be entered
in a meta-analysis
Sridhar 2008
Methods RCT; 104 weeks; control group: usual care
Participants Eligible: 297
Randomized: 122 (I: 61; C: 61)
Mean age both groups: 70 yrs
Sex (% male): both groups: 49%
Inclusion criteria: diagnosis of COPD and admitted between 2000 and 2004 with an
acute exacerbation of COPD
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Exclusion criteria: significant comorbidity (severe heart disease or cancer, or any con-
dition that would preclude participation in the physical therapy component of a PR
program)
Interventions Intervention program of 24 months:
- Patients started with a PR program for 4 weeks, including general education about
disease and treatment, and physical training program
- After 4 weeks, patients received a home visit, including a written COPD action plan
for exacerbations. The GPs provided medication
- Patients received monthly telephone calls and a home visit every 3 months until 24
months follow-up. They reinforced advice regarding treatments, smoking cessation, the
need to continue their exercise therapy and reinforced the self management education
Included HCP: GP, nurse, physiotherapist
Outcomes CRQ, mortality, exacerbations, hospital admissions, lung function
Notes Main component of program: exercise + action plan
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “122 patients were suitable and
were recruited and randomised by the use
of randomnumbers to the intervention and
control group”
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and treating therapists not
likely to have been blinded to group allo-
cation
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk Drop-out rates comparable between groups
Selective reporting (reporting bias) Low risk The study protocol is not available but it
is clear that the published reports include
all expected outcomes, including those that
were pre-specified
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Strijbos 1996
Methods RCT; 18 months; intervention group 1: hospital based PR, intervention group 2: home
based PR, control group: usual care
Participants Eligible: 50
Randomized: 50; I group 1: 18, I group 2: 17, C: 15
Completed: 41
Mean age I 1: 61 yrs, I 2: 60 yrs, C: 63
Sex (% male): I 1: 93%, I2: 80%, C: 80%
Inclusion criteria: diagnosis COPD as evidenced by history, physical examination, chest
radiograph and pulmonary function test results, PaCO2 at rest of less than 6.5 kPa, and
PaO2 at rest of more than 7.5 kPa; FEV1 < 65% predicted
Major exclusion: ischaemic heart disease, musculoskeletal disorders or other disabling
diseases that could restrict the rehab therapy
Interventions 12-week rehabilitation program:
- Both groups: exercise twice a week during 12 weeks, 1 hour each session
- In the hospital group exercise was administered by a physiotherapist (1 hour twice a
week) and patients were instructed to practice daily exercise for at least 15 min. Patient
education 3 times/1 hour by a respiratory nurse
- In the home-care group, exercise was carried out at home by the local physiotherapist
and home-care nurse, under supervision of the GP. Patients received an individualized
exercise program from physiotherapist of 30 minutes (24 sessions), and were instructed
to exercise at least 15 to 30 min. They received 3 times education by a nurse and 3 times
a visit by the physician or GP
- Both groups were intended to continue exercise daily at home, after completion of the
program
Included HCP: nurse, physiotherapist and GP or pulmonologist
Outcomes 4minute walking test (4MWT), cycle test (measured as maximum watts, W-max) and
interviews
Notes Main component of program: exercise
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “patients were randomly assigned
to intervention or control group”. Infor-
mation is insufficient to be confident that
the allocation sequence was genuinely ran-
domised
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and treating therapists not
likely to have been blinded to group allo-
cation
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Strijbos 1996 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk We were unable to ascertain whether out-
come assessors were blinded to treatment
group assignment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comparable low drop-out rates in both
groups
Selective reporting (reporting bias) Low risk The study protocol is not available but it
is clear that the published reports include
all expected outcomes, including those that
were pre-specified
Theander 2009
Methods RCT; 3 months; control group: usual care
Participants Eligible: 30
Randomized: 30; I:15, C:15
Completed: 26
Mean age I: 66; C: 64 yrs
Sex (% male): I: 25%; C: 71%
Inclusion criteria: diagnosis of COPD: according to British guidelines, with FEV1 be-
tween 60% to 25% post bronchodilation, and age ≤ 75 yrs
Major exclusions: disabling or severe disease other than COPD, impaired pulmonary
function due to other disease, long-term oxygen therapy, alpha1-antitrypsine deficiency,
cancer disease, untreated obstructive sleep apnea syndrome and no COPD-related symp-
toms affecting their activities of daily life
Interventions Multidisciplinary program:
- Physiotherapy 2 days per week (1 hour) for 12 weeks, with additional home training
after q month
-Dietician support (3 sessions of 1 hour): education and, if needed, additional nutritional
supplementation
- Occupational therapist: education and teaching
- Nurse (two sessions of 1 hour): education and self care advice
Included HCP: physiotherapist, dietician, occupational therapist, nurse
Outcomes BMI, FEV1, fatigue impact scale, 6MWD, grip strength, SGRQ, SF-36
Notes Main component of program: exercise
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “For the randomisation we pre-
pared 80 sealed opaque envelopes with as-
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Theander 2009 (Continued)
signment information: 40 for the rehabili-
tation group and 40 for the control group”
Allocation concealment (selection bias) Low risk Quote: “Randomization procedures were
performed by an independent person from
the research group, who took a random en-
velope from the prepared box with sealed
envelopes”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and treating therapists not
likely to have been blinded to group allo-
cation
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “The data collectionwas performed
by members of the rehabilitation group.
The data collection was not blinded to the
data collector”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comparable drop-out rates
Selective reporting (reporting bias) Low risk The study protocol is not available but it
is clear that the published reports include
all expected outcomes, including those that
were pre-specified
Trappenburg 2011
Methods RCT; follow-up 6 months; control group: usual care
Participants Eligible: 391
Randomized: 233, I: 111, C: 122
Completed (6 months): 193; I: 91, C: 102
Mean age: I 66 years, C: 65 years
Sex (% male): I: 65% C: 69%
Inclusion criteria: COPD diagnosed by spirometry, age > 40 years, smoking history of >
20 years or 15 pack-years, diagnosis of COPD as a major functionally limiting disease,
current use of bronchodilator therapy
Major exclusions: primary diagnosis of asthma, primary diagnosis of cardiac disease,
presence of disease that could either affect mortality or participation in the study
Interventions 6-month self management/action plan program:
- Individualized action plan with treatment prescriptions related to a color-coded symp-
tom status to enhance an adequate response to periods of symptom deterioration
- The action plan included ongoing support of a case manager, in concordance with a
GP/respiratory physician. There were 2 reinforcement sessions by telephone at 1 and 4
months
Included HCP: GP, nurse, pulmonologist
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Trappenburg 2011 (Continued)
Outcomes Exacerbation rates and recovery time, SGRQ, HADS, courses of antibiotics, corticos-
teroids, ED visits for exacerbation, CCQ score during exacerbation
Notes Main component of program: self management/action plan
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomisation was carried out
using the minimization technique to bal-
ance the control and intervention groups
for centre and gender”
Allocation concealment (selection bias) Low risk Quote: “to conceal the assignment se-
quence, a central web-based service was
used”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “an informed consent to postponed
information procedure is used, keeping the
patient unaware of the AP being the ma-
jor study aim. This implies that all patients
are informed about the fact that, besides
the outcome assessment aiming at gaining
more insight in daily symptom variations,
the study has another purpose. Patients are
told that they will be informed about this
additional research question only after fol-
low up because informing during recruit-
ment would affect study results”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “investigators were blinded to allo-
cation”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “monthly discontinuation rates and
reasons for withdrawal are comparable in
both study arms”
Selective reporting (reporting bias) Low risk The study protocol is not available but it
is clear that the published reports include
all expected outcomes, including those that
were pre-specified
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van Wetering 2010
Methods RCT; follow-up: 24 months, control group: usual care (pharmacotherapy according to
guidelines, short smoking cessation advice by chest physician and recommendation to
eat more in case of nutritional depletion)
Participants Eligible: 199
Randomized: 199; I: 102, C: 97
Completed 4 months: I: 87; C: 88
Completed 24 months: I: 77; C: 81
Mean age I: 66 yrs, C: 67 yrs
Sex: I: 71%; C: 71%
Inclusion criteria: diagnosis of COPD according to guidelines, other inclusion criteria:
impaired exercise capacity, W-max < 70%, GOLD 2+3 and clinical stable at inclusion.
Major exclusion criteria: prior rehabilitation and patients with serious co-morbidity that
precluded exercise therapy were excluded
Interventions 24-month program including:
- Intensive 4-month standardized, supervised physiotherapy 2/week (30 min), with
home-based exercises
- Patients participated in an individualized education program
- All smokers were offered smoking cessation counseling
- Nutritionally depleted patients received counseling from a dietician
- During the 20-month active maintenance phase, patients were instructed to train at
home and visited the physiotherapist once a month. Dietician support was continued
Included HCP: nurse, physiotherapist, dietician
Outcomes SGRQ, total score and number of exacerbations, MRC dyspnoea scale, exercise per-
formance (measured as maximum Watts: W-max), 6MWD, muscle strength, isometric
quadriceps peak torque, maximal inspiratory mouth pressure, fat-free mass and lung
function
Notes Main component of program: exercise
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “patients were randomised to IN-
TERCOM or usual care using a comput-
erised procedure with concealed patient al-
location”
Allocation concealment (selection bias) Low risk Quote: “patients were randomised to IN-
TERCOM or usual care using a comput-
erised procedure with concealed patient al-
location”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and treating therapists not
likely to have been blinded to group allo-
cation
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van Wetering 2010 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “all outcome measurements were
assessed single blind”
Incomplete outcome data (attrition bias)
All outcomes
Low risk The results were analyzed by intention-to-
treat
Selective reporting (reporting bias) Low risk The study protocol is not available but it
is clear that the published reports include
all expected outcomes, including those that
were pre-specified
Wakabayashi 2011
Methods RCT; follow-up 12 months; control group: single intervention (education)
Participants Eligible: 102
Randomized: 102; I: 52, C: 50
Completed: 85; I: 42, C: 43
Clinical diagnosis of COPD, > 65 years, exclusively visit the clinic with monthly sched-
uled appointments, have a history of cigarette smoking
Exclusion criteria: history of atopy or any apparent asthmatic features, were illiterate or
had cognitive impairment score of less than 26 on MMSE, lived in a residential care
facility or a nursing home, had exacerbations during preceding 3 months, or had other
respiratory diseases such as bronchiectasis, any type of pulmonary fibrosis or congestive
heart failure
Interventions Patients underwent a program of educational sessions for 6 months, individually tailored
according to their domain scores on the LINQ questionnaire, which was designed to
assess the need for information from a patients’ perspective. The program was given by
respiratory nurses and pulmonary physicians. There were six domains: 1) understanding
of COPD, 2) pharmacological treatments, 3) exercise, 4) avoidance of exacerbations,
including action plan with instructions in the event of exacerbations, 5) smoking cessa-
tion, 6) nutrition. All patients were provided with a booklet that was used during each
session. After the intensive education period, each patient was followed up for 6 months
in the same way as the patients in the usual care group
Included HCP: nurse, pulmonologist
Outcomes FEV1, MRC, SGRQ, 6MWD, Lung Information Needs Questionnaire (LINQ), BMI,
BODE index (body mass index, dyspnoea, airflow obstruction, exercise capacity), Ac-
tivities of Daily Living (ADL), co-morbidities, hospitalizations
Notes Main component of program: self management/action plan
Risk of bias
Bias Authors’ judgement Support for judgement
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Wakabayashi 2011 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “a case manager independent of the
study randomly assigned patients to either
group I or group U using a computer-gen-
erated list”
Allocation concealment (selection bias) Low risk Quote: “Patients allocations were sealed in
numbered envelopes by an independent
evaluator, not involved in the interven-
tions”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and treating therapists not
likely to have been blinded to group allo-
cation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “an independent evaluator, who as-
sessed outcomes at the beginning of the
study, after initial integrated education (6
months), and after follow-up period (6
months)”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comparable drop-out rates between
groups
Selective reporting (reporting bias) Low risk The study protocol is not available but it
is clear that the published reports include
all expected outcomes, including those that
were pre-specified
Wijkstra 1994
Methods RCT; follow-up 12 weeks; control group: no treatment
Participants Randomized: 45
Completed: 43 (I: 28; C: 15)
Mean age I: 64 yrs, C: 62 yrs
Sex (% male): I: 82%, C: 93%
Inclusion criteria: diagnosis of COPD with FEV1 % < 60%, FEV1/IVC < 50%
Exclusion criteria: evidence of ischaemic heart disease, intermittent claudication, mus-
culoskeletal disorders or other disabling diseases that could restrict the rehab program
Interventions Intervention program of 12 weeks:
- Patients were supervised by a multidisciplinary team: pulmonologist, physiotherapist,
nurse, GP
- Patients visited physiotherapist twice a week for 12 weeks and the program consisted of
conventional physiotherapy, upper limb training, inspiratory muscle training, exercise
training. They had to practice twice a day for half an hour at home
- Furthermore, they received education at home from a nurse (once a month)
- They visited the GP once a month and he supervised clinical status and maintenance
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Wijkstra 1994 (Continued)
treatment
Included HCP: GP, physiotherapist, nurse
Outcomes Lung function, CRQ, cycle ergometer test
Notes Main component of program: exercise
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were stratified for their
FEV1% predicted. After this stratification,
the patients were randomly allocated”
Allocation concealment (selection bias) Low risk Quote: “(after randomisation), they were
randomly allocated to one of three groups,
each of 15 patients”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and treating therapists not
likely to have been blinded to group allo-
cation
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk We could not ascertain how and whether
outcome assessors were blinded to treat-
ment group assignment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 2 (out of 30) drop-outs in rehabilita-
tion group versus no drop-outs in control
group
Selective reporting (reporting bias) Low risk All outcomes reported
Wood-Baker 2006
Methods Cluster-RCT; follow-up 12 months, control group: education + usual care
Participants Eligible: 218
Randomized: 138; I: 67, C: 72
Completed (12 months): 112; I: 54, C: 58
Mean age I: 69 yrs, C: 71 yrs
Sex (% male): I: 49%, C: 71%
Inclusion criteria: COPDdiagnosed by spirometry, age > 50 yrs, tobacco smoking history
of greater than 10 pack-years and FEV1 < 65% predicted
Exclusion criteria: nursing home residents
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Wood-Baker 2006 (Continued)
Interventions Control + intervention group: COPD information booklet, individual education session
with nurse. Intervention group: written self management plan, which was developed in
consultation with their treating GP. Patients were encouraged to make early contact with
their GP during an exacerbation
Included HCP: GP, nurse
Outcomes SGRQ, exacerbations (courses of antibiotics/prednisone), ED and hospital admissions,
GP consultations, spirometry, mortality, physical exercise (pedometer)
Notes Prior to commencement of the randomisation process, only 50% of the included GPs
attended one of a series of educational workshops on the management of COPD
Main component of program: self management/action plan
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”Practices were randomised to the
intervention or control group using a com-
puter generated randomisation software
package“
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk It is not likely that participants and person-
nel have been blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: ”The baseline, 6- and 12-month as-
sessments involved face to face contact with
a research nurse at the GP’s surgery or pa-
tients’ home“
Incomplete outcome data (attrition bias)
All outcomes
Low risk 13 intervention patients versus 14 control
patients missing at 6 months, reasons sim-
ilar”
Selective reporting (reporting bias) Low risk The study protocol is not available but it
is clear that the published reports include
all expected outcomes, including those that
were pre-specified
Recruitment bias Low risk No information provided
Baseline imbalance between groups High risk Baseline imbalance between groups
Loss to follow-up of clusters Low risk No missing clusters
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Wood-Baker 2006 (Continued)
Adequate analysis methods for CRT High risk No adjusting for cluster-randomized trials
4MWT: four-minute walking test
6MWT/6MWD: six-minute walking test/six-minute walking distance
ADL: activities of daily living
BMI: body mass index
C: control
COOP: Dartmouth Primary Care Co-operative Quality of Life questionnaire
COPD: chronic obstructive pulmonary disease
CRQ: Chronic Respiratory Questionnaire
ED: emergency department
FEV1: forced expiratory volume in one second
FVC: forced vital capacity
GOLD: Global Initiative for Chronic Obstructive Lung Disease
GP: general practitioner
HADS: Hospital Anxiety and Depression Scale
HCP: health care provider
HRQoL: health-related quality of life
I: intervention
MACL: Mood Adjective Check List
MCO: managed care organization
MMSE: Mini-Mental State Examination
MRC: Medical Research Council
PR: pulmonary rehabilitation
RCT: randomised controlled trial
SGRQ: St. George’s Respiratory Questionnaire
SIP: Sickness Impact Profile
VAS: visual analogue scale
VC: vital capacity
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aimonino 2008 Intervention duration less than 3 months
Bischoff 2012 No multidisciplinary intervention
Carrieri 2005 Active treatment in control group
Casas 2006 Intervention duration less than 3 months
De Godoy 2003 Active treatment in control group
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(Continued)
Eaton 2009 Intervention duration less than 3 months
Effing 2009 Active treatment in control group
Efraimsson 2008 Fewer than 2 different health care providers included
Elliott 2004 Fewer than 2 different health care providers included
Garcia 2007 Duration of intervention less than 3 months
Gohl 2006 No multidisciplinary intervention and fewer than 2 components
Goldstein 1994 Fewer than 2 components of intervention
Guell 2008 Active treatment as control group
Hughes 2000 No results solely for COPD
Liu 2006 Not a RCT
Maltais 2008 No usual care as control group
Martin 2004 Fewer than 2 components of intervention
McGeoch 2006 Fewer than 2 components of intervention
Monninkhof 2003 No usual care as control group
Ries 2003 Active treatment as control group
Soler 2006 Active treatment as control group
Steele 2008 Active treatment as control group
Zhou 2010 COPD diagnosis was not inclusion criteria
COPD: chronic obstructive pulmonary disease
RCT: randomised controlled trial
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Characteristics of studies awaiting assessment [ordered by study ID]
Baumann 2012
Methods Aim: to investigate whether relevant improvements in physical capabilities and quality of life in patients with chronic
obstructive pulmonary disease (COPD) could be achieved by a long-term, low-intensity, once weekly rehabilitation
program using limited resources. 100 patients with moderate to severe COPD were randomised to a continuous
outpatient interdisciplinary
rehabilitation program or standard care
Participants 100 patients with moderate to severe COPD
Interventions Physiotherapy-led supervised outpatient training sessions were performed once weekly in addition to educational
elements
Outcomes Outcome measures at baseline and after 26 weeks were 6MWT, cycle ergometry and health-related quality of life
Notes
Fan 2012
Methods A randomised, controlled trial comparing CCMP with guideline-based usual care
Setting: 20 Veterans Affairs hospital-based outpatient clinics
Participants Patients hospitalised for COPD in the past year
Interventions The CCMP included COPD education during 4 individual sessions and 1 group session, an action plan for iden-
tification and treatment of exacerbations, and scheduled proactive telephone calls for case management. Patients in
both the intervention and usual care groups received a COPD informational booklet; their primary care providers
received a copy of COPD guidelines and were advised to manage their patients according to these guidelines
Outcomes The primary outcome was time to first COPD hospitalisation. Staff blinded to study group performed telephone-
based assessment of COPD exacerbations and hospitalizations, and all hospitalizations were blindly adjudicated.
Secondary outcomes included non-COPD health care use, all-cause mortality, health-related quality of life, patient
satisfaction, disease knowledge and self efficacy
Notes
Zwar 2012
Methods Cluster-randomized controlled trial with blinded outcome assessment of 44 general practices in south-western Sydney
comprising 451 people with a diagnosis of COPD, conducted between 2006 and 2009
Participants COPD patients
Interventions Participants from intervention group practices were visited at their home by a registered nurse with specific training
in COPD care who worked with the general practitioner, the patient and other health professionals to develop and
implement an individualized care plan based on best-practice guidelines. Participants from control group practices
received usual care
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Zwar 2012 (Continued)
Outcomes The primary outcome was disease-related quality of life measured using the St George’s Respiratory Questionnaire
(SGRQ) at 12-month follow-up. Other outcomes were overall quality of life, lung function, smoking status, immu-
nization status, patient knowledge of COPD and health service use
Notes
CCMP: comprehensive care management program
COPD: chronic obstructive pulmonary disease
Characteristics of ongoing studies [ordered by study ID]
Bower 2012
Trial name or title A cluster randomised controlled trial of the clinical and cost-effectiveness of a ’whole systems’ model of self
management support for the management of long-term conditions in primary care: trial protocol
Methods The evaluation involves a large-scale, multi-site study of the implementation, effectiveness and cost-effective-
ness of this model of self management support using a cluster-randomized controlled trial
Participants Patients with 3 long-term conditions: diabetes, chronic obstructive pulmonary disease (COPD) and irritable
bowel syndrome (IBS)
Interventions The implementation and evaluation of self management support through an evidence-based ’whole systems’
model involving patient support, training for primary care teams and service re-organization, all integrated
into routine delivery within primary care
Outcomes The outcome measures include healthcare utilization and quality of life
Starting date
Contact information TRIAL REGISTRATION NUMBER: ISRCTN: ISRCTN90940049
Notes
Bunker 2012
Trial name or title A pragmatic cluster randomised controlled trial of early intervention for chronic obstructive pulmonary disease
by practice nurse-general practitioner teams
Methods A pragmatic cluster-randomized trial will test the hypothesis that intervention by a practice nurse-general
practitioner (GP) team leads to improved health-related quality of life and greater adherence with clinical
practice guidelines for patients with newly diagnosed COPD, compared with usual care. 40 general practices
in greater metropolitan Sydney Australia will be recruited to identify patients at risk of COPD and invite
them to attend a case finding appointment. Practices will be randomised to deliver either practice nurse-GP
partnership care, or usual care, to patients newly diagnosed with COPD
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Bunker 2012 (Continued)
Participants Patients with newly diagnosed COPD
Interventions The active intervention will involve the practice nurse and GP working in partnership with the patient
in developing and implementing a care plan involving (as appropriate), smoking cessation, immunization,
pulmonary rehabilitation, medication review, assessment and correction of inhaler technique, nutritional
advice, management of psycho-social issues, patient education and management of co-morbidities
Outcomes The primary outcome measure is health-related quality of life, assessed with the St George’s Respiratory
Questionnaire 12 months after diagnosis. Secondary outcome measures include validated disease-specific
and general health-related quality of life measures, smoking and immunization status, medications, inhaler
technique and lung function. Outcomes will be assessed by project officers blinded to patients’ randomisation
groups
Starting date
Contact information TRIAL REGISTRATION: ACTRN12610000592044
Notes
Byrnes 2012
Trial name or title CAPICHe
Methods Intention-to-treat study applying a prospective, randomised design comparing usual care with extensive
outreach to encourage use of telephone health coaching for those people identified from a risk scoring
algorithm as having a higher likelihood of future health costs
Participants The trial population has been limited to people with one or more of the following selected chronic conditions:
namely, low back pain, diabetes, coronary artery disease, heart failure and chronic obstructive pulmonary
disease.This trial will enroll at least 64,835 sourced from the approximately 3 million Bupa Australia private
health insured members located across Australia
Interventions
Outcomes The primary outcome will be the total (non-maternity) cost per member as reported to the private health
insurer (i.e. charged to the insurer) 12 months following entry into the trial for each person
Starting date Study recruitment will be completed in early 2012 and the results will be available in late 2013
Contact information Australian New Zealand Clinical Trials Registry
Reference: ACTRN12611000580976
Notes
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Freund 2011
Trial name or title Primary care practice-based care management for chronically ill patients (PraCMan)
Methods Cluster-randomized controlled trial with primary care practices as unit of randomisation. Patients are ran-
domised in clusters of 15 to 20 patients per practice. Each patient is assigned to a care management team
consisting of 1 primary care practice and 1 healthcare assistant
Participants Primary care practices: participation of the practice in a centered care contract, at least 1 primary care
practitioner, ability to perform on-site spirometry and home visits. Patients: suffering from type 2 diabetes
mellitus, COPD, chronic heart failure or any combination, high risk for future hospitalisation, age 18 years or
older. Major exclusions: active cancer disease, moderate to severe dementia, permanent residency in a nursing
home, participation in a concurrent clinical trial, severe physical and mental disorders or other problems that
hinder active participation in the intervention
Interventions The intervention consists of 3 elements: 1) assessment of medical/non-medical needs and resources, including
for example allergies, nutritional problems, depressions, falls, physical activity, smoking status. 2) planning
and setting long-term goals for care management, 3) monitoring and structured follow-up. Prior to the
intervention, all case management teams will be trained
Outcomes Hospitalizations,mortality, EQ-5D, SF-12, PACIC, PHQ9,MARS,RAPA, smoking status, selfmanagement,
pharmacy data, healthcare costs, ADL, comorbidity, home visits, COPD exacerbations, BMI, dyspnoea, FEV
Starting date July 2010
Contact information tobias.freund@med.uni-heidelberg.de
Notes ISRCTN56104508
Gomez 2006
Trial name or title Efficacy of respiratory rehabilitation on patients with moderate COPD in primary care and maintenance of
benefits at 2 years
Methods RCT; 3 groups in parallel with blind evaluation. Control group: customary care. 56 patients per group are
needed
Participants Patients with a diagnosis of moderate COPD according to GOLD
Interventions 3 groups: 1) pulmonary rehabilitation (educational sessions, respiratory physiotherapy, low-intensity physical
exercise) for 12 weeks and program maintenance for 24 months; 2) pulmonary rehabilitation for 12 weeks
without maintenance program, 3) control group
Outcomes Quality of life with Chronic Respiratory Questionnaire, 6MWD, Borg dyspnoea Scale,MRCDyspnea Score,
lung function
Starting date Finished, results not yet published
Contact information
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Gomez 2006 (Continued)
Notes
Jones 2009a
Trial name or title Effect of a case management study on primary care use and prescribing for AECOPD
Methods RCT
Participants Patients admitted to hospital with an exacerbation of COPD
Interventions Intensive case management (including hospital and home visits), exercise, education and access to support 7
days a week (phone line) and nurse/doctor review 5 days a week. Control group: usual care
Outcomes Data on all GP and practice nurse visits to either surgery or home and prescriptions for antibiotics and steroids
(including all primary and secondary care prescriptions) were collected during the 12-month study period
Starting date
Contact information
Notes Results submitted, not accepted yet
Kruis 2013
Trial name or title RECODE
Methods RECODE is a cluster-randomized trial with 2 years of follow-up, during which 40 clusters of primary care
teams (including 1086 COPD patients) are randomised to IDM or usual care
Participants COPD patients
Interventions The intervention started with a 2-day multidisciplinary course in which health care providers are trained
as a team in essential components of effective COPD IDM in primary care. During the course, the team
redesigns the care process and defines responsibilities of different caregivers. They are trained in how to use
feedback on process and outcome data to guide implement guideline-driven integrated healthcare. Practice-
tailored feedback reports are provided at baseline, and at 6 and 12 months. The team learns the details of
an ICT program that supports recording of process and outcome measures. Afterwards, the team designs a
time-contingent individual practice plan, agreeing on steps to be taken in order to integrate a COPD IDM
program into daily practice. After 6 and 12 months, there is a refresher course for all teams simultaneously to
enable them to learn from each other’s experience
Outcomes Health status of patients at 12months is the primary outcome,measured by theClinical COPDQuestionnaire
(CCQ) Secondary outcomes include effects on quality of care, disease-specific and generic health-related
quality of life, COPD exacerbations, dyspnoea, costs of healthcare utilization and productivity loss
Starting date 1 September 2010
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Kruis 2013 (Continued)
Contact information a.l.kruis@lumc.nl; Netherlands Trial Register (NTR): NTR2268
Notes
Murphy 2011
Trial name or title The effectiveness of a structured education pulmonary rehabilitation programme for improving the health
status of people with Chronic Obstructive Pulmonary Disease (COPD): The PRINCE study
Methods This study evaluated the effectiveness of a structured education pulmonary rehabilitation program (SEPRP),
delivered at the level of the general practice, on the health status of people with COPD. A cluster-randomized
controlled trial was employed with the General Practice as the unit of randomisation
Participants All adults with a diagnosis of COPD were eligible to participate
Interventions The experimental group received a SEPRP, designed in consultation with people with COPD, experts, general
practitioners and practice nurses. It was delivered 2 hours per week over 8 weeks by practice nurses and
physiotherapists. The control group received ’usual care’
Outcomes The primary outcome measure was health status measured by the Chronic Respiratory Questionnaire (CRQ)
at 12 to 14 weeks
Starting date
Contact information
Notes
Roman 2013
Trial name or title Efficacy of pulmonary rehabilitation in patients with moderate chronic obstructive pulmonary disease: a
randomised controlled trial
Methods This study aimed to assess the efficacy of a 3-month Pulmonary Rehabilitation (PR) program with a further 9
months of maintenance (RHBM group) compared with both PR for 3 months without further maintenance
(RHB group) and
usual care in improving the quality of life of patients with moderate COPD. The authors conducted a parallel-
group, randomised clinical trial in Majorca primary health care in which 97 patients with moderate COPD
were assigned to the 3 groups
Participants Moderate COPD
Interventions See above
Outcomes Health outcomes were quality of life, exercise capacity, pulmonary function and exacerbations
Starting date
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Roman 2013 (Continued)
Contact information ISRCTN94514482
Notes
6MWD: six-minute walking distance
ADL: activities of daily living
BMI: body mass index
COPD: chronic obstructive pulmonary disease
FEV: forced expiratory volume
GOLD: Global Initiative for Chronic Obstructive Lung Disease
IDM: integrated disease management
MRC: Medical Research Council
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Integrated disease management versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 SGRQ: short-term (3 to 12
months)
13 Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 SGRQ: Total 13 1425 Mean Difference (IV, Random, 95% CI) -3.71 [-5.83, -1.59]
1.2 SGRQ: Symptoms 11 1377 Mean Difference (IV, Random, 95% CI) -2.39 [-5.31, 0.53]
1.3 SGRQ: Activity 11 1352 Mean Difference (IV, Random, 95% CI) -2.70 [-4.84, -0.55]
1.4 SGRQ: Impact 11 1355 Mean Difference (IV, Random, 95% CI) -4.04 [-5.96, -2.11]
2 SGRQ: long-term (> 12 months) 2 Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 SGRQ: Total 2 189 Mean Difference (IV, Random, 95% CI) -0.22 [-7.43, 6.99]
2.2 SGRQ: Symptoms 2 191 Mean Difference (IV, Random, 95% CI) 5.65 [-8.88, 20.18]
2.3 SGRQ: Activity 2 191 Mean Difference (IV, Random, 95% CI) -2.13 [-7.89, 3.63]
2.4 SGRQ: Impact 2 182 Mean Difference (IV, Random, 95% CI) -1.62 [-5.50, 2.25]
3 Subgroup analysis SGRQ (total
score) based on type of setting
13 1425 Mean Difference (IV, Random, 95% CI) -3.77 [-5.90, -1.64]
3.1 Primary care 6 456 Mean Difference (IV, Random, 95% CI) -4.68 [-8.80, -0.56]
3.2 Secondary care 7 969 Mean Difference (IV, Random, 95% CI) -3.41 [-5.97, -0.85]
4 Subgroup analysis SGRQ (total
score) based on type of study
design
13 1425 Mean Difference (IV, Random, 95% CI) -3.71 [-5.83, -1.59]
4.1 RCTs 12 1304 Mean Difference (IV, Random, 95% CI) -4.22 [-6.14, -2.30]
4.2 CRCTs 1 121 Mean Difference (IV, Random, 95% CI) 2.3 [-1.62, 6.22]
5 Subgroup analysis SGRQ (total
score) based on type of control
group
13 1425 Mean Difference (IV, Random, 95% CI) -3.71 [-5.83, -1.59]
5.1 Control group: usual care 9 744 Mean Difference (IV, Random, 95% CI) -4.09 [-6.35, -1.84]
5.2 Control group:
mono-disciplinary treatment
4 681 Mean Difference (IV, Random, 95% CI) -2.98 [-7.69, 1.74]
6 Subgroup analysis SGRQ (total
score) based on dominant
component of intervention
11 1315 Mean Difference (IV, Random, 95% CI) -3.61 [-5.67, -1.55]
6.1 Dominant component self
management
5 942 Mean Difference (IV, Random, 95% CI) -2.76 [-5.88, 0.36]
6.2 Dominant component
exercise
6 373 Mean Difference (IV, Random, 95% CI) -4.74 [-7.05, -2.43]
7 CRQ: short-term (3 to 12
months)
4 Mean Difference (IV, Random, 95% CI) Subtotals only
7.1 CRQ: Dyspnea 4 160 Mean Difference (IV, Random, 95% CI) 1.02 [0.67, 1.36]
7.2 CRQ: Fatigue 4 161 Mean Difference (IV, Random, 95% CI) 0.82 [0.46, 1.17]
7.3 CRQ: Emotion 4 161 Mean Difference (IV, Random, 95% CI) 0.61 [0.26, 0.95]
7.4 CRQ: Mastery 4 161 Mean Difference (IV, Random, 95% CI) 0.75 [0.38, 1.12]
8 CRQ: Long-term (> 12 months) 2 Mean Difference (IV, Random, 95% CI) Subtotals only
8.1 CRQ: Dyspnea 2 151 Mean Difference (IV, Random, 95% CI) 0.47 [-0.31, 1.25]
8.2 CRQ: Fatigue 2 151 Mean Difference (IV, Random, 95% CI) 0.45 [0.05, 0.85]
8.3 CRQ: Emotion 2 151 Mean Difference (IV, Random, 95% CI) 0.53 [0.10, 0.95]
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8.4 CRQ: Mastery 2 151 Mean Difference (IV, Random, 95% CI) 0.80 [0.37, 1.23]
9 General health QoL: SIP mean
difference
2 Mean Difference (IV, Random, 95% CI) Subtotals only
9.1 SIP total 2 183 Mean Difference (IV, Random, 95% CI) -1.06 [-3.00, 0.89]
9.2 SIP: physical 2 183 Mean Difference (IV, Random, 95% CI) -2.63 [-5.55, 0.30]
9.3 SIP: psychosocial 2 183 Mean Difference (IV, Random, 95% CI) -0.86 [-3.17, 1.44]
10 Functional exercise capacity:
6MWD mean difference
14 Mean Difference (IV, Random, 95% CI) Subtotals only
10.1 6MWD: short-term (3
to 12 months)
14 871 Mean Difference (IV, Random, 95% CI) 43.86 [21.83, 65.89]
10.2 6MWD: long-term (> 12
months)
2 184 Mean Difference (IV, Random, 95% CI) 16.84 [3.01, 30.67]
11 Subgroup analysis 6MWD
based on type of setting
14 Mean Difference (IV, Random, 95% CI) Subtotals only
11.1 Primary care 7 427 Mean Difference (IV, Random, 95% CI) 45.16 [8.65, 81.67]
11.2 Secondary care 7 438 Mean Difference (IV, Random, 95% CI) 49.18 [14.28, 84.08]
11.3 Tertiary care 1 35 Mean Difference (IV, Random, 95% CI) 85.0 [30.43, 139.57]
12 Subgroup analysis 6MWD
based on type of control group
14 871 Mean Difference (IV, Random, 95% CI) 43.86 [21.83, 65.89]
12.1 Control group: mono
disciplinary treatment
4 180 Mean Difference (IV, Random, 95% CI) 35.99 [-5.34, 77.31]
12.2 Control group: usual
care
10 691 Mean Difference (IV, Random, 95% CI) 46.59 [19.68, 73.51]
13 Subgroup analysis 6MWD
based on dominant component
of intervention
14 871 Mean Difference (IV, Random, 95% CI) 43.86 [21.83, 65.89]
13.1 Dominant component:
exercise
12 653 Mean Difference (IV, Random, 95% CI) 51.47 [26.53, 76.40]
13.2 Dominant component:
structured follow-up
1 133 Mean Difference (IV, Random, 95% CI) 3.50 [-28.31, 35.31]
13.3 Dominant component:
individually tailored education
program
1 85 Mean Difference (IV, Random, 95% CI) 0.4 [-39.64, 40.44]
14 Maximal exercise capacity:
cycle test (W-max)
4 298 Mean Difference (IV, Random, 95% CI) 6.99 [2.96, 11.02]
15 Number of patients
experiencing at least one
exacerbation: short-term (3-12
months)
2 407 Odds Ratio (M-H, Random, 95% CI) 1.21 [0.77, 1.91]
16 Number of patients
experiencing at least one
exacerbation: long-term (> 12
months)
2 301 Odds Ratio (M-H, Fixed, 95% CI) 1.53 [0.90, 2.60]
17 All hospital admissions:
short-term (3 to 12 months)
2 266 Odds Ratio (M-H, Random, 95% CI) 0.62 [0.36, 1.07]
18 All hospital admissions:
long-term (> 12 months)
2 283 Odds Ratio (M-H, Random, 95% CI) 0.78 [0.38, 1.57]
19 Respiratory-related hospital
admissions: short-term (3 to 12
months)
7 1470 Odds Ratio (M-H, Random, 95% CI) 0.68 [0.47, 0.99]
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20 Respiratory-related hospital
admissions: long-term (> 12
months)
1 179 Odds Ratio (M-H, Random, 95% CI) 0.59 [0.28, 1.22]
21 Hospital days per patient (all
causes): short-term (3 to 12
months)
6 741 Mean Difference (IV, Random, 95% CI) -3.78 [-5.90, -1.67]
22 Hospital days per patient:
long-term (> 12 months)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
23 ED visits 4 1161 Odds Ratio (M-H, Random, 95% CI) 0.64 [0.33, 1.25]
24 Number of patients using at
least one course of oral steroids
3 348 Odds Ratio (M-H, Random, 95% CI) 1.13 [0.64, 2.01]
25 Number of patients using at
least one course of antibiotics
2 236 Odds Ratio (M-H, Random, 95% CI) 1.43 [0.24, 8.48]
26 MRC dyspnea score 3 345 Mean Difference (IV, Random, 95% CI) -0.30 [-0.48, -0.11]
27 Borg score 3 145 Mean Difference (IV, Random, 95% CI) 0.14 [-0.70, 0.98]
28 Mortality 5 1235 Odds Ratio (M-H, Random, 95% CI) 0.85 [0.49, 1.46]
28.1 Short-term (3 to 12
months)
4 1113 Odds Ratio (M-H, Random, 95% CI) 0.96 [0.52, 1.74]
28.2 Long-term (> 12
months)
1 122 Odds Ratio (M-H, Random, 95% CI) 0.45 [0.16, 1.28]
29 FEV1 (liter) 3 Mean Difference (IV, Random, 95% CI) Subtotals only
29.1 FEV1 (liter): short-term 2 234 Mean Difference (IV, Random, 95% CI) 0.00 [-0.14, 0.14]
29.2 FEV1 (liter): long-term 1 104 Mean Difference (IV, Random, 95% CI) -0.11 [-0.28, 0.06]
30 FEV1 (% predicted) 9 Mean Difference (IV, Random, 95% CI) Subtotals only
30.1 FEV1 (% predicted):
short-term
4 280 Mean Difference (IV, Random, 95% CI) -0.57 [-3.54, 2.39]
30.2 FEV1 (% predicted;
mean change): short-term
4 514 Mean Difference (IV, Random, 95% CI) 2.15 [0.38, 3.91]
30.3 FEV1 (% predicted):
long-term
1 104 Mean Difference (IV, Random, 95% CI) -4.60 [-11.26, 2.06]
31 Anxiety and depression
(HADS)
2 Mean Difference (IV, Random, 95% CI) Subtotals only
31.1 HADS: depression 2 316 Mean Difference (IV, Random, 95% CI) 0.21 [-0.39, 0.81]
31.2 HADS: anxiety 2 316 Mean Difference (IV, Random, 95% CI) 0.22 [-0.41, 0.85]
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Analysis 1.1. Comparison 1 Integrated disease management versus control, Outcome 1 SGRQ: short-term
(3 to 12 months).
Review: Integrated disease management interventions for patients with chronic obstructive pulmonary disease
Comparison: 1 Integrated disease management versus control
Outcome: 1 SGRQ: short-term (3 to 12 months)
Study or subgroup IDM Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 SGRQ: Total
Bourbeau 2003 88 -6.4 (11.8) 84 -2.3 (11.5) 11.6 % -4.10 [ -7.58, -0.62 ]
Boxall 2005 23 -5.8 (11.8) 23 -1.4 (13.3) 5.6 % -4.40 [ -11.67, 2.87 ]
Dheda 2004 10 -21 (20.4) 15 -0.2 (12.6) 2.0 % -20.80 [ -34.96, -6.64 ]
Engstrom 1999 26 0.3 (17.3) 24 0.5 (16.8) 3.9 % -0.20 [ -9.65, 9.25 ]
Fernandez 2009 27 -14.7 (13.8) 14 -2.5 (12.7) 4.6 % -12.20 [ -20.65, -3.75 ]
Gottlieb 2011 17 -5.2 (14.2) 18 0.42 (11.3) 4.5 % -5.62 [ -14.15, 2.91 ]
Koff 2009 19 -10.3 (14.7) 19 -0.6 (12.2) 4.5 % -9.70 [ -18.29, -1.11 ]
Rice 2010 225 1.3 (13.21) 209 6.24 (13.44) 13.6 % -4.94 [ -7.45, -2.43 ]
Theander 2009 12 -7.6 (10.8) 14 -2.6 (12.2) 4.3 % -5.00 [ -13.84, 3.84 ]
Trappenburg 2011 82 0.4 (11.5) 95 1.2 (10.5) 12.0 % -0.80 [ -4.06, 2.46 ]
van Wetering 2010 87 -3.9 (10.3) 88 0.3 (9.4) 12.7 % -4.20 [ -7.12, -1.28 ]
Wakabayashi 2011 42 -2.07 (9.46) 43 -1.57 (10.3) 10.1 % -0.50 [ -4.70, 3.70 ]
Wood-Baker 2006 60 -1.1 (11.2) 61 -3.4 (10.8) 10.7 % 2.30 [ -1.62, 6.22 ]
Subtotal (95% CI) 718 707 100.0 % -3.71 [ -5.83, -1.59 ]
Heterogeneity: Tau2 = 6.97; Chi2 = 27.19, df = 12 (P = 0.01); I2 =56%
Test for overall effect: Z = 3.43 (P = 0.00061)
2 SGRQ: Symptoms
Bourbeau 2003 88 -1.5 (19.4) 84 -1.1 (15.7) 15.2 % -0.40 [ -5.66, 4.86 ]
Boxall 2005 23 2 (18.9) 23 -0.6 (19.3) 5.7 % 2.60 [ -8.44, 13.64 ]
Engstrom 1999 26 -7.5 (23.5) 24 -4.1 (23) 4.4 % -3.40 [ -16.29, 9.49 ]
Fernandez 2009 27 -22.8 (20.4) 14 -9.1 (17.3) 5.0 % -13.70 [ -25.59, -1.81 ]
Gottlieb 2011 21 -3.14 (20.7) 20 -3.63 (18.6) 4.9 % 0.49 [ -11.54, 12.52 ]
Koff 2009 19 -12.8 (24.1) 19 -3.3 (22.2) 3.5 % -9.50 [ -24.23, 5.23 ]
Rice 2010 252 -0.26 (20.42) 234 5.38 (20.92) 20.3 % -5.64 [ -9.32, -1.96 ]
Theander 2009 12 -10.6 (22.3) 14 0.5 (29.3) 2.0 % -11.10 [ -30.97, 8.77 ]
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(. . . Continued)
Study or subgroup IDM Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Trappenburg 2011 84 -3.6 (21.1) 97 -0.6 (20.3) 13.1 % -3.00 [ -9.06, 3.06 ]
van Wetering 2010 87 -3 (17.7) 88 -1.4 (16.9) 15.5 % -1.60 [ -6.73, 3.53 ]
Wood-Baker 2006 60 -2.5 (20.8) 61 -8.9 (19.9) 10.5 % 6.40 [ -0.86, 13.66 ]
Subtotal (95% CI) 699 678 100.0 % -2.39 [ -5.31, 0.53 ]
Heterogeneity: Tau2 = 7.44; Chi2 = 15.38, df = 10 (P = 0.12); I2 =35%
Test for overall effect: Z = 1.60 (P = 0.11)
3 SGRQ: Activity
Bourbeau 2003 88 -4.5 (15.1) 84 -1.8 (14.7) 13.8 % -2.70 [ -7.15, 1.75 ]
Boxall 2005 23 -5.9 (12.8) 23 -1 (15.4) 5.7 % -4.90 [ -13.08, 3.28 ]
Engstrom 1999 26 0.7 (17.8) 24 -0.4 (14.2) 5.0 % 1.10 [ -7.79, 9.99 ]
Fernandez 2009 27 -11.2 (13.9) 14 0 (12.1) 5.7 % -11.20 [ -19.43, -2.97 ]
Gottlieb 2011 18 1.29 (24) 19 -2.22 (23.2) 1.9 % 3.51 [ -11.71, 18.73 ]
Koff 2009 19 -8.8 (20.7) 19 -0.5 (17.4) 2.8 % -8.30 [ -20.46, 3.86 ]
Rice 2010 240 1.47 (14.03) 226 5.37 (14.13) 22.9 % -3.90 [ -6.46, -1.34 ]
Theander 2009 12 -2.5 (13.1) 14 -2.7 (14) 3.8 % 0.20 [ -10.23, 10.63 ]
Trappenburg 2011 84 2.7 (16.4) 96 2.8 (17.1) 12.2 % -0.10 [ -5.00, 4.80 ]
van Wetering 2010 87 -3.9 (14) 88 0.9 (13.1) 15.5 % -4.80 [ -8.82, -0.78 ]
Wood-Baker 2006 60 2.5 (15.5) 61 -0.7 (14.7) 10.8 % 3.20 [ -2.18, 8.58 ]
Subtotal (95% CI) 684 668 100.0 % -2.70 [ -4.84, -0.55 ]
Heterogeneity: Tau2 = 3.51; Chi2 = 14.33, df = 10 (P = 0.16); I2 =30%
Test for overall effect: Z = 2.47 (P = 0.014)
4 SGRQ: Impact
Bourbeau 2003 88 -9.1 (13.7) 84 -2.9 (15.7) 12.4 % -6.20 [ -10.61, -1.79 ]
Boxall 2005 23 -8.1 (17.1) 23 -2 (17.6) 3.3 % -6.10 [ -16.13, 3.93 ]
Engstrom 1999 26 2.6 (19.4) 24 2.5 (20.1) 2.8 % 0.10 [ -10.87, 11.07 ]
Fernandez 2009 27 -14.3 (16.3) 14 -1.8 (16.9) 2.9 % -12.50 [ -23.28, -1.72 ]
Gottlieb 2011 18 -4.77 (12.8) 20 -0.08 (8.7) 6.2 % -4.69 [ -11.73, 2.35 ]
Koff 2009 19 -6.6 (18.1) 19 -0.6 (13.7) 3.2 % -6.00 [ -16.21, 4.21 ]
Rice 2010 246 1.61 (16.16) 223 7.66 (16.63) 19.3 % -6.05 [ -9.02, -3.08 ]
Theander 2009 12 -9.7 (15.5) 14 -3.4 (10.7) 3.1 % -6.30 [ -16.71, 4.11 ]
Trappenburg 2011 84 -0.01 (12.3) 95 0.8 (9.8) 17.6 % -0.81 [ -4.10, 2.48 ]
van Wetering 2010 87 -4.1 (11.2) 88 0.5 (12.2) 16.6 % -4.60 [ -8.07, -1.13 ]
Wood-Baker 2006 60 -2.7 (13.1) 61 -3.2 (11.7) 12.4 % 0.50 [ -3.93, 4.93 ]
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Study or subgroup IDM Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 690 665 100.0 % -4.04 [ -5.96, -2.11 ]
Heterogeneity: Tau2 = 2.69; Chi2 = 13.95, df = 10 (P = 0.18); I2 =28%
Test for overall effect: Z = 4.11 (P = 0.000040)
-20 -10 0 10 20
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Analysis 1.2. Comparison 1 Integrated disease management versus control, Outcome 2 SGRQ: long-term
(> 12 months).
Review: Integrated disease management interventions for patients with chronic obstructive pulmonary disease
Comparison: 1 Integrated disease management versus control
Outcome: 2 SGRQ: long-term (> 12 months)
Study or subgroup IDM Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 SGRQ: Total
Gottlieb 2011 15 -0.47 (17.8) 17 -5.93 (11) 29.5 % 5.46 [ -4.96, 15.88 ]
van Wetering 2010 77 -1.37 (8.073) 80 1.23 (8.0498) 70.5 % -2.60 [ -5.12, -0.08 ]
Subtotal (95% CI) 92 97 100.0 % -0.22 [ -7.43, 6.99 ]
Heterogeneity: Tau2 = 17.53; Chi2 = 2.17, df = 1 (P = 0.14); I2 =54%
Test for overall effect: Z = 0.06 (P = 0.95)
2 SGRQ: Symptoms
Gottlieb 2011 16 3.92 (18.5) 18 -10.58 (19.9) 41.2 % 14.50 [ 1.59, 27.41 ]
van Wetering 2010 77 -1.5 (12.1095) 80 -0.94 (11.8959) 58.8 % -0.56 [ -4.32, 3.20 ]
Subtotal (95% CI) 93 98 100.0 % 5.65 [ -8.88, 20.18 ]
Heterogeneity: Tau2 = 89.87; Chi2 = 4.82, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.76 (P = 0.45)
3 SGRQ: Activity
Gottlieb 2011 16 -0.61 (28.4) 18 -7.22 (22.6) 10.2 % 6.61 [ -10.79, 24.01 ]
van Wetering 2010 77 -1.29 (11.4952) 80 1.83 (11.4487) 89.8 % -3.12 [ -6.71, 0.47 ]
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Study or subgroup IDM Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 93 98 100.0 % -2.13 [ -7.89, 3.63 ]
Heterogeneity: Tau2 = 6.27; Chi2 = 1.15, df = 1 (P = 0.28); I2 =13%
Test for overall effect: Z = 0.72 (P = 0.47)
4 SGRQ: Impact
Gottlieb 2011 15 -0.74 (14.3) 17 -3 (6.4) 20.6 % 2.26 [ -5.59, 10.11 ]
van Wetering 2010 70 -1.34 (8.3666) 80 1.29 (8.7654) 79.4 % -2.63 [ -5.37, 0.11 ]
Subtotal (95% CI) 85 97 100.0 % -1.62 [ -5.50, 2.25 ]
Heterogeneity: Tau2 = 2.95; Chi2 = 1.33, df = 1 (P = 0.25); I2 =25%
Test for overall effect: Z = 0.82 (P = 0.41)
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Analysis 1.3. Comparison 1 Integrated disease management versus control, Outcome 3 Subgroup analysis
SGRQ (total score) based on type of setting.
Review: Integrated disease management interventions for patients with chronic obstructive pulmonary disease
Comparison: 1 Integrated disease management versus control
Outcome: 3 Subgroup analysis SGRQ (total score) based on type of setting
Study or subgroup IDM Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Primary care
Boxall 2005 23 -5.8 (11.8) 23 -1.4 (13.3) 5.7 % -4.40 [ -11.67, 2.87 ]
Fernandez 2009 27 -14.7 (13.8) 14 -2.5 (12.7) 4.6 % -12.20 [ -20.65, -3.75 ]
Gottlieb 2011 17 -5.2 (14.2) 18 0.42 (11.3) 4.6 % -5.62 [ -14.15, 2.91 ]
Koff 2009 19 -10.3 (14.7) 19 -0.6 (12.2) 4.5 % -9.70 [ -18.29, -1.11 ]
van Wetering 2010 87 -3.9 (10.3) 88 0.3 (9.4) 13.0 % -4.20 [ -7.12, -1.28 ]
Wood-Baker 2006 60 -1.1 (11.2) 61 -3.4 (10.8) 10.9 % 2.30 [ -1.62, 6.22 ]
Subtotal (95% CI) 233 223 43.3 % -4.68 [ -8.80, -0.56 ]
Heterogeneity: Tau2 = 15.77; Chi2 = 14.97, df = 5 (P = 0.01); I2 =67%
Test for overall effect: Z = 2.23 (P = 0.026)
2 Secondary care
Bourbeau 2003 88 -6.4 (11.8) 84 -2.3 (11.5) 11.8 % -4.10 [ -7.58, -0.62 ]
Dheda 2004 10 -21 (20.4) 15 -0.2 (12.6) 2.0 % -20.80 [ -34.96, -6.64 ]
Engstrom 1999 26 0.3 (17.3) 24 0.5 (16.8) 3.9 % -0.20 [ -9.65, 9.25 ]
Rice 2010 225 1.3 (13.21) 209 6.24 (13.44) 13.9 % -4.94 [ -7.45, -2.43 ]
Theander 2009 12 -7.6 (10.8) 14 -2.6 (12.2) 4.3 % -5.00 [ -13.84, 3.84 ]
Trappenburg 2011 82 0.4 (11.5) 95 1.2 (10.5) 12.2 % -0.80 [ -4.06, 2.46 ]
Wakabayashi 2011 42 -2.2 (12.2) 43 -1.6 (12.3) 8.5 % -0.60 [ -5.81, 4.61 ]
Subtotal (95% CI) 485 484 56.7 % -3.41 [ -5.97, -0.85 ]
Heterogeneity: Tau2 = 4.86; Chi2 = 11.51, df = 6 (P = 0.07); I2 =48%
Test for overall effect: Z = 2.61 (P = 0.0091)
Total (95% CI) 718 707 100.0 % -3.77 [ -5.90, -1.64 ]
Heterogeneity: Tau2 = 6.88; Chi2 = 26.49, df = 12 (P = 0.01); I2 =55%
Test for overall effect: Z = 3.47 (P = 0.00053)
Test for subgroup differences: Chi2 = 0.27, df = 1 (P = 0.61), I2 =0.0%
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Analysis 1.4. Comparison 1 Integrated disease management versus control, Outcome 4 Subgroup analysis
SGRQ (total score) based on type of study design.
Review: Integrated disease management interventions for patients with chronic obstructive pulmonary disease
Comparison: 1 Integrated disease management versus control
Outcome: 4 Subgroup analysis SGRQ (total score) based on type of study design
Study or subgroup IDM Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 RCTs
Bourbeau 2003 88 -6.4 (11.8) 84 -2.3 (11.5) 11.6 % -4.10 [ -7.58, -0.62 ]
Boxall 2005 23 -5.8 (11.8) 23 -1.4 (13.3) 5.6 % -4.40 [ -11.67, 2.87 ]
Dheda 2004 10 -21 (20.4) 15 -0.2 (12.6) 2.0 % -20.80 [ -34.96, -6.64 ]
Engstrom 1999 26 0.3 (17.3) 24 0.5 (16.8) 3.9 % -0.20 [ -9.65, 9.25 ]
Fernandez 2009 27 -14.7 (13.8) 14 -2.5 (12.7) 4.6 % -12.20 [ -20.65, -3.75 ]
Gottlieb 2011 17 -5.2 (14.2) 18 0.42 (11.3) 4.5 % -5.62 [ -14.15, 2.91 ]
Koff 2009 19 -10.3 (14.7) 19 -0.6 (12.2) 4.5 % -9.70 [ -18.29, -1.11 ]
Rice 2010 225 1.3 (13.21) 209 6.24 (13.44) 13.6 % -4.94 [ -7.45, -2.43 ]
Theander 2009 12 -7.6 (10.8) 14 -2.6 (12.2) 4.3 % -5.00 [ -13.84, 3.84 ]
Trappenburg 2011 82 0.4 (11.5) 95 1.2 (10.5) 12.0 % -0.80 [ -4.06, 2.46 ]
van Wetering 2010 87 -3.9 (10.3) 88 0.3 (9.4) 12.7 % -4.20 [ -7.12, -1.28 ]
Wakabayashi 2011 42 -2.07 (9.46) 43 -1.57 (10.3) 10.1 % -0.50 [ -4.70, 3.70 ]
Subtotal (95% CI) 658 646 89.3 % -4.22 [ -6.14, -2.30 ]
Heterogeneity: Tau2 = 3.88; Chi2 = 18.44, df = 11 (P = 0.07); I2 =40%
Test for overall effect: Z = 4.30 (P = 0.000017)
2 CRCTs
Wood-Baker 2006 60 -1.1 (11.2) 61 -3.4 (10.8) 10.7 % 2.30 [ -1.62, 6.22 ]
Subtotal (95% CI) 60 61 10.7 % 2.30 [ -1.62, 6.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
Total (95% CI) 718 707 100.0 % -3.71 [ -5.83, -1.59 ]
Heterogeneity: Tau2 = 6.97; Chi2 = 27.19, df = 12 (P = 0.01); I2 =56%
Test for overall effect: Z = 3.43 (P = 0.00061)
Test for subgroup differences: Chi2 = 8.57, df = 1 (P = 0.00), I2 =88%
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Analysis 1.5. Comparison 1 Integrated disease management versus control, Outcome 5 Subgroup analysis
SGRQ (total score) based on type of control group.
Review: Integrated disease management interventions for patients with chronic obstructive pulmonary disease
Comparison: 1 Integrated disease management versus control
Outcome: 5 Subgroup analysis SGRQ (total score) based on type of control group
Study or subgroup IDM Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Control group: usual care
Bourbeau 2003 88 -6.4 (11.8) 84 -2.3 (11.5) 11.6 % -4.10 [ -7.58, -0.62 ]
Boxall 2005 23 -5.8 (11.8) 23 -1.4 (13.3) 5.6 % -4.40 [ -11.67, 2.87 ]
Dheda 2004 10 -21 (20.4) 15 -0.2 (12.6) 2.0 % -20.80 [ -34.96, -6.64 ]
Engstrom 1999 26 0.3 (17.3) 24 0.5 (16.8) 3.9 % -0.20 [ -9.65, 9.25 ]
Gottlieb 2011 17 -5.2 (14.2) 18 0.42 (11.3) 4.5 % -5.62 [ -14.15, 2.91 ]
Koff 2009 19 -10.3 (14.7) 19 -0.6 (12.2) 4.5 % -9.70 [ -18.29, -1.11 ]
Theander 2009 12 -7.6 (10.8) 14 -2.6 (12.2) 4.3 % -5.00 [ -13.84, 3.84 ]
Trappenburg 2011 82 0.4 (11.5) 95 1.2 (10.5) 12.0 % -0.80 [ -4.06, 2.46 ]
van Wetering 2010 87 -3.9 (10.3) 88 0.3 (9.4) 12.7 % -4.20 [ -7.12, -1.28 ]
Subtotal (95% CI) 364 380 61.0 % -4.09 [ -6.35, -1.84 ]
Heterogeneity: Tau2 = 3.19; Chi2 = 11.51, df = 8 (P = 0.17); I2 =31%
Test for overall effect: Z = 3.56 (P = 0.00037)
2 Control group: mono-disciplinary treatment
Fernandez 2009 27 -14.7 (13.8) 14 -2.5 (12.7) 4.6 % -12.20 [ -20.65, -3.75 ]
Rice 2010 225 1.3 (13.21) 209 6.24 (13.44) 13.6 % -4.94 [ -7.45, -2.43 ]
Wakabayashi 2011 42 -2.07 (9.46) 43 -1.57 (10.3) 10.1 % -0.50 [ -4.70, 3.70 ]
Wood-Baker 2006 60 -1.1 (11.2) 61 -3.4 (10.8) 10.7 % 2.30 [ -1.62, 6.22 ]
Subtotal (95% CI) 354 327 39.0 % -2.98 [ -7.69, 1.74 ]
Heterogeneity: Tau2 = 17.36; Chi2 = 15.20, df = 3 (P = 0.002); I2 =80%
Test for overall effect: Z = 1.24 (P = 0.22)
Total (95% CI) 718 707 100.0 % -3.71 [ -5.83, -1.59 ]
Heterogeneity: Tau2 = 6.97; Chi2 = 27.19, df = 12 (P = 0.01); I2 =56%
Test for overall effect: Z = 3.43 (P = 0.00061)
Test for subgroup differences: Chi2 = 0.17, df = 1 (P = 0.68), I2 =0.0%
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Analysis 1.6. Comparison 1 Integrated disease management versus control, Outcome 6 Subgroup analysis
SGRQ (total score) based on dominant component of intervention.
Review: Integrated disease management interventions for patients with chronic obstructive pulmonary disease
Comparison: 1 Integrated disease management versus control
Outcome: 6 Subgroup analysis SGRQ (total score) based on dominant component of intervention
Study or subgroup IDM Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Dominant component self management
Bourbeau 2003 88 -6.4 (11.8) 84 -2.3 (11.5) 13.6 % -4.10 [ -7.58, -0.62 ]
Koff 2009 19 -10.3 (14.7) 19 -0.6 (12.2) 4.6 % -9.70 [ -18.29, -1.11 ]
Rice 2010 225 1.3 (13.21) 209 6.24 (13.44) 16.7 % -4.94 [ -7.45, -2.43 ]
Trappenburg 2011 82 0.4 (11.5) 95 1.2 (10.5) 14.2 % -0.80 [ -4.06, 2.46 ]
Wood-Baker 2006 60 -1.1 (11.2) 61 -3.4 (10.8) 12.3 % 2.30 [ -1.62, 6.22 ]
Subtotal (95% CI) 474 468 61.3 % -2.76 [ -5.88, 0.36 ]
Heterogeneity: Tau2 = 8.33; Chi2 = 13.74, df = 4 (P = 0.01); I2 =71%
Test for overall effect: Z = 1.73 (P = 0.083)
2 Dominant component exercise
Boxall 2005 23 -5.8 (11.8) 23 -1.4 (13.3) 5.9 % -4.40 [ -11.67, 2.87 ]
Engstrom 1999 26 0.3 (17.3) 24 0.5 (16.8) 3.9 % -0.20 [ -9.65, 9.25 ]
Fernandez 2009 27 -14.7 (13.8) 14 -2.5 (12.7) 4.7 % -12.20 [ -20.65, -3.75 ]
Gottlieb 2011 17 -5.2 (14.2) 18 0.42 (11.3) 4.6 % -5.62 [ -14.15, 2.91 ]
Theander 2009 12 -7.6 (10.8) 14 -2.6 (12.2) 4.3 % -5.00 [ -13.84, 3.84 ]
van Wetering 2010 87 -3.9 (10.3) 88 0.3 (9.4) 15.3 % -4.20 [ -7.12, -1.28 ]
Subtotal (95% CI) 192 181 38.7 % -4.74 [ -7.05, -2.43 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 4.07, df = 5 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 4.02 (P = 0.000057)
Total (95% CI) 666 649 100.0 % -3.61 [ -5.67, -1.55 ]
Heterogeneity: Tau2 = 4.97; Chi2 = 19.57, df = 10 (P = 0.03); I2 =49%
Test for overall effect: Z = 3.44 (P = 0.00058)
Test for subgroup differences: Chi2 = 1.00, df = 1 (P = 0.32), I2 =0.0%
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Analysis 1.7. Comparison 1 Integrated disease management versus control, Outcome 7 CRQ: short-term
(3 to 12 months).
Review: Integrated disease management interventions for patients with chronic obstructive pulmonary disease
Comparison: 1 Integrated disease management versus control
Outcome: 7 CRQ: short-term (3 to 12 months)
Study or subgroup IDM Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 CRQ: Dyspnea
Cambach 1997 14 1.2 (1.2) 8 0 (0.8) 17.2 % 1.20 [ 0.36, 2.04 ]
Gu¨ell 2000 30 0.98 (1.1338) 30 -0.03 (0.9695) 42.4 % 1.01 [ 0.47, 1.54 ]
Gu¨ell 2006 18 0.8 (1.2) 17 -0.2 (1.2) 19.1 % 1.00 [ 0.20, 1.80 ]
Wijkstra 1994 28 0.86 (1) 15 -0.04 (1.3) 21.2 % 0.90 [ 0.15, 1.65 ]
Subtotal (95% CI) 90 70 100.0 % 1.02 [ 0.67, 1.36 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.28, df = 3 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 5.73 (P < 0.00001)
2 CRQ: Fatigue
Cambach 1997 15 1.25 (1) 8 0 (1) 17.2 % 1.25 [ 0.39, 2.11 ]
Gu¨ell 2000 30 0.75 (0.9969) 30 -0.05 (1.2433) 39.0 % 0.80 [ 0.23, 1.37 ]
Gu¨ell 2006 18 0.2 (1.1) 17 -0.5 (1.3) 19.8 % 0.70 [ -0.10, 1.50 ]
Wijkstra 1994 28 0.88 (1.3) 15 0.25 (1.08) 23.9 % 0.63 [ -0.10, 1.36 ]
Subtotal (95% CI) 91 70 100.0 % 0.82 [ 0.46, 1.17 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.32, df = 3 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 4.50 (P < 0.00001)
3 CRQ: Emotion
Cambach 1997 15 0.71 (1.14) 8 0.29 (1) 14.6 % 0.42 [ -0.48, 1.32 ]
Gu¨ell 2000 30 0.819 (1.2871) 30 0.11 (1.1886) 30.1 % 0.71 [ 0.09, 1.34 ]
Gu¨ell 2006 18 0.3 (1) 17 -0.4 (1.2) 22.0 % 0.70 [ -0.03, 1.43 ]
Wijkstra 1994 28 0.56 (0.99) 15 0.03 (0.93) 33.3 % 0.53 [ -0.07, 1.13 ]
Subtotal (95% CI) 91 70 100.0 % 0.61 [ 0.26, 0.95 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.40, df = 3 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 3.46 (P = 0.00055)
4 CRQ: Mastery
Cambach 1997 15 1 (1.25) 8 -0.25 (1) 15.8 % 1.25 [ 0.31, 2.19 ]
Gu¨ell 2000 30 0.917 (1.2324) 30 0.15 (1.5062) 28.6 % 0.77 [ 0.07, 1.46 ]
Gu¨ell 2006 18 0.6 (1.1) 17 0 (1.1) 26.1 % 0.60 [ -0.13, 1.33 ]
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(. . . Continued)
Study or subgroup IDM Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Wijkstra 1994 28 0.6 (1.2) 15 0 (1.03) 29.6 % 0.60 [ -0.09, 1.29 ]
Subtotal (95% CI) 91 70 100.0 % 0.75 [ 0.38, 1.12 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.44, df = 3 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 3.95 (P = 0.000079)
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Analysis 1.8. Comparison 1 Integrated disease management versus control, Outcome 8 CRQ: Long-term (>
12 months).
Review: Integrated disease management interventions for patients with chronic obstructive pulmonary disease
Comparison: 1 Integrated disease management versus control
Outcome: 8 CRQ: Long-term (> 12 months)
Study or subgroup IDM Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 CRQ: Dyspnea
Gu¨ell 2000 24 1.029 (1.4011) 23 0.11 (1.1414) 43.6 % 0.92 [ 0.19, 1.65 ]
Sridhar 2008 55 -0.72 (1.2) 49 -0.84 (1.2) 56.4 % 0.12 [ -0.34, 0.58 ]
Subtotal (95% CI) 79 72 100.0 % 0.47 [ -0.31, 1.25 ]
Heterogeneity: Tau2 = 0.23; Chi2 = 3.32, df = 1 (P = 0.07); I2 =70%
Test for overall effect: Z = 1.18 (P = 0.24)
2 CRQ: Fatigue
Gu¨ell 2000 24 0.231 (1.1562) 23 -0.32 (1.4387) 28.6 % 0.55 [ -0.19, 1.30 ]
Sridhar 2008 55 0.06 (1.35) 49 -0.35 (1.11) 71.4 % 0.41 [ -0.06, 0.88 ]
Subtotal (95% CI) 79 72 100.0 % 0.45 [ 0.05, 0.85 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 2.21 (P = 0.027)
3 CRQ: Emotion
Gu¨ell 2000 24 0.651 (1.1856) 23 0.12 (1.3572) 34.1 % 0.54 [ -0.19, 1.27 ]
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(. . . Continued)
Study or subgroup IDM Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Sridhar 2008 55 0.16 (1.43) 49 -0.36 (1.3) 65.9 % 0.52 [ 0.00, 1.04 ]
Subtotal (95% CI) 79 72 100.0 % 0.53 [ 0.10, 0.95 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 2.42 (P = 0.016)
4 CRQ: Mastery
Gu¨ell 2000 24 0.935 (1.1415) 23 -0.05 (1.3812) 35.4 % 0.99 [ 0.26, 1.72 ]
Sridhar 2008 55 0.43 (1.33) 49 -0.27 (1.45) 64.6 % 0.70 [ 0.16, 1.24 ]
Subtotal (95% CI) 79 72 100.0 % 0.80 [ 0.37, 1.23 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.39, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 3.64 (P = 0.00027)
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Analysis 1.9. Comparison 1 Integrated disease management versus control, Outcome 9 General health
QoL: SIP mean difference.
Review: Integrated disease management interventions for patients with chronic obstructive pulmonary disease
Comparison: 1 Integrated disease management versus control
Outcome: 9 General health QoL: SIP mean difference
Study or subgroup IDM Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 SIP total
Engstrom 1999 26 -0.07 (5.099) 24 1.02 (5.3889) 44.5 % -1.09 [ -4.00, 1.82 ]
Littlejohns 1991 68 -0.63 (9.2129) 65 0.4 (5.8518) 55.5 % -1.03 [ -3.64, 1.58 ]
Subtotal (95% CI) 94 89 100.0 % -1.06 [ -3.00, 0.89 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.07 (P = 0.29)
2 SIP: physical
Engstrom 1999 26 0.28 (5.099) 24 1.13 (6.8586) 41.4 % -0.85 [ -4.22, 2.52 ]
Littlejohns 1991 68 -5.53 (7.5604) 65 -1.65 (5.9325) 58.6 % -3.88 [ -6.18, -1.58 ]
Subtotal (95% CI) 94 89 100.0 % -2.63 [ -5.55, 0.30 ]
Heterogeneity: Tau2 = 2.42; Chi2 = 2.11, df = 1 (P = 0.15); I2 =53%
Test for overall effect: Z = 1.76 (P = 0.079)
3 SIP: psychosocial
Engstrom 1999 26 -0.2 (6.1188) 24 0.41 (5.8788) 48.1 % -0.61 [ -3.94, 2.72 ]
Littlejohns 1991 68 -2.38 (11.2786) 65 -1.28 (7.1836) 51.9 % -1.10 [ -4.30, 2.10 ]
Subtotal (95% CI) 94 89 100.0 % -0.86 [ -3.17, 1.44 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.73 (P = 0.46)
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Analysis 1.10. Comparison 1 Integrated disease management versus control, Outcome 10 Functional
exercise capacity: 6MWD mean difference.
Review: Integrated disease management interventions for patients with chronic obstructive pulmonary disease
Comparison: 1 Integrated disease management versus control
Outcome: 10 Functional exercise capacity: 6MWD mean difference
Study or subgroup IDM Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 6MWD: short-term (3 to 12 months)
Bendstrup 1997 16 113.1 (71.2) 16 36.1 (41.6) 7.3 % 77.00 [ 36.59, 117.41 ]
Boxall 2005 23 39 (69.6) 23 4.2 (75.1) 7.2 % 34.80 [ -7.05, 76.65 ]
Cambach 1997 12 51 (57) 7 46 (43) 6.9 % 5.00 [ -40.33, 50.33 ]
Engstrom 1999 26 38 (90.3) 24 0.8 (101.9) 6.2 % 37.20 [ -16.34, 90.74 ]
Fernandez 2009 27 79 (82) 14 13 (86) 6.1 % 66.00 [ 11.36, 120.64 ]
Gottlieb 2011 21 49.4 (94) 20 3.8 (81) 6.1 % 45.60 [ -8.03, 99.23 ]
Gu¨ell 2000 30 85.067 (52.2801) 30 15.17 (60.6384) 8.3 % 69.90 [ 41.25, 98.55 ]
Gu¨ell 2006 18 63 (92) 17 -22 (72) 6.1 % 85.00 [ 30.43, 139.57 ]
Littlejohns 1991 68 -1.4 (90.89) 65 -4.9 (96.05) 8.0 % 3.50 [ -28.31, 35.31 ]
Mendes 2010 56 81.5886 (59.6774) 29 -38.03 (59.8996) 8.5 % 119.62 [ 92.80, 146.45 ]
Theander 2009 12 40.6 (27.2) 14 16.5 (45.8) 8.3 % 24.10 [ -4.40, 52.60 ]
van Wetering 2010 87 -1.4 (36.38) 88 -15.3 (36.59) 9.4 % 13.90 [ 3.09, 24.71 ]
Wakabayashi 2011 42 0.4 (84.4) 43 0 (103.2) 7.3 % 0.40 [ -39.64, 40.44 ]
Wijkstra 1994 28 9 (87) 15 -28 (141) 4.4 % 37.00 [ -41.29, 115.29 ]
Subtotal (95% CI) 466 405 100.0 % 43.86 [ 21.83, 65.89 ]
Heterogeneity: Tau2 = 1307.19; Chi2 = 75.79, df = 13 (P<0.00001); I2 =83%
Test for overall effect: Z = 3.90 (P = 0.000095)
2 6MWD: long-term (> 12 months)
Gottlieb 2011 15 -0.47 (68.9391) 17 -5.93 (45.3542) 11.4 % 5.46 [ -35.55, 46.47 ]
van Wetering 2010 73 -15.1 (46.1376) 79 -33.4 (46.2186) 88.6 % 18.30 [ 3.61, 32.99 ]
Subtotal (95% CI) 88 96 100.0 % 16.84 [ 3.01, 30.67 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.33, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 2.39 (P = 0.017)
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Analysis 1.11. Comparison 1 Integrated disease management versus control, Outcome 11 Subgroup
analysis 6MWD based on type of setting.
Review: Integrated disease management interventions for patients with chronic obstructive pulmonary disease
Comparison: 1 Integrated disease management versus control
Outcome: 11 Subgroup analysis 6MWD based on type of setting
Study or subgroup IDM Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Primary care
Boxall 2005 23 39 (69.6) 23 4.2 (75.1) 14.8 % 34.80 [ -7.05, 76.65 ]
Cambach 1997 12 51 (57) 7 46 (43) 14.3 % 5.00 [ -40.33, 50.33 ]
Fernandez 2009 27 79 (82) 14 13 (86) 13.0 % 66.00 [ 11.36, 120.64 ]
Gottlieb 2011 21 49.4 (94) 20 3.8 (81) 13.2 % 45.60 [ -8.03, 99.23 ]
Mendes 2010 33 73.21 (50.21) 29 -38.03 (59.89) 16.6 % 111.24 [ 83.52, 138.96 ]
van Wetering 2010 87 -1.4 (36.38) 88 -15.3 (36.59) 18.1 % 13.90 [ 3.09, 24.71 ]
Wijkstra 1994 28 9 (87) 15 -28 (141) 10.0 % 37.00 [ -41.29, 115.29 ]
Subtotal (95% CI) 231 196 100.0 % 45.16 [ 8.65, 81.67 ]
Heterogeneity: Tau2 = 1886.99; Chi2 = 44.58, df = 6 (P<0.00001); I2 =87%
Test for overall effect: Z = 2.42 (P = 0.015)
2 Secondary care
Bendstrup 1997 16 113.1 (71.2) 16 36.1 (41.6) 13.9 % 77.00 [ 36.59, 117.41 ]
Engstrom 1999 26 38 (90.3) 24 0.8 (101.9) 12.2 % 37.20 [ -16.34, 90.74 ]
Gu¨ell 2000 30 85.067 (52.2801) 30 15.17 (60.6384) 15.3 % 69.90 [ 41.25, 98.55 ]
Littlejohns 1991 68 -1.4 (90.89) 65 -4.9 (96.05) 14.9 % 3.50 [ -28.31, 35.31 ]
Mendes 2010 23 93.61 (70.57) 29 -38.03 (59.89) 14.4 % 131.64 [ 95.49, 167.79 ]
Theander 2009 12 40.6 (27.2) 14 16.5 (45.8) 15.3 % 24.10 [ -4.40, 52.60 ]
Wakabayashi 2011 42 0.4 (84.4) 43 0 (103.2) 13.9 % 0.40 [ -39.64, 40.44 ]
Subtotal (95% CI) 217 221 100.0 % 49.18 [ 14.28, 84.08 ]
Heterogeneity: Tau2 = 1857.84; Chi2 = 40.59, df = 6 (P<0.00001); I2 =85%
Test for overall effect: Z = 2.76 (P = 0.0057)
3 Tertiary care
Gu¨ell 2006 18 63 (92) 17 -22 (72) 100.0 % 85.00 [ 30.43, 139.57 ]
Subtotal (95% CI) 18 17 100.0 % 85.00 [ 30.43, 139.57 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.05 (P = 0.0023)
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Analysis 1.12. Comparison 1 Integrated disease management versus control, Outcome 12 Subgroup
analysis 6MWD based on type of control group.
Review: Integrated disease management interventions for patients with chronic obstructive pulmonary disease
Comparison: 1 Integrated disease management versus control
Outcome: 12 Subgroup analysis 6MWD based on type of control group
Study or subgroup IDM Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Control group: mono disciplinary treatment
Cambach 1997 12 51 (57) 7 46 (43) 6.9 % 5.00 [ -40.33, 50.33 ]
Fernandez 2009 27 79 (82) 14 13 (86) 6.1 % 66.00 [ 11.36, 120.64 ]
Gu¨ell 2006 18 63 (92) 17 -22 (72) 6.1 % 85.00 [ 30.43, 139.57 ]
Wakabayashi 2011 42 0.4 (84.4) 43 0 (103.2) 7.3 % 0.40 [ -39.64, 40.44 ]
Subtotal (95% CI) 99 81 26.3 % 35.99 [ -5.34, 77.31 ]
Heterogeneity: Tau2 = 1165.85; Chi2 = 8.84, df = 3 (P = 0.03); I2 =66%
Test for overall effect: Z = 1.71 (P = 0.088)
2 Control group: usual care
Bendstrup 1997 16 113.1 (71.2) 16 36.1 (41.6) 7.3 % 77.00 [ 36.59, 117.41 ]
Boxall 2005 23 39 (69.6) 23 4.2 (75.1) 7.2 % 34.80 [ -7.05, 76.65 ]
Engstrom 1999 26 38 (90.3) 24 0.8 (101.9) 6.2 % 37.20 [ -16.34, 90.74 ]
Gottlieb 2011 21 49.4 (94) 20 3.8 (81) 6.1 % 45.60 [ -8.03, 99.23 ]
Gu¨ell 2000 30 85.067 (52.2801) 30 15.17 (60.6384) 8.3 % 69.90 [ 41.25, 98.55 ]
Littlejohns 1991 68 -1.4 (90.89) 65 -4.9 (96.05) 8.0 % 3.50 [ -28.31, 35.31 ]
Mendes 2010 56 81.5893 (59.6766) 29 -38.03 (59.8996) 8.5 % 119.62 [ 92.80, 146.45 ]
Theander 2009 12 40.6 (27.2) 14 16.5 (45.8) 8.3 % 24.10 [ -4.40, 52.60 ]
van Wetering 2010 87 -1.4 (36.38) 88 -15.3 (36.59) 9.4 % 13.90 [ 3.09, 24.71 ]
Wijkstra 1994 28 9 (87) 15 -28 (141) 4.4 % 37.00 [ -41.29, 115.29 ]
Subtotal (95% CI) 367 324 73.7 % 46.59 [ 19.68, 73.51 ]
Heterogeneity: Tau2 = 1472.74; Chi2 = 66.90, df = 9 (P<0.00001); I2 =87%
Test for overall effect: Z = 3.39 (P = 0.00069)
Total (95% CI) 466 405 100.0 % 43.86 [ 21.83, 65.89 ]
Heterogeneity: Tau2 = 1307.21; Chi2 = 75.79, df = 13 (P<0.00001); I2 =83%
Test for overall effect: Z = 3.90 (P = 0.000095)
Test for subgroup differences: Chi2 = 0.18, df = 1 (P = 0.67), I2 =0.0%
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Analysis 1.13. Comparison 1 Integrated disease management versus control, Outcome 13 Subgroup
analysis 6MWD based on dominant component of intervention.
Review: Integrated disease management interventions for patients with chronic obstructive pulmonary disease
Comparison: 1 Integrated disease management versus control
Outcome: 13 Subgroup analysis 6MWD based on dominant component of intervention
Study or subgroup IDM Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Dominant component: exercise
Bendstrup 1997 16 113.1 (71.2) 16 36.1 (41.6) 7.3 % 77.00 [ 36.59, 117.41 ]
Boxall 2005 23 39 (69.6) 23 4.2 (75.1) 7.2 % 34.80 [ -7.05, 76.65 ]
Cambach 1997 12 51 (57) 7 46 (43) 6.9 % 5.00 [ -40.33, 50.33 ]
Engstrom 1999 26 38 (90.3) 24 0.8 (101.9) 6.2 % 37.20 [ -16.34, 90.74 ]
Fernandez 2009 27 79 (82) 14 13 (86) 6.1 % 66.00 [ 11.36, 120.64 ]
Gottlieb 2011 21 49.4 (94) 20 3.8 (81) 6.1 % 45.60 [ -8.03, 99.23 ]
Gu¨ell 2000 30 85.067 (52.2801) 30 15.17 (60.6384) 8.3 % 69.90 [ 41.25, 98.55 ]
Gu¨ell 2006 18 63 (92) 17 -22 (72) 6.1 % 85.00 [ 30.43, 139.57 ]
Mendes 2010 56 81.5893 (59.6766) 29 -38.03 (59.8996) 8.5 % 119.62 [ 92.80, 146.45 ]
Theander 2009 12 40.6 (27.2) 14 16.5 (45.8) 8.3 % 24.10 [ -4.40, 52.60 ]
van Wetering 2010 87 -1.4 (36.38) 88 -15.3 (36.59) 9.4 % 13.90 [ 3.09, 24.71 ]
Wijkstra 1994 28 9 (87) 15 -28 (141) 4.4 % 37.00 [ -41.29, 115.29 ]
Subtotal (95% CI) 356 297 84.6 % 51.47 [ 26.53, 76.40 ]
Heterogeneity: Tau2 = 1452.68; Chi2 = 69.56, df = 11 (P<0.00001); I2 =84%
Test for overall effect: Z = 4.05 (P = 0.000052)
2 Dominant component: structured follow-up
Littlejohns 1991 68 -1.4 (90.89) 65 -4.9 (96.05) 8.0 % 3.50 [ -28.31, 35.31 ]
Subtotal (95% CI) 68 65 8.0 % 3.50 [ -28.31, 35.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.83)
3 Dominant component: individually tailored education program
Wakabayashi 2011 42 0.4 (84.4) 43 0 (103.2) 7.3 % 0.40 [ -39.64, 40.44 ]
Subtotal (95% CI) 42 43 7.3 % 0.40 [ -39.64, 40.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
Total (95% CI) 466 405 100.0 % 43.86 [ 21.83, 65.89 ]
Heterogeneity: Tau2 = 1307.21; Chi2 = 75.79, df = 13 (P<0.00001); I2 =83%
Test for overall effect: Z = 3.90 (P = 0.000095)
Test for subgroup differences: Chi2 = 7.49, df = 2 (P = 0.02), I2 =73%
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Analysis 1.14. Comparison 1 Integrated disease management versus control, Outcome 14 Maximal exercise
capacity: cycle test (W-max).
Review: Integrated disease management interventions for patients with chronic obstructive pulmonary disease
Comparison: 1 Integrated disease management versus control
Outcome: 14 Maximal exercise capacity: cycle test (W-max)
Study or subgroup IDM Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Engstrom 1999 26 9.4 (25.5) 24 0.8 (24) 8.6 % 8.60 [ -5.12, 22.32 ]
Strijbos 1996 15 14 (18) 15 1.3 (20) 8.8 % 12.70 [ -0.92, 26.32 ]
van Wetering 2010 87 5.2 (14.9238) 88 -0.4 (15.9474) 77.7 % 5.60 [ 1.02, 10.18 ]
Wijkstra 1994 28 8 (31) 15 -8 (28) 4.9 % 16.00 [ -2.24, 34.24 ]
Total (95% CI) 156 142 100.0 % 6.99 [ 2.96, 11.02 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.02, df = 3 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 3.40 (P = 0.00068)
Test for subgroup differences: Not applicable
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Analysis 1.15. Comparison 1 Integrated disease management versus control, Outcome 15 Number of
patients experiencing at least one exacerbation: short-term (3-12 months).
Review: Integrated disease management interventions for patients with chronic obstructive pulmonary disease
Comparison: 1 Integrated disease management versus control
Outcome: 15 Number of patients experiencing at least one exacerbation: short-term (3-12 months)
Study or subgroup IDM Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bourbeau 2003 85/96 81/95 28.5 % 1.34 [ 0.57, 3.11 ]
Trappenburg 2011 55/103 56/113 71.5 % 1.17 [ 0.68, 1.99 ]
Total (95% CI) 199 208 100.0 % 1.21 [ 0.77, 1.91 ]
Total events: 140 (IDM), 137 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.83 (P = 0.40)
Test for subgroup differences: Not applicable
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Analysis 1.16. Comparison 1 Integrated disease management versus control, Outcome 16 Number of
patients experiencing at least one exacerbation: long-term (> 12 months).
Review: Integrated disease management interventions for patients with chronic obstructive pulmonary disease
Comparison: 1 Integrated disease management versus control
Outcome: 16 Number of patients experiencing at least one exacerbation: long-term (> 12 months)
Study or subgroup IDM Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sridhar 2008 53/61 53/61 31.5 % 1.00 [ 0.35, 2.86 ]
van Wetering 2010 63/89 52/90 68.5 % 1.77 [ 0.95, 3.29 ]
Total (95% CI) 150 151 100.0 % 1.53 [ 0.90, 2.60 ]
Total events: 116 (IDM), 105 (Control)
Heterogeneity: Chi2 = 0.84, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 1.56 (P = 0.12)
Test for subgroup differences: Not applicable
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Analysis 1.17. Comparison 1 Integrated disease management versus control, Outcome 17 All hospital
admissions: short-term (3 to 12 months).
Review: Integrated disease management interventions for patients with chronic obstructive pulmonary disease
Comparison: 1 Integrated disease management versus control
Outcome: 17 All hospital admissions: short-term (3 to 12 months)
Study or subgroup IDM Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Littlejohns 1991 12/68 14/65 40.7 % 0.78 [ 0.33, 1.84 ]
Rea 2004 29/82 26/51 59.3 % 0.53 [ 0.26, 1.07 ]
Total (95% CI) 150 116 100.0 % 0.62 [ 0.36, 1.07 ]
Total events: 41 (IDM), 40 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.48, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 1.72 (P = 0.085)
Test for subgroup differences: Not applicable
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Analysis 1.18. Comparison 1 Integrated disease management versus control, Outcome 18 All hospital
admissions: long-term (> 12 months).
Review: Integrated disease management interventions for patients with chronic obstructive pulmonary disease
Comparison: 1 Integrated disease management versus control
Outcome: 18 All hospital admissions: long-term (> 12 months)
Study or subgroup IDM Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Sridhar 2008 29/55 24/49 44.1 % 1.16 [ 0.54, 2.51 ]
van Wetering 2010 33/89 46/90 55.9 % 0.56 [ 0.31, 1.02 ]
Total (95% CI) 144 139 100.0 % 0.78 [ 0.38, 1.57 ]
Total events: 62 (IDM), 70 (Control)
Heterogeneity: Tau2 = 0.14; Chi2 = 2.12, df = 1 (P = 0.15); I2 =53%
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
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Analysis 1.19. Comparison 1 Integrated disease management versus control, Outcome 19 Respiratory-
related hospital admissions: short-term (3 to 12 months).
Review: Integrated disease management interventions for patients with chronic obstructive pulmonary disease
Comparison: 1 Integrated disease management versus control
Outcome: 19 Respiratory-related hospital admissions: short-term (3 to 12 months)
Study or subgroup IDM Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bourbeau 2003 31/96 48/95 21.2 % 0.47 [ 0.26, 0.84 ]
Boxall 2005 5/23 5/23 6.1 % 1.00 [ 0.25, 4.06 ]
Koff 2009 1/19 3/19 2.3 % 0.30 [ 0.03, 3.14 ]
Rea 2004 18/82 20/51 15.4 % 0.44 [ 0.20, 0.94 ]
Rice 2010 62/372 86/371 31.5 % 0.66 [ 0.46, 0.95 ]
Smith 1999 33/47 25/45 13.2 % 1.89 [ 0.80, 4.45 ]
Trappenburg 2011 7/109 9/118 10.2 % 0.83 [ 0.30, 2.31 ]
Total (95% CI) 748 722 100.0 % 0.68 [ 0.47, 0.99 ]
Total events: 157 (IDM), 196 (Control)
Heterogeneity: Tau2 = 0.08; Chi2 = 9.18, df = 6 (P = 0.16); I2 =35%
Test for overall effect: Z = 2.02 (P = 0.043)
Test for subgroup differences: Not applicable
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Analysis 1.20. Comparison 1 Integrated disease management versus control, Outcome 20 Respiratory-
related hospital admissions: long-term (> 12 months).
Review: Integrated disease management interventions for patients with chronic obstructive pulmonary disease
Comparison: 1 Integrated disease management versus control
Outcome: 20 Respiratory-related hospital admissions: long-term (> 12 months)
Study or subgroup IDM Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
van Wetering 2010 15/89 23/90 100.0 % 0.59 [ 0.28, 1.22 ]
Total (95% CI) 89 90 100.0 % 0.59 [ 0.28, 1.22 ]
Total events: 15 (IDM), 23 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 1.21. Comparison 1 Integrated disease management versus control, Outcome 21 Hospital days per
patient (all causes): short-term (3 to 12 months).
Review: Integrated disease management interventions for patients with chronic obstructive pulmonary disease
Comparison: 1 Integrated disease management versus control
Outcome: 21 Hospital days per patient (all causes): short-term (3 to 12 months)
Study or subgroup IDM Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bourbeau 2003 96 7.2 (19.5) 95 12.5 (21.2) 9.7 % -5.30 [ -11.08, 0.48 ]
Boxall 2005 23 5.6 (2.96) 23 8.8 (4.71) 25.4 % -3.20 [ -5.47, -0.93 ]
Engstrom 1999 26 4.9 (13.77) 24 1.6 (8.33) 8.7 % 3.30 [ -2.95, 9.55 ]
Farrero 2001 46 7.43 (15.6) 48 18.2 (24.55) 5.5 % -10.77 [ -19.05, -2.49 ]
Rea 2004 82 1.1 (7.8) 51 4 (7.8) 22.5 % -2.90 [ -5.63, -0.17 ]
Trappenburg 2011 109 6.6 (2.8) 118 11.9 (9.8) 28.2 % -5.30 [ -7.14, -3.46 ]
Total (95% CI) 382 359 100.0 % -3.78 [ -5.90, -1.67 ]
Heterogeneity: Tau2 = 3.22; Chi2 = 11.00, df = 5 (P = 0.05); I2 =55%
Test for overall effect: Z = 3.51 (P = 0.00044)
Test for subgroup differences: Not applicable
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Analysis 1.22. Comparison 1 Integrated disease management versus control, Outcome 22 Hospital days per
patient: long-term (> 12 months).
Review: Integrated disease management interventions for patients with chronic obstructive pulmonary disease
Comparison: 1 Integrated disease management versus control
Outcome: 22 Hospital days per patient: long-term (> 12 months)
Study or subgroup IDM Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
van Wetering 2010 87 4.9 (14) 88 4.3 (10) 0.60 [ -3.01, 4.21 ]
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Analysis 1.23. Comparison 1 Integrated disease management versus control, Outcome 23 ED visits.
Review: Integrated disease management interventions for patients with chronic obstructive pulmonary disease
Comparison: 1 Integrated disease management versus control
Outcome: 23 ED visits
Study or subgroup IDM Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bourbeau 2003 39/96 60/95 29.6 % 0.40 [ 0.22, 0.71 ]
Rea 2004 5/83 7/52 16.9 % 0.41 [ 0.12, 1.37 ]
Rice 2010 51/372 85/371 34.1 % 0.53 [ 0.36, 0.78 ]
Smith 1999 14/47 6/45 19.3 % 2.76 [ 0.95, 7.98 ]
Total (95% CI) 598 563 100.0 % 0.64 [ 0.33, 1.25 ]
Total events: 109 (IDM), 158 (Control)
Heterogeneity: Tau2 = 0.30; Chi2 = 10.26, df = 3 (P = 0.02); I2 =71%
Test for overall effect: Z = 1.30 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 1.24. Comparison 1 Integrated disease management versus control, Outcome 24 Number of
patients using at least one course of oral steroids.
Review: Integrated disease management interventions for patients with chronic obstructive pulmonary disease
Comparison: 1 Integrated disease management versus control
Outcome: 24 Number of patients using at least one course of oral steroids
Study or subgroup IDM Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Farrero 2001 20/60 27/62 34.0 % 0.65 [ 0.31, 1.35 ]
Littlejohns 1991 33/68 24/65 36.3 % 1.61 [ 0.81, 3.22 ]
Rea 2004 31/52 21/41 29.6 % 1.41 [ 0.62, 3.21 ]
Total (95% CI) 180 168 100.0 % 1.13 [ 0.64, 2.01 ]
Total events: 84 (IDM), 72 (Control)
Heterogeneity: Tau2 = 0.11; Chi2 = 3.47, df = 2 (P = 0.18); I2 =42%
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Not applicable
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Analysis 1.25. Comparison 1 Integrated disease management versus control, Outcome 25 Number of
patients using at least one course of antibiotics.
Review: Integrated disease management interventions for patients with chronic obstructive pulmonary disease
Comparison: 1 Integrated disease management versus control
Outcome: 25 Number of patients using at least one course of antibiotics
Study or subgroup IDM Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Littlejohns 1991 54/68 34/65 50.5 % 3.52 [ 1.64, 7.54 ]
Rea 2004 36/62 29/41 49.5 % 0.57 [ 0.25, 1.33 ]
Total (95% CI) 130 106 100.0 % 1.43 [ 0.24, 8.48 ]
Total events: 90 (IDM), 63 (Control)
Heterogeneity: Tau2 = 1.48; Chi2 = 9.81, df = 1 (P = 0.002); I2 =90%
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Not applicable
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Analysis 1.26. Comparison 1 Integrated disease management versus control, Outcome 26 MRC dyspnea
score.
Review: Integrated disease management interventions for patients with chronic obstructive pulmonary disease
Comparison: 1 Integrated disease management versus control
Outcome: 26 MRC dyspnea score
Study or subgroup IDM Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Mendes 2010 56 -0.8929 (0.9663) 29 -0.66 (0.9738) 17.1 % -0.24 [ -0.67, 0.20 ]
van Wetering 2010 87 -0.3 (0.9327) 88 0.1 (0.9381) 42.3 % -0.40 [ -0.68, -0.12 ]
Wakabayashi 2011 42 -0.2 (0.9324) 43 0.01 (0.0736) 40.6 % -0.21 [ -0.49, 0.07 ]
Total (95% CI) 185 160 100.0 % -0.30 [ -0.48, -0.11 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.96, df = 2 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 3.21 (P = 0.0013)
Test for subgroup differences: Not applicable
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Analysis 1.27. Comparison 1 Integrated disease management versus control, Outcome 27 Borg score.
Review: Integrated disease management interventions for patients with chronic obstructive pulmonary disease
Comparison: 1 Integrated disease management versus control
Outcome: 27 Borg score
Study or subgroup IDM Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Boxall 2005 23 -0.13 (1.3) 23 0.22 (1.4) 48.7 % -0.35 [ -1.13, 0.43 ]
Gottlieb 2011 19 0.3 (2.4) 20 -0.7 (1.4) 29.7 % 1.00 [ -0.24, 2.24 ]
Gu¨ell 2000 30 0.166 (2.9084) 30 0.1 (3.2754) 21.5 % 0.07 [ -1.50, 1.63 ]
Total (95% CI) 72 73 100.0 % 0.14 [ -0.70, 0.98 ]
Heterogeneity: Tau2 = 0.22; Chi2 = 3.26, df = 2 (P = 0.20); I2 =39%
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Not applicable
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Analysis 1.28. Comparison 1 Integrated disease management versus control, Outcome 28 Mortality.
Review: Integrated disease management interventions for patients with chronic obstructive pulmonary disease
Comparison: 1 Integrated disease management versus control
Outcome: 28 Mortality
Study or subgroup IDM Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Short-term (3 to 12 months)
Farrero 2001 23/60 21/62 22.4 % 1.21 [ 0.58, 2.54 ]
Littlejohns 1991 3/73 9/79 11.4 % 0.33 [ 0.09, 1.28 ]
Rice 2010 36/372 48/371 30.3 % 0.72 [ 0.46, 1.14 ]
Smith 1999 33/48 25/48 20.2 % 2.02 [ 0.88, 4.65 ]
Subtotal (95% CI) 553 560 84.3 % 0.96 [ 0.52, 1.74 ]
Total events: 95 (IDM), 103 (Control)
Heterogeneity: Tau2 = 0.21; Chi2 = 7.25, df = 3 (P = 0.06); I2 =59%
Test for overall effect: Z = 0.15 (P = 0.88)
2 Long-term (> 12 months)
Sridhar 2008 6/61 12/61 15.7 % 0.45 [ 0.16, 1.28 ]
Subtotal (95% CI) 61 61 15.7 % 0.45 [ 0.16, 1.28 ]
Total events: 6 (IDM), 12 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.51 (P = 0.13)
Total (95% CI) 614 621 100.0 % 0.85 [ 0.49, 1.46 ]
Total events: 101 (IDM), 115 (Control)
Heterogeneity: Tau2 = 0.20; Chi2 = 8.86, df = 4 (P = 0.06); I2 =55%
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Chi2 = 1.52, df = 1 (P = 0.22), I2 =34%
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Analysis 1.29. Comparison 1 Integrated disease management versus control, Outcome 29 FEV1 (liter).
Review: Integrated disease management interventions for patients with chronic obstructive pulmonary disease
Comparison: 1 Integrated disease management versus control
Outcome: 29 FEV1 (liter)
Study or subgroup IDM Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 FEV1 (liter): short-term
Bourbeau 2003 96 0.96 (0.32) 95 1.01 (0.36) 65.1 % -0.05 [ -0.15, 0.05 ]
Wijkstra 1994 28 1.3 (0.3) 15 1.2 (0.3) 34.9 % 0.10 [ -0.09, 0.29 ]
Subtotal (95% CI) 124 110 100.0 % 0.00 [ -0.14, 0.14 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 1.93, df = 1 (P = 0.16); I2 =48%
Test for overall effect: Z = 0.03 (P = 0.97)
2 FEV1 (liter): long-term
Sridhar 2008 55 0.95 (0.42) 49 1.06 (0.44) 100.0 % -0.11 [ -0.28, 0.06 ]
Subtotal (95% CI) 55 49 100.0 % -0.11 [ -0.28, 0.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
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Analysis 1.30. Comparison 1 Integrated disease management versus control, Outcome 30 FEV1 (%
predicted).
Review: Integrated disease management interventions for patients with chronic obstructive pulmonary disease
Comparison: 1 Integrated disease management versus control
Outcome: 30 FEV1 (% predicted)
Study or subgroup IDM Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 FEV1 (% predicted): short-term
Farrero 2001 46 25 (6) 48 24 (6) 62.0 % 1.00 [ -1.43, 3.43 ]
Fernandez 2009 27 34 (13) 14 38 (11) 13.4 % -4.00 [ -11.57, 3.57 ]
Gu¨ell 2000 30 33.5 (12.01) 30 38.3 (14.8) 16.0 % -4.80 [ -11.62, 2.02 ]
Wakabayashi 2011 42 62.1 (19.9) 43 60.8 (25.3) 8.6 % 1.30 [ -8.36, 10.96 ]
Subtotal (95% CI) 145 135 100.0 % -0.57 [ -3.54, 2.39 ]
Heterogeneity: Tau2 = 2.16; Chi2 = 3.70, df = 3 (P = 0.30); I2 =19%
Test for overall effect: Z = 0.38 (P = 0.70)
2 FEV1 (% predicted; mean change): short-term
Littlejohns 1991 68 -2.06 (11.36) 65 -0.15 (19.98) 10.1 % -1.91 [ -7.47, 3.65 ]
Mendes 2010 56 13.74 (13.37) 29 9.91 (14.95) 7.5 % 3.83 [ -2.64, 10.30 ]
van Wetering 2010 87 0.87 (6.72) 88 -1.74 (9.76) 50.7 % 2.61 [ 0.13, 5.09 ]
Wood-Baker 2006 60 0.5 (10.2) 61 -1.8 (7.1) 31.7 % 2.30 [ -0.84, 5.44 ]
Subtotal (95% CI) 271 243 100.0 % 2.15 [ 0.38, 3.91 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.45, df = 3 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 2.38 (P = 0.017)
3 FEV1 (% predicted): long-term
Sridhar 2008 55 41.1 (17.1) 49 45.7 (17.48) 100.0 % -4.60 [ -11.26, 2.06 ]
Subtotal (95% CI) 55 49 100.0 % -4.60 [ -11.26, 2.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.35 (P = 0.18)
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Analysis 1.31. Comparison 1 Integrated disease management versus control, Outcome 31 Anxiety and
depression (HADS).
Review: Integrated disease management interventions for patients with chronic obstructive pulmonary disease
Comparison: 1 Integrated disease management versus control
Outcome: 31 Anxiety and depression (HADS)
Study or subgroup IDM Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 HADS: depression
Littlejohns 1991 68 0.44 (2.6441) 65 0.11 (2.4214) 48.3 % 0.33 [ -0.53, 1.19 ]
Trappenburg 2011 86 -0.2 (2.7821) 97 -0.3 (2.9547) 51.7 % 0.10 [ -0.73, 0.93 ]
Subtotal (95% CI) 154 162 100.0 % 0.21 [ -0.39, 0.81 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.69 (P = 0.49)
2 HADS: anxiety
Littlejohns 1991 68 1.06 (2.9746) 65 0.55 (2.6232) 43.3 % 0.51 [ -0.44, 1.46 ]
Trappenburg 2011 86 -0.4 (2.7821) 97 -0.4 (2.9547) 56.7 % 0.0 [ -0.83, 0.83 ]
Subtotal (95% CI) 154 162 100.0 % 0.22 [ -0.41, 0.85 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.63, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.69 (P = 0.49)
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A D D I T I O N A L T A B L E S
Table 1. Characteristics of included studies
Study Country N (ran-
domised)
N (com-
pleted)
Num-
ber of com-
ponents in-
tervention
Number of
health care
providers
Main com-
ponent in-
tervention
Setting Control
group
Aiken 2006 US 41 18 5 2 SF PRIM U
Bendstrup
1997
Denmark 42 32 4 7 E SEC U
Bourbeau
2003
Canada 191 165 4 4 SM SEC U
Boxall 2005 Australia 60 46 2 3 E PRIM U
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Table 1. Characteristics of included studies (Continued)
Cambach
1997
Netherlands 43 23 2 2 E PRIM DRUG
Dheda 2004 UK 33 25 4 2 SF SEC U
Engstrom
1999
Sweden 55 50 4 5 E SEC U
Farrero
2001
Spain 122 94 2 2 SF SEC U
Fernandez
2009
Spain 50 41 2 2 E PRIM EDU
Gottlieb
2011
Denmark 61 26 4 Multidisci-
plinary
team, not
specified
E PRIM U
Güell 2000 Spain 60 47 3 3 E SEC U
Güell 2006 Spain 40 25 2 4 E TERT DRUG
Koff 2009 US 40 38 4 2 SM PRIM U
Littlejohns
1991
UK 152 133 4 3 SF SEC U
Mendes
2010
Brazil 117 85 2 2 E PRIM/SEC U
Rea 2004 New
Zealand
135 117 5 4 SM/SF PRIM/SEC U
Rice 2010 US 743 743 3 2 SM SEC EDU
Smith 1999 Australia 96 36 8 3 SF PRIM/SEC U
Sridhar
2008
UK 122 104 4 3 E/SM PRIM/SEC U
Strijbos
1996
Netherlands 50 41 3 3 E PRIM/SEC U
Theander
2009
Sweden 30 26 4 4 E SEC U
Trappen-
burg
Netherlands 233 193 3 3 SM SEC U
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Table 1. Characteristics of included studies (Continued)
Wak-
abayashi
2011
Japan 102 85 4 2 IT EDU SEC EDU
Wetering
2010
Netherlands 199 175 4 3 E SEC U
Wijkstra
1995
Netherlands 45 43 2 3 E PRIM U
Wood-
Baker 2006
Australia 135 112 3 2 SM PRIM EDU
Main component: SF: structural follow-up; SM: self management; E: exercise; IT EDU: individually tailored education
Setting: PRIM: primary care; SEC: secondary care; TERT: tertiary care
Control group: U: usual care; DRUG: optimization of drug treatment; EDU: education
Table 2. Components of IDM in each included study
Author Educa-
tion
Self
man-
age-
ment
Exacer-
bation/
action
plan
Exercise Psy-
choso-
cial/
occupa-
tional
Smok-
ing
Opti-
mal
medica-
tion
Nutri-
tion
Follow-
up
Case
man-
age-
ment
Multi-
disci-
plinary
Aiken
2006
x x x x x
Bend-
strup
1997
x x x x
Bourbeau
2003
x x x x
Boxall
2005
x x
Cam-
bach
1997
x x
Dheda
2004
x x x x
En-
gstrom
x x x x
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Table 2. Components of IDM in each included study (Continued)
1999
Farrero
2001
x x
Fernan-
dez
x x
Gottlieb
2011
x x x x
Güell
2000
x x x
Güell
2006
x x
Koff
2009
x x x x
Little-
johns
1991
x x x x
Mendes
2010
x x
Rea
2004
x x x x x
Rice
2010
x x x
Smith
1999
x x x x x x x x
Sridhar
2008
x x x x
Strijbos
1996
x x x
Thean-
der 2009
x x x x
Trap-
penburg
2011
x x x
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Table 2. Components of IDM in each included study (Continued)
Wak-
abayashi
2011
x x x x
Weter-
ing 2010
x x x x
Wijkstra
1995
x x
Wood-
Baker
2006
x x x
A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1. Pulmonary Disease, Chronic Obstructive/
2. COPD.mp.
3. Chronic Obstructive Pulmonary Disease.mp.
4. Chronic Obstructive Airway Disease.mp.
5. Chronic Obstructive Lung Disease.mp.
6. pulmonary emphysema.mp.
7. chronic bronchitis.mp.
8. COAD.mp.
9. Chronic Airflow Obstruction.mp.
10. or/1-9
11. disease management/
12. Disease management.mp.
13. exp Managed Care Programs/
14. managed care.mp.
15. (insurance and “case management”).mp.
16. exp Patient Care Planning/
17. “patient care plan$”.mp.
18. “nursing care plan$”.mp.
19. “goals of care”.mp.
20. “care goal”.mp.
21. exp “Delivery of Health Care, Integrated”/
22. (integrated and (health$ or care$ or delivery or system$)).mp.
23. disease state management.mp.
24. Comprehensive Health Care/
25. “comprehensive health care”.mp.
26. ((interdisciplin$ or multidisciplin$) and (care or health$ or delivery or system$)).mp.
27. Primary Nursing/
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28. “primary nursing”.mp.
29. “community based”.mp.
30. Patient-Centered Care/
31. Patient Care Management/
32. (patient adj3 (care or management)).mp.
33. practice guideline/
34. education, medical, continuing/ or education, nursing, continuing/
35. exp community health services/
36. Primary Health Care/
37. “patient care team”.mp.
38. “critical pathways”.mp.
39. “case management”.mp.
40. Self Care/
41. (continuity adj3 “patient care”).mp.
42. guideline$.mp.
43. “clinical protocol”.mp.
44. “patient education”.mp.
45. (self-care or “self care”).mp.
46. reminder systems.mp. or Reminder Systems/
47. Health Education/
48. Health Promotion/
49. (health adj3 (education or promotion)).mp.
50. Community Health Planning/
51. ambulatory care.mp.
52. feedback.mp.
53. or/11-52
54. 10 and 53
55. (clinical trial or controlled clinical trial or randomised controlled trial).pt.
56. (randomised or randomised).ab,ti.
57. placebo.ab,ti.
58. dt.fs.
59. randomly.ab,ti.
60. trial.ab,ti.
61. groups.ab,ti.
62. or/55-61
63. Animals/
64. Humans/
65. 63 not (63 and 64)
66. 62 not 65
67. 54 and 66
[Limited to pub. Date > = 1990]
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Appendix 2. EMBASE search strategy
1. chronic obstructive lung disease/
2. COPD.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manu-
facturer]
3. Chronic Obstructive Pulmonary Disease.mp.
4. Chronic Obstructive Airway Disease.mp.
5. Chronic Obstructive Lung Disease.mp.
6. pulmonary emphysema.mp.
7. chronic bronchitis.mp.
8. COAD.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manu-
facturer]
9. Chronic Airflow Obstruction.mp.
10. or/1-9
11. disease management/
12. Disease management.mp.
13. managed care/
14. managed care.mp.
15. (insurance and “case management”).mp.
16. patient care planning/
17. “patient care plan$”.mp.
18. “nursing care plan$”.mp.
19. “goals of care”.mp.
20. “care goal”.mp.
21. integrated health care system/
22. (integrated adj5 (health$ or care$ or delivery or system$)).mp.
23. disease state management.mp.
24. health care/
25. “comprehensive health care”.mp.
26. ((interdisciplin$ or multidisciplin$) adj5 (care or health$ or delivery or system$)).mp.
27. primary nursing/
28. “primary nursing”.mp.
29. “community based”.mp.
30. patient care/
31. (patient adj3 (care or management)).mp.
32. practice guideline/
33. medical education/
34. exp community care/
35. primary health care/
36. “patient care team”.mp.
37. “critical pathways”.mp.
38. “case management”.mp.
39. self care/
40. (continuity adj3 “patient care”).mp.
41. guideline$.mp.
42. “clinical protocol”.mp.
43. “patient education”.mp.
44. (self-care or “self care”).mp.
45. reminder system/
46. reminder systems.mp.
47. health education/
48. health promotion/
49. (health adj3 (education or promotion)).mp.
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50. health care planning/
51. ambulatory care.mp.
52. feedback.mp.
53. or/11-52
54. 10 and 53
55. Randomized Controlled Trial/
56. randomisation/
57. Controlled Study/
58. Clinical Trial/
59. controlled clinical trial/
60. Double Blind Procedure/
61. Single Blind Procedure/
62. Crossover Procedure/
63. or/55-62
64. (clinica$ adj3 trial$).mp.
65. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (mask$ or blind$ or method$)).mp.
66. exp Placebo/
67. placebo$.mp.
68. random$.mp.
69. ((control$ or prospectiv$) adj3 (trial$ or method$ or stud$)).mp.
70. (crossover$ or cross-over$).mp.
71. or/64-70
72. 63 or 71
73. exp ANIMAL/
74. Nonhuman/
75. Human/
76. 73 or 74
77. 76 not 75
78. 72 not 77
79. 54 and 78
[Limited to pub. Date >=1990]
Appendix 3. CINAHL search strategy
S1 (MH “Pulmonary Disease, Chronic Obstructive+”)
S2 COPD
S3 “chronic Obstructive Pulmonary Disease”
S4 “Chronic Obstructive Airway Disease”
S5 “Chronic Obstructive Lung Disease”
S6 “pulmonary emphysema”
S7 “chronic bronchitis”
S8 COAD
S9 “Chronic Airflow Obstruction”
S10 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9
S11 (MH “Disease Management”)
S12 “Disease management”
S13 (MH “Managed Care Programs+”)
S14 “managed care”
S15 insurance and “case management”
S16 (MH “Patient Care Plans+”)
S17 “patient care plan*”
S18 “nursing care plan*”
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S19 “goals of care”
S20 “care goal”
S21 (MH “Health Care Delivery, Integrated”)
S22 (integrated and (health* or care* or delivery or system*))
S23 “disease state management”
S24 “Comprehensive Health Care”
S25 ((interdisciplin* or multidisciplin*) and (care or health* or delivery or system*))
S26 (MH “Primary Nursing”)
S27 “primary nursing”
S28 “community based”
S29 (MH “Patient Centered Care”)
S30 “patient care”
S31 “patient management”
S32 (MH “Education, Medical, Continuing”)
S33 Education, Nursing, Continuing
S34 (MH “Community Health Services+”)
S35 (MH “Primary Health Care”)
S36 “patient care team”
S37 (MH “Critical Path”)
S38 “case management”
S39 (MH “Self Care”)
S40 (MH “Continuity of Patient Care”)
S41 guideline*
S42 “clinical protocol”
S43 “patient education”
S44 self-care or “self care”
S45 (MH “Reminder Systems”)
S46 “reminder system*”
S47 (MH “Health Education”)
S48 (MH “Health Promotion+”)
S49 (health N3 educat*) or (health N3 promot*)
S50 “Community Health Planning”
S51 “ambulatory care”
S52 feedback
S53 S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19 or S20 or S21 or S22 or S23 or S24 or S25 or S26 or S27 or
S28 or S29 or S30 or S31 or S32 or S33 or S34 or S35 or S36 or S37 or S38 or S39 or S40 or S41 or S42 or S43 or S44 or S45 or S46
or S47 or S48 or S49 or S50 or S51 or S52
S54 S10 and S53
S55 (DE “RANDOMIZED CONTROLLED TRIALS”)
S56 (MH “Double-Blind Studies”)
S57 (MH “Random Assignment”)
S58 (MH “Placebos”)
S59 placebo*
S60 random*
S61 crossover* or cross-over*
S62 clinical* and (trial* or study or studies)
S63 (single* or double* or triple*) and blind*
S64 S55 or S56 or S57 or S58 or S59 or S60 or S61 or S62 or S63
S65 S54 and S64 [Limiters - Exclude MEDLINE records; Published Date from: 19900101-20111231 ]
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Appendix 4. CENTRAL search strategy
#1 MeSH descriptor Pulmonary Disease, Chronic Obstructive explode all trees
#2 COPD
#3 “chronic Obstructive Pulmonary Disease”
#4 “Chronic Obstructive Airway Disease”
#5 “Chronic Obstructive Lung Disease”
#6 “pulmonary emphysema”
#7 “chronic bronchitis”
#8 COAD
#9 “Chronic Airflow Obstruction”
#10 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9)
#11 MeSH descriptor Disease Management, this term only
#12 “Disease management”
#13 MeSH descriptor Managed Care Programs explode all trees
#14 “managed care”
#15 insurance and “case management”
#16 MeSH descriptor Patient Care Planning explode all trees
#17 “patient care plan*”
#18 “nursing care plan*”
#19 “goals of care”
#20 “care goal”
#21 MeSH descriptor Delivery of Health Care, Integrated explode all trees
#22 (integrated and (health* or care* or delivery or system*))
#23 “disease state management”
#24 MeSH descriptor Comprehensive Health Care, this term only
#25 “comprehensive health care”
#26 ((interdisciplin* or multidisciplin*) and (care or health* or delivery or system*))
#27 MeSH descriptor Primary Nursing, this term only
#28 “primary nursing”
#29 “community based”
#30 MeSH descriptor Patient-Centered Care explode all trees
#31 MeSH descriptor Patient Care Management, this term only
#32 “patient care”
#33 “patient management”
#34 MeSH descriptor Education, Medical, Continuing, this term only
#35 MeSH descriptor Education, Nursing, Continuing, this term only
#36 MeSH descriptor Community Health Services explode all trees
#37 MeSH descriptor Primary Health Care, this term only
#38 “patient care team”
#39 “critical pathways”
#40 “case management”
#41 MeSH descriptor Self Care, this term only
#42 continuity NEAR/3 “patient care”
#43 guideline*
#44 “clinical protocol”
#45 “patient education”
#46 self-care or “self care”
#47 MeSH descriptor Reminder Systems explode all trees
#48 “reminder system*”
#49 MeSH descriptor Health Education, this term only
#50 MeSH descriptor Health Promotion explode all trees
#51 health NEAR/3 (educat* or promot*)
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#52 MeSH descriptor Community Health Planning, this term only
#53 “ambulatory care”
#54 feedback
#55 (#11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR
#25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR
#40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 OR #53 OR #54)
#56 (#55 AND #10)
#57 (#56), from 1990 to 2013
Appendix 5. Cochrane Airways Group Register search strategy
#45=COPD
AND
(“disease management” or “managed care” or insurance* or “case management” or “care plan” or (goal* and care) or (integrat* and
(system* or delivery or care or health*)) or (comprehensive and “health care”) or ((interdisciplin* or multidisciplin*) and (care or
health* or delivery or system*)) or “primary nursing” or patient-cent* or “patient care” or “patient manag*” or “practice guideline*” or
“community health” or “primary health care” or “critical pathway*” or self-care or “self care” or “clinical protocol*” or “patient educat*”
or reminder* or (health and (educat* or promot*)) or ((community or health) and plan*) or “ambulatory care” or feedback)
[Limited to pub. date>=1990]
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S O U R C E S O F S U P P O R T
Internal sources
• LUMC, Leiden, Netherlands.
Leiden University Medical Centre
• iMTA, Rotterdam, Netherlands.
Institute for Medical Technology Assessment
External sources
• ZonMW, Netherlands.
The Netherlands Organisation for Health Research and Development
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We added Borg score next to the MRC Dyspnea Score as an instrument to measure dyspnoea under ’Secondary outcomes’.
We did not search the DARE database for non-Cochrane reviews.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Disease Management; ∗Quality of Life; Delivery of Health Care, Integrated [∗methods]; Exercise Tolerance; Hospitalization [statistics
& numerical data]; Patient Care Team; Pulmonary Disease, Chronic Obstructive [physiopathology; ∗therapy]; Randomized Controlled
Trials as Topic
MeSH check words
Aged; Female; Humans; Male
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